

**Name:**

**MICHAEL A. CALIGIURI, M.D.**

Office Address: 519 James, 300 W 10<sup>th</sup> Ave, Columbus, OH 43210  
Office Phone: 614-293-7521 (Fax 293-3132)  
E mail: [michael.caligiuri@osumc.edu](mailto:michael.caligiuri@osumc.edu)  
Date of Birth: January 8, 1956  
Place of Birth: Buffalo, New York  
Citizenship: U.S.A  
Marital Status: Married (1985)  
Spouse: Ana Maria de Jesús Caligiuri, R.D., MPH  
Children: Cristina Marie (24), Marie Louise (22), Michael Robert (21)

**Education:**

1979 B.A. S.U.N.Y./Buffalo (*In absentia*, Humanities & Health Science)  
1982 M.A. Stanford University (Physiology)  
1983 M.D. Stanford University School of Medicine

**Postdoctoral Training:**

1983-1989 Clinical Fellow in Medicine, Harvard Medical School, Boston, MA  
1983-1986 Internship and Residency in Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA  
1986-1989 Fellowship in Medical Oncology, Bone Marrow Transplantation, & Immunology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

**Licensure and Certification:**

1997- Ohio State License Registration No. 72689  
1989-1997 New York License Registration No. 179974  
1989- ABIM/Subspecialty Board of Medical Oncology No. 109397  
1986-1990 Massachusetts License Registration No. 55903  
1986- American Board of Internal Medicine No. 109397  
1983- Diplomat of the National Board of Medical Examiners

**Academic Appointments:**

2008- Chief Executive Officer, The James Cancer Hospital & Solove Research Institute  
The Ohio State University (OSU)  
2003- Vice President for Health Sciences, Cancer Programs, OSU  
2003- Director, The OSU Comprehensive Cancer Center  
2003-07 Deputy Director, James Cancer Hospital and Solove Research Institute  
The Ohio State University  
2000-07 Director, Division of Hematology and Oncology  
OSU Department of Internal Medicine

**Academic Appointments con't:**

1997-	The John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research Professor, Department of Internal Medicine Professor, Department of Molecular Virology, Immunology, Medical Genetics
1997- 00	Co-Director, Division of Hematology and Oncology Department of Internal Medicine The Ohio State University School of Medicine and Public Health
1997-03	Associate Director for Clinical Research The OSU Comprehensive Cancer Center
1997	Professor Department of Medicine Department of Microbiology/Immunology Roswell Park Cancer Institute and State University of New York at Buffalo School of Medicine
1994-1997	Associate Professor (with tenure) Department of Medicine Department of Microbiology/Immunology Roswell Park Cancer Institute and State University of New York at Buffalo School of Medicine
1990-1994	Assistant Professor Roswell Park Cancer Institute Department of Medicine State University of New York at Buffalo School of Medicine
1989	Instructor in Medicine Department of Medicine Dana Farber Cancer Institute Harvard Medical School

**Grant Support (Current):**

09/12/97–11/30/15	1) NCI/NIH, <b>P30</b> CA16058 Title: OSU Comprehensive Cancer Center Support (CORE) Grant P.I. Michael A. Caligiuri, M.D. Funding: \$15,023,945 (total direct)
10/01/02- 9/30/17	2) NCI/NIH <b>P01</b> CA95426-01 Title: Innate Immunity: Elucidation and Modulation for Cancer Therapy P.I. Michael A. Caligiuri, M.D. Funding: \$6,250,000 (total direct)
05/01/95-04/30/18	3) NCI/NIH <b>7 R37CA</b> 68458-10 (NCI MERIT Award 2010) Title: IL-15: Characterization through Experimental Immunology P.I. Michael A. Caligiuri, M.D. Funding: \$1,250,000 (total direct)

**Grant Support (Current):**

- 12/01/01-11/30/013 4) NCI/NIH **R01** CA89341-10  
Title: Functional Characterization of MLL Gene Fusions  
P.I. Michael A. Caligiuri, M.D.  
Funding: \$1,250,000 (total direct)
- 07/01/04-06/30/14 5) NCI/NIH **T32** CA09338-27  
Title: Oncology Training Grant  
P.I. Michael A. Caligiuri, M.D.  
Funding: \$2,064,160 (total direct)
- 08/01/09-07/30/14 6) NCI/NIH **P50** CA140158 Leukemia **SPORE**  
Title: Experimental Therapeutics of Leukemia  
P.I. John Byrd (Co-PI G. Marcucci, C. Bloomfield)  
Project 4 P.I. Caligiuri MA, Marcucci G, Blum W  
Title of Project 4: Preclinical and Clinical Investigation of *MLL*-PTD AML  
Funding \$11,500,000 (total direct)

**Grant Support (Terminated or Transferred to other PI):**

- 04/01/03-03/31/14 1) NCI/NIH, **U10** CA101140  
Title: CALGB Leukemia Correlative Sciences  
P.I. Michael A. Caligiuri, M.D.  
Funding: \$4,830,000 (total direct)  
*Transferred to G. Marcucci, MD January 1, 2011*
- 10/01/05-9/30/09 2) Leukemia and Lymphoma Soc of America/Translational Research Award  
Title: Development of a vaccine to prevent EBV post transplant lymphoma  
P.I. Michael A. Caligiuri, M.D.  
Funding: \$600,000 (total direct)
- 04/01/04-09/30/08 3) OHIO Third Frontier Award  
Title: The Prevention, Diagnosis and Treatment of Lung Cancer  
P.I. Michael A. Caligiuri, M.D.  
Funding: \$21,400,000 (total direct)
- 9/01/03-08/31/08 4) NCI/NIH, **K23** CA102155  
Title: Combined cytokine-monoclonal antibody therapy in lymphoma  
P.I. Porcu Pierluigi, M.D.  
**Mentor:** Michael A. Caligiuri, M.D.  
Funding: \$627,375
- 09/01/02-08/30/07 5) NCI/NIH, **K01** CA096887  
Title: Flt3 Genotypes in Acute Myeloid Leukemia  
P.I. Susan P. Whitman, Ph.D.  
**Mentor:** Michael A. Caligiuri, M.D.  
Funding: \$811,722
- 7/01/02-06/30/07 6) NCI/NIH, **K08** CA93518  
Title: Mechanism of IL-2 in potentiating rituximab therapy for EBV lymphoma  
P.I. Charles Eisenbeis, M.D., Ph.D.  
**Mentor:** Michael A. Caligiuri, M.D.  
Funding: \$673,920

**Grant Support (Terminated or Transferred to other PI) continued:**

- 07/01/02-06/30/07                    7) NCI/NIH **K08** CA89317  
Aberrant DNA Methylation in Acute Myeloid Leukemia  
P.I. Laura J. Rush, DVM  
**Mentor:** Michael A. Caligiuri, M.D.  
Funding: \$575,917
- 03/01/02-02/28/07                    8) NCI/NIH, **K01** CA97953  
Title: Cytokines and NF- $\kappa$ b regulation of cancer cachexia  
P.I. Denis Guttridge, Ph.D.  
**Mentor:** Michael A. Caligiuri, M.D.  
Funding: \$711,820
- 04/01/01- 03/31/06                    9) NCI/NIH, **K08** CA90469-01  
Title: LARG, A Novel Leukemia-Associated Guanine Exchange Factor  
P.I. Guido Marcucci, M.D.  
**Mentor:** Michael A. Caligiuri, M.D.  
Funding: \$522,000
- 07/01/00-06/30/03                    10) American Cancer Society  
P.I. Michael A. Caligiuri, M.D.  
Title: Institutional Research Grant  
Funding: \$225,000  
*Transferred to G. Otterson, M.D.*
- 03/01/02-12/31/04                    11) Lymphoma Research Foundation  
Title: Rituximab in adoptive innate immune cell therapy  
P.I. Sherif S. Farag, MD, Ph.D.  
**Mentor:** Michael A. Caligiuri, M.D.  
Funding: \$225,000
- 07/01/99-03/31/03                    12) NCI/NIH **R01** CA65670-04  
Title: Devising Therapy for AIDS Central Nervous System Lymphoma  
P.I. Michael A. Caligiuri, M.D.  
Funding: \$1,066,999 (total direct)
- 03/01/01-02/28/03                    13) NCI/NIH **R21** CA91683  
Title: Novel Immune Modulation in AIDS and AIDS Malignancy  
P.I. Michael A. Caligiuri, M.D.  
Funding: \$662,344
- 10/01/98-9/30/02                    14) NCI/NIH **R21** CA81542-01  
Title: Natural Killer Cell Development and Function in HIV-1  
P.I. Michael A. Caligiuri, M.D.  
Funding: \$328,000
- 09/16/99-07/31/04                    15) NCI/NIH **7 U01** CA70079-02  
Title: Biologic Response Modifiers in AIDS Malignancies  
P.I. Michael A. Caligiuri, M.D. (9/99-12/02; transferred to Manisha Shah, MD)
- 04/01/00-03/31/03                    16) NCI/NIH **U10** CA31946  
P.I. Richard L. Schilsky –  
Subcontract PI: Michael A. Caligiuri, M.D.  
Title: CALGB Correlative Sciences In Leukemia and Lymphoma

**Grant Support (Terminated or Transferred to other PI) continued:**

- 07/01/01- 06/30/02                    17) NCI/NIH, **K01** Howard Tenin Award  
Title: Cytokines and NF- $\kappa$ B Regulation of Cancer Cachexia  
PI: Denis Guttridge, Ph.D.  
**Mentor:** Michael A. Caligiuri, M.D.
- 08/01/99-07/31/00                    18) Howard Hughes Medical Institute Medical Student Fellowship  
Title: Characterization of NK Cell Function in AIDS  
PI: Megan Cooper (OSU School of Medicine)  
**Mentor:** Michael A. Caligiuri, M.D.
- 12/01/97-11/30/00                    19) NIH **1R01** CA 71599-01  
P.I. Elizabeth Repasky, Ph.D.  
Title: Whole body hyperthermia & the anti-tumor immune response  
Role: Co-Investigator
- 07/01/95-06/30/00                    20) NIH **K11** Physician Scientist Award  
P.I. William E. Carson, III, M.D.  
Title: Interleukin 15 and Natural Killer Cell Immunity  
**Mentor:** Michael A. Caligiuri, M.D.
- 07/01/95-06/30/98                    21) Leukemia Society of America  
Title: *ALL1* Self Fusion: Targeting a Novel Molecular Mechanism  
of Leukemogenesis for Diagnosis, Prognosis, and Treatment  
P.I. Michael A. Caligiuri, M.D.
- 09/30/94-09/29/97                    22) NIH R01 CA65670-01  
Title: The Role of Cytokines in Lymphomagenesis of AIDS  
P.I. Michael A. Caligiuri, M.D.
- 09/30/95-09/29/97                    23) NIH R01 CA65670-02 - Minority Supplement  
Title: The Role of Cytokines and Lymphomagenesis of AIDS  
P.I. Michael A. Caligiuri, M.D.
- 08/01/96-07/31/97                    24) Howard Hughes Medical Institute Medical Student Fellowship  
Title: Characterization of NK Cell Function in AIDS Malignancies  
PI: Todd Fehniger SUNY **Mentor:** Michael A. Caligiuri, M.D.
- 08/01/92-07/31/96                    25) NIH 1R01 CA57974-01  
Title: EBV-Vaccination Assessed in SCID/Human Chimeras  
P.I. Richard Bankert, Ph.D., D.V.M.  
Participation: Co-Principal Investigator
- 04/01/95-03/31/96                    26) 7U10CA31964-14  
Title: Cooperative Group AIDS Malignancy Research  
P.I. Richard Schilsky, M.D.  
Participation: Section Principal Investigator

**Grant Support (Terminated or Transferred to other PI) continued:**

- |                   |  |
|-------------------|--|
| 07/01/90-06/30/95 | 27) NIH K11-CA01572 Physician Scientist Award<br>Title: Characterization of Thymic Derived Natural Killer Cells<br>P.I. Michael A. Caligiuri, M.D.<br>Terminated 9/94 when R01 was awarded |
| 06/15/91-07/31/93 | 28) The Dr. Louis Sklarow Memorial Fund Award<br>Title: Functional Characterization of a Novel Population of Human Lymphocytes<br>P.I. Michael A. Caligiuri, M.D.                          |
| 11/01/92-09/30/93 | 29) Cancer and Leukemia Group B/Chairman's Development Fund National Cancer Institute Award # CA31946-11, Co-P.I.<br>Title: The Leukemia Storage Facility                                  |
| 07/01/90-06/30/91 | 30) Buffalo Medical Foundation Grant   |
| 07/01/90-06/30/91 | 31) American Cancer Society Institutional Grant  |

**Awards and Honors:****National**

- |      |   |
|------|---|
| 2010 | NCI MERIT Award, National Cancer Institute  |
| 2010 | Eminent Lecture, The National Cancer Institute  |
| 2009 | Mario Baldini Visiting Professor, Harvard Med School-Beth Israel Hospital                   |
| 2008 | Election to Alpha Omega Alpha Honor Medical Society (as Faculty)                            |
| 2008 | John Wayne Clinical Research Award, Society of Surgical Oncologists                         |
| 2005 | Presidential Symposium (speaker), American Society of Hematology                            |
| 2004 | Election to the Association of American Physicians  |
| 2003 | Election as Fellow, American Association for the Advancement of Science                     |
| 1999 | Emil J. Freireich Award in Clinical Cancer Research, MD Anderson Cancer Center, Houston, TX |
| 1998 | Election to the American Society for Clinical Investigation                                 |
| 1998 | Election as Fellow, American College of Physicians  |

**State**

- |      |  |
|------|--|
| 2004 | American Cancer Society John P. Minton Hero of Hope Research Champion Medal of Honor Award |
|------|--|

**Institutional**

2011	Diversity & Inclusion Shining Star for Faculty Mentorship, The Ohio State University College of Medicine
2003	Sigmund Fidei, Saint Joseph's Collegiate Institute
2002	Distinguished University Scholar, The Ohio State University
1995	Commendation for Excellence in Teaching, SUNY at Buffalo School of Medicine
1988	Recipient of the Claudia Adams Barr Investigatorship in Cancer Research, Dana Farber Cancer Institute & Harvard Medical School
1980	Medical Alumni Scholars Program, Stanford University School of Medicine
1980	Summa Cum Laude, State University of New York (SUNY) at Buffalo
1977	Phi Beta Kappa, SUNY at Buffalo
1976	Undergraduate Research Grant from SUNY at Buffalo
1974	National Science Foundation, Summer Research Fellowship, Roswell Park
1974	Sidney Farber Award for Outstanding Achievement in Research, Roswell Park

**Clinical Responsibilities:**

1997-2003	Attending Physician Hematologic Malignancy Service, OSU
1997-2004	Director, Hematology/Oncology Fellowship Program, OSU
1990-1997	Attending Physician Hematologic Malignancy Service, Roswell Park

**Institutional and NCI-Sponsored Cooperative Group Protocols (PI or co-PI):**

2001	In-vitro Study of Antileukemic Activity of NK Cell Clones from Haplotype Mismatched Family Donors.
2001	CALGB 100102: A phase I/II Study of non-myeloablative conditioning followed by transplantation of "megadose" highly-purified haplotype mismatched CD34 cells and Induction of graft-versus-leukemia effect by KIR class I epitope-mismatched NK cells.
2001	Rituximab and Hu1D10 for post-transplant lymphoproliferative disorder (AIDS Malignancy Consortium)
2001	Phase I study of an Epstein-Barr virus (EBV) immunodominant peptide vaccine with or without adjuvant GM-CSF in prospective kidney transplant patients for prevention of EBV-associated post-transplant lymphoproliferative disorder.
2001	Gancyclovir and AZT for the treatment of primary central nervous system EBV+ lymphoma
2001	Soluble TNF receptor plus gemcitabine for advanced pancreatic cancer (Phase I/Institutional/Active)
2000	G3139 (BCL2 antisense) plus FLAG in refractory acute leukemia
2000	Stem Cell Factor (c-kit ligand) and Interleukin 2 in AIDS and AIDS malignancy
2000	Herceptin and interleukin 2 in relapsed/refractory breast cancer
2000	Rituximab and interleukin 2 in relapsed/refractory CD20+ malignancies
1999	Gancyclovir and AZT for the treatment of primary central nervous system EBV+ lymphoma
1997	CALGB 9720: Phase III study of MDR modulation with PSC-833 followed by immunotherapy with rIL-2 vs no further therapy in previously untreated patients with AML >60 years.
1996	CALGB 9620: Phase III study of MDR modulation with PSC-833 followed by immunotherapy with rIL-2 vs no further therapy in previously untreated patients with AML < 60 years.
1996	CALGB 9550 and AMC 003: Low Dose IL-2 Therapy in AIDS Lymphoma
1996	CALGB 9661: A Pilot Study of Low-Dose IL-2 Plus Recombinant Human Anti-Her2 Monoclonal Antibody in Solid Tumors

- 1995 Extended Low Dose Interleukin 2 Therapy: A Phase II Study of Subcutaneous Administration in patients with AIDS malignancies
- 1994 CALGB 9420: Phase I Evaluation of Modulation of MDR with PSC-833 in patients with AML  $\geq$  60 years followed by rIL-2, post-completion of chemotherapy
- 1993 Intermediate Dose Subcutaneous Pulse IL-2 Therapy: A Phase I Study in Patients Receiving Low Dose Subcutaneous IL-2
- 1992 Extended Low Dose Interleukin 2 Therapy: A Phase I Study of Subcutaneous Administration in patients with AIDS malignancies
- 1991 Extended Low Dose Interleukin 2 Therapy Following First Remission In Acute Myelogenous Leukemia

### **Contributions to National/International Professional Organizations:**

#### **Academic Advisory Boards/Cancer Center External Scientific Advisory Boards (ESAB)**

2011-	ESAB: Fox Chase Cancer Center
2011-	ESAB: Mayo Clinic Cancer Center
2010-	ESAB: Lymphoma Research Foundation (LRF)
2010-	ESAB: Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2009-	ESAB: (Chair) New York University Cancer Center
2009-	ESAB: University of Utah Huntsman Cancer Center
2008-	ESAB: Roswell Park Cancer Institute
2006-	P01 BMT Memorial Sloan Kettering Cancer Center (R. O'Reilly, PI)
2006-	ESAB: Cancer Institute of New Jersey
2005-07	ESAB: Boston University Cancer Research Center
2004-09	P01: "Targeted Therapies for Infant Leukemia", CHOP, (C. Felix, PI)
2004-	ESAB: (Chair) University of California at Irvine
2004-	ESAB: University of Chicago Cancer Center
2004-	ESAB: Case Western Reserve University Ireland Cancer Center
2004-	ESAB: (Chair) University of Puerto Rico Cancer Center
2003-08	ESAB: (Chair) University of Maryland Greenbaum Cancer Center
2003-07	ESAB: Penn State Cancer Center
2003-07	ESAB: San Antonio Cancer Institute
2002-2011	ESAB: Georgetown University Lombardi Cancer Center
2001-07	Chair, U54 University of Puerto Rico and The MD Anderson Cancer Center: Partners in Excellence for Cancer (G. Berenstein, PI)
2001-04	Program Project "Cell Survival and Cancer", Kimmel Cancer Center
2001-06	Program Project "Leukemia", Dana Farber Cancer Institute
2000-04	Cure For Lymphoma Foundation (Co-Chair, Scientific Advisory Board)
1995-97	Association for Research of Childhood Cancer

#### **American Association of Cancer Research (AACR)**

2011-	Member, Council of Scientific Advisors
2011-	Member, Steering Committee for Clinical and Translational Cancer Research
2011-	Member ex officio, Finance and Audit Committee
2011	Member, Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research Scientific Review Committee
2011	Chair, Search Committee for Editor-in-Chief, <i>Molecular Cancer Therapeutics</i>
2008-11	Member, Cancer Immunology Steering Comm Working Group
2008-09	Program Chair, 100 <sup>th</sup> Annual Meeting
2005-07	Chair, Search Committee for Editor-in-Chief, <i>Cancer Research</i>
2009	Chair, Search Committee for Editor-in-Chief, <i>Clinical Cancer Research</i>
2004-05	Chair, 2005 Scientists-Survivor Workshop
2004	Rosenthal Award Clinical Cancer Research Awards Committee
2003-	Chair, Publications Committee
2000-	Member, Publications Committee
2003	Chair, Immunology Subsection B AACR Program Committee



2002	AACR Meeting Chair and Conference Organizer AACR-NCI-EORTC Conference, "Molecular Targets and Cancer Therapeutics Frankfurt, Germany.
2002-07	AACR/ASCO Workshop: Methods in Clinical Cancer Research
2001	Member, Scientific Committee AACR-NCI-EORTC conference
2001-04	Member, Science Policy and Legislative Affairs Committee (SPLAC)
2000-02	Associate Editor, <i>Cancer Research</i>
2000-04	Scientist-Survivor Program
1999	Chair Immunology Subsection B, AACR Program Committee
1998	Member, Rosenthal Foundation Award Committee
1998	Chair, Membership Committee
1997-98	Member, Membership Committee
1996-99	Program Committee
1996	Chair, Clinical Molecular Oncology Section, Program Committee
1996	Chair, Scientific Program on Cytokines in Tumor Immunobiology

#### American Cancer Society (Ohio)

2000	Member, Public Issues Committee
1999	Member, Nominating Committee
1998	Board of Trustees
1994	Committee on Immunology (Ad Hoc-national)

#### American Society of Clinical Oncology

2002-04	Grants Selection Committee for Young Investigator and Clinical Research Career Development Awards
1997	Subcommittee Chair/Immunobiologic and Biologic Therapy
1997-2000	Education Committee
1996-2001	Publications Committee
1994	Program Committee
1994	Cancer Biology/Immunology Committee

#### American Society of Hematology

2011-2015	Elected Councillor
2011-2015	Member, Executive Committee
2011-	Member, Clinical Research Training Institute (CRTI) Oversight Subcommittee
2008-2011	Member, Awards Committee
2005	Invited Speaker, Presidential Symposium
2005	Co-Chair Scientific Program
2003-2006	Audit & Investment Finance Committee
2001	Invited Special Education Session at ASH Meeting (Lymphocyte biology)
1999-2001	Reviewer for abstracts: Acute Leukemia Clinical Investigation

#### Association of American Cancer Institutes

2009-2011	President
2007-2009	Vice President (President elect)
2005-2011	Member, Board of Directors

#### Cure for Lymphoma Foundation

2000-2004	Vice Chair, Scientific Advisory Board
-----------	---------------------------------------

#### Damon Runyon Cancer Research Foundation

2011-	Member, Damon Runyon-Rachleff Innovation Award Review Committee
-------	---

#### Friends of Cancer Research

2011-	Friends FDA Advisory Committee
2011-	Friends Comparative Effectiveness Research (CER) Advisory Committee

**Howard Hughes Medical Institute**

2001 Ask a Scientist Program  
 1997, 2000 Medical Student Mentor

**Institute of Medicine**

2011 Member, IOM National Cancer Policy Forum, Panel on Facilitating Collaborations  
 to Develop Combination Investigational Cancer Therapies  
 2009-11 Member, IOM National Cancer Policy Forum

**Leukemia Society of America**

1997-03 Medical and Scientific Affairs Committee  
 2000-03 Member, Young Investigator Award Review Committee

**Lymphoma Research Foundation**

2010- Member, Board of Scientific Advisors

**National Cancer Institute**

2009- Member, National Cancer Advisory Board Ad Hoc Working Group  
 2008- Member, Board of Scientific Advisors  
 2006-08 Member, Board of Scientific Counselors for Clinical Sciences/Epi  
 2005-06 Co-Chair, Adolescent & Young Adult Oncology Progress Review Group  
 2005-07 Member, Translational Research Working Group  
 2005 Reviewer, Special Emphasis Panel (LRP-30 and LRP-40)  
 2001-04 Member, IRG-A (CCC Parent) Committee  
 2000-01 Member, Experimental Immunology Study Section (elected early resignation)  
 1999 Reviewer Committee RFA AI-98-001, Human Immunology Centers of Excellence  
 1998 Member, National Comprehensive Cancer Network, Lymphoma Panel 1996  
 Invited Speaker, Developmental Diagnostics Working Group  
 Meeting on the Development of Clinical Resources  
 1996 Ad hoc reviewer, Committee for RFA CA-96-009, Immunobiology  
 of AIDS Lymphoma  
 1994 Ad hoc reviewer, Committee for Breast Cancer Research. (3/1/95)  
 1994 NIH Site Review Committee, Memorial Sloan Kettering, Cancer  
 Chemotherapy Program Project (June 6-8, 1994)  
 1994 Ad hoc reviewer, Committee for RFA CA-92-98, Clinical Trials of Cancer

**National Institute of Allergy and Infectious Disease**

1999 Ad hoc reviewer, Committee Human Immunology Ctr of Excellence  
 1991 Ad hoc reviewer, Committee on Chronic Fatigue Syndrome

**Pelotonia**

2008 Co-founder  
 2008- Member, Board of Directors

**Prologue**

2003-2009 Member, Board of Directors  
 2005-2009 Member, Compensation Committee

**Society for Natural Immunity**

2011- Member, Scientific Advisory Committee for the 2012 Annual Meeting of the  
 Society for Natural Immunity  
 2002 Meeting Chairman, 19<sup>th</sup> International Natural Killer Workshop  
 and 7<sup>th</sup> Annual Meeting of the Society for Natural Immunity

**Transplantation Society**

1996-1997 Organizing Committee-Basic Sciences Symposium

**United States of America President's Cancer Panel**

2004 Host, The Ohio State University  
 1994 Invited speaker, AIDS Malignancy

**USA National Cancer Institute-Sponsored Cooperative Oncology Group**

Cancer and Leukemia Group B (CALGB)  
 1999- Member, Board of Directors  
 1999-2011 Chair, Leukemia Correlative Science Committee  
 1996-1999 Chair, AIDS Malignancy Working Group (CALGB)  
 1996-1999 Member, Correlative Sciences, Leukemia and Lymphoma Committee  
 1994 -1996 Vice Chair, CALGB Pharmacology & Exper Therapeutics (PET) Comm  
 1994 Head, Biologics Subcommittee

**New York State:**

1992-1997 Member, New York State Stem Cell Committee  
 1991-1997 Member, Governor's Council on Transplantation

**University Service:**

**Ohio State University**

2011- Member, Davis Heart and Lung Research Institute Internal Advisory Board Committee, OSU  
 2008- Member, Medical Center Executive Committee, OSU  
 2008- Member, President's Council, OSU  
 2008- Member, James Cancer Hospital Foundation Board, OSU  
 2008- Co-Chair, Medical Center Coordinating Council, OSU  
 2007-08 Member, Medical Center Coordinating Council, OSU  
 2007 Member, Health Science Coordinating Council, OSU  
 2005-06 Member, Pediatrics Chair Search Committee, OSU  
 2005-07 Member, Agenda Committee, OSU  
 2005 Member, Strategic Planning Implementation Committee, OSU  
 2004-08 Member, Research Resource Coordinating Committee, OSU  
 2004- Member, Professional Affairs Committee, James Institute Board, OSU  
 2004- Vice Chair, Personnel Committee, James Institute Board, OSU  
 2004- Co-Chair, Project Cancer Steering Committee, OSU  
 2004-06 Member, Chief Information Officer Search Committee, OSU  
 2003- Member, James Cancer Hsp & Solove Research Institute Board, OSU  
 2002- Member, Research in the Investment Fund Committee, OSU  
 2003- Vice President for Health Science-Cancer Programs  
 2003- Member, Strategic Planning Committee, OSU  
 2003-07 Member, Medical Center Executive Committee, OSU  
 2003-04 Chair, Pathology Chair Search Committee, OSU  
 2002 Advisory Committee, University Vice President for Research, OSU  
 2002 Member, Strategic Planning Subcommittee, College of Medicine, OSU  
 2001 Member, Biomedical Research Plan Committee (Mech of Health and Disease)  
 2000 Member, Biomedical Engineering Faculty Search Committee, OSU  
 1997- 2005 Member, Practice Plan Committee, Dept. Internal Med, OSU  
 1999-2004 Member, Promotion & Tenure Advisory Comm, Dept. Internal Med, OSU  
 1999 Ad hoc Presidential Committee for Study of Medical School Practice Plan  
 1998-2001 Member, Biomedical Science Human Subject Committee IRB, OSU  
 1998-2002 Member, Appointment, Promotion & Tenure Advisory Committee, OSU  
 1998 Member, Internship Recruitment Committee, OSU  
 1998 Academic Enrichment Proposal Reviewer, OSU

1998-	Member, Institutional Post-M.D. Internal Review Committee, OSU
1998	Member, Search Committee for Psychiatry Chair, OSU
1997	Member, Search Committee for Anatomic Pathology Director, OSU
1997-0	Member, Faculty Committee on Patents and Copyrights, OSU
1997-	Member, Medical Scientist Training Program (MSTP), OSU
1997-2007	Member, Dept of Medicine Finance Committee

#### **OSU Comprehensive Cancer Center (OSUCCC) or Division of Hematology/Oncology, OSU**

2003-	Chair, OSUCCC Executive Committee
1997-2003	Associate Director for Clinical Research, OSUCCC
1997-2003	Director, Immunology Program, OSUCCC
1998-1999	Interim Co-Director, Experimental Therapeutics Program, OSUCCC
1998-1999	Member, Clinical Scientific Review Committee, OSUCCC
1998-2004	Co-Chair, Space Committee, OSUCCC
1996	Co-Chair, Award Committee, OSUCCC
1997-2007	Head, Finance Committee, Division of Hematology/Oncology
1997-2004	Director, Fellowship Program, Division of Hematology/Oncology
1997-	Member, Executive Committee, OSUCCC
1997-	Member, Research & Planning Committee, OSU
1997-2004	Member, PA/PCRM/NP, OSU

#### **State University of New York at Buffalo**

1995-97	Member, Committee for Appointment and Promotion to Research Ranks, S.U.N.Y./Buffalo School of Medicine
1993	Member, Ad Hoc Planning Committee for Faculty Development and Enhancement, Dept. of Medicine, S.U.N.Y./Buffalo School of Medicine
1992	Member, Medical School Faculty Council Committee's Affiliated Institutions, Clinical Affairs and Graduate Medical Education Committee, S.U.N.Y./Buffalo School of Medicine
1991-1997	Member, S.U.N.Y./Buffalo School of Medicine Medical Scientist Training Program (MSTP) Steering Committee
1990-1997	Member, S.U.N.Y./Buffalo School of Medicine Student Research Committee Evaluation and Sponsorship of Medical Student Research

#### **Roswell Park Cancer Institute**

1996-1997	President, Medical Staff, RPCI
1996-1997	Member, Scientific Staff Cost Containment Committee, RPCI
1996-1997	Elected Representative, Counsel of the Association of Scientists, RPCI
1996-1997	Member, Sponsored Program Committee, RPCI
1993-1996	Vice President, Medical Staff, RPCI
1993-1997	Member, Quality Assurance Committee, RPCI
1991-1997	Member, BRSG Grant Review Committee, RPCI
1991-1997	Member, American Cancer Society Inst. Research Grant Committee
1991-1997	Member, Farber Award Committee for the College and High School
1990-1997	National Science Foundation Summer Research Award Recipients, RPCI
1990-1997	Member, Infectious Disease Search Committee, RPCI
1990-1997	Member, Bone Marrow Transplant Unit Building Committee, RPCI

#### **Brigham and Women's Hospital**

1984-1986	Member, Free Care Committee, Brigham and Women's Hospital
1986	Member, Internship Selection Committee, Brigham and Women's Hospital

#### **Stanford University Medical School**

1980-1982	Member, Stanford University Medical School Admissions Committee
-----------	---

#### **Community Participation:**

2009	Invited Speaker, Multiple Myeloma Opportunities for Research & Education
2008-	Co-founder, Pelotonia, grass roots biking event thus far raising \$22M for cancer
2004	Invited Speaker for Columbus Rotary Club, Columbus, Ohio
2002, 03	Invited Speaker for Mirrors Induction Ceremony, OSU
2001	Invited Speaker for Rotary Club, Marion, Ohio
2000	Invited Speaker for Leukemia & Lymphoma Society, Light The Night Walk
2000, 01, 02	Invited Speaker for American Cancer Society's Holiday Reception
1999	Invited Speaker for ACS/Babe Zaharias Classic Golf Banquet
1999	Invited Keynote Speaker for OSU/ACS Relay for Life Fundraiser
1998	Invited Speaker for American Cancer Society's Holiday Reception
2000	Invited Keynote Speaker for Science in the Cinema "Acute Leukemia"
1996	Invited Keynote Speaker for Roswell Park's Cancer Survivor Day
1996	Invited Speaker Leukemia Society of America Board of Trustees Meeting
1994, 96, 97	Speaker at Telethon, Leukemia Society of America
1987-1988	Member, American Cancer Society/Brookline Division

**Editorial Boards:**

2010-	Oncology Times
2002-	Blood (Associate Editor)
2001-	Blood Reviews
2001-05	Molecular Cancer Therapeutics
2000-03	Cancer Research
2000-02	Biomedical Microdevices: BioMEMS and Biomedical Nanotechnology
1996-02	Journal of Clinical Immunology
1996-99	Cancer Immunology & Immunotherapy
1996-2006	Clinical Cancer Research

**Professional Memberships:**

2011-	Member, The Ohio State Medical Association
2008-	Member, Alpha Omega Alpha Honor Medical Society
2004-	Member, Association of American Physicians
2003-	Fellow, American Association for the Advancement of Science
1998-	Fellow, American College of Physicians
1998-	Member, American Society for Clinical Investigation
1997-1999	Member, The Transplantation Society
1997-	Member, The American Association of Immunology
1992-	Member, The Society for Natural Immunity
1992-2005	Member, The Society for Hematology and Stem Cells
1991-	Member, American Society of Clinical Oncology
1990-	Member, American College of Physicians
1990-	Member, American Society of Hematology
1990-	Member, American Association for Cancer Research

**Journal Referee (Partial listing):**

Blood	Journal of Experimental Hematology
Cancer Research	American Journal of Hematology
Journal of Experimental Medicine	Clinical Cancer Research
Journal of Clinical Investigation	Leukemia
Journal of Clinical Oncology	Cancer Cell
Nature	Journal of Immunology
Nature Medicine	BioTechniques
New England Journal of Medicine	European Journal of Immunology
Proceedings of the National Academy of Science	Nature Immunology

**Teaching (See also: Lectures at the Ohio State University):**

**Teaching Responsibilities:**

1997-04	Director, Fellowship Program, Division of Hematology/Oncology
1998	Physical Exam Preceptorship, OSU
1997-99	Coordinator, CCC Medical Grand Rounds, OSU
1997-02	Coordinator, Hematology/Oncology Fellowship Course, OSU
1993-97	Coordinator, Medical Grand Rounds, RPCI
1991-94	Coordinator, SUNY/Buffalo School of Medicine 3 <sup>rd</sup> Year Teaching Elective in Medical Oncology

**Current Laboratory Students:** (\* indicates M.A. Caligiuri as principal mentor for degree)

<b>NAME</b>	<b>TYPE OF STUDENT</b>	<b>FIELD OF STUDY</b>
Il-Kyoo Park, PhD	Postdoctoral	NK Cell Biology
Anjali Mishra, PhD	Postdoctoral	NK Cell Biology/IL-15 Immunobiology
Kelsie Bernot, PhD	Postdoctoral	AML
Susan Schmidt	Doctoral* <sup>†</sup>	NK Cell Biology
Edward Briercheck	Doctoral* <sup>†</sup>	NK Cell Biology
Nicholas Zorko	Doctoral* <sup>†</sup>	AML
Maura Muñoz	Medical Student	AML
Christine Hwang	Undergraduate	NK Cell Biology
Lauren Falkenberg	Undergraduate	NK Cell Biology
Ronald Siebenaler	Undergraduate	AML
Nicholas Harrison	Undergraduate	NK Cell Biology
Gabriele Marcucci	Undergraduate	AML
Laura Sullivan	Undergraduate	NK Cell Biology
Nnamdi Kalu	Undergraduate	NK Cell Biology
Srirama Josyula	Undergraduate	NK Cell Biology
Tyler Cole	Undergraduate	NK Cell Biology
Jordan Cole	Undergraduate	NK Cell Biology
Daniel Yanes	Undergraduate	AML

<sup>†</sup> in the combined MD/PhD program or the combined DVM/PhD program.

**Student Awards to Members of the Caligiuri Laboratory:**

Aderotimi Ajayi	1997-1998 Arthur Alfonso Schomburg Graduate Fellowship Award 1995-1997 Recipient of R01 Minority Supplement Award
Michael Ament	1997 Third Honors at SUNY/Buffalo School of Medicine Student Research Forum
Robert Baiocchi, MD/PhD	1998 Recipient ASH Medical Student Scholarship Award 1998 Landacre Day Student Research Forum Oral Abstract Presentation, OSU 1998 Recipient ASH Travel Award, OSU 1996 American Society of Hematology Summer Medical Student Scholar Award
Brian Becknell, MD/PhD	2008 College of Medicine MD/PhD Medical Scientist Program, OSU 2008 College of Medicine Medical Scientist Award, OSU 2008 Grant Morrow III, MD Award Dept of Pediatrics, OSU
Don Benson, MD	2005 Recipient of a T32 NIH Postdoctoral Training Award 2006 ASCO Young Investigator Award 2006 ASCO Merit Award 2009 ASCO Career Development Award 2009 American Cancer Society Pilot Grant 2009 CLL Global Research Foundation grant 2009 Multiple Myeloma Research Foundation Fellow's Award 2009 Business First Forty Under 40 Award 2010 DiscoverMMORE award 2010 Leukemia and Lymphoma Society Chairman's Citation Award 2010 Pelotonia IDEA Grant 2010 Department of Medicine Mentor of the Year Award
Kelsie M. Bernot, PhD	2009-2011 Recipient of a T32 NIH Postdoctoral Training Award, OSU

Brad Blaser, MD/PhD	2010 Travel Award, The Ohio State University Medical Center Trainee Research Day 2011 Travel Award, The Ohio State University Medical Center Trainee Research Day 2008 Recipient of the Dept of Internal Medicine Research Award, OSU 2008 College of Medicine Medical Scientist Award, OSU 2008 College of Medicine MD/PhD Medical Scientist Program, OSU
Eric Bluman, MD/PhD	1995 Recipient of The Rockefeller Univ. Award Eastern Research Forum 1994 First Honors at SUNY/Buffalo School of Medicine Student Research Forum
Edward Briercheck	2011 Recipient of Pelotonia Predoctoral Research Fellowship, OSU
Marie Louise Caligiuri-de Jesús	2007 McGraw-Hill for outstanding research, Central Ohio (High school) 2007 First Place, Biology Teachers Award, State of Ohio (High school) 2007 First Place, Future Physician-Scientist Award, State of Ohio (High school) 2007 Fourth Place for Science and Medicine, International INTEL ISEF Competition 2006 First Place, Microbiology Award, State of Ohio (High school)
William Carson, MD	1998 Recipient of the V Foundation Scholar Award 1995 Recipient of the ASCO Young Investigator Award 1995 Recipient of NIH K-11 Physician Scientist Training Grant
Jason Chandler, MD	2008 Recipient of a T32 NIH Postdoctoral Training Award
Anita Chong	2007 The Cohen Scholarship, OSU
Shauna Collins	2011 Third Place, Denman Undergraduate Research Award, OSU
Megan Cooper, MD/PhD	2004 Recipient of the OSU Medical Scientist Student Award 2002 Recipient of American Medical Women's Association Carroll L. Birch Award 2001 Recipient of first prize Oral Presentation, Vet School annual competition 2001 American Society Hematology Summer Medical Student Scholar Award 1999 Recipient American Society Hematology Travel Award, OSU 1999 Recipient of Howard Hughes Medical Student Fellowship Award 1997-2000 Landacre Day Student Research Forum Oral Abstract Presentation, OSU 1998 Recipient of Bertha Bouroncle Fellowship Award (Student Honors)
Amber Costan	2005 OSU Honors Undergraduate Student Research Fellowship
Adrienne Dorrance	2005 Recipient of International Lady Tata Memorial Trust Research Award in Leukemia 2006 Recipient of International Lady Tata Memorial Trust Research Award in Leukemia
Charles Eisenbeis MD/PhD	2002 NCI K08 Award 2000 Cure for Lymphoma Fellowship Award
Lauren Falkenberg	2010-11 NCI R01 Minority Supplement Award
Todd Fehniger, MD/PhD	2002 Recipient of the Physician Scientist Award, OSU Graduation 2000 Recipient of the Huang Award from American Association of Immunology 2000 First Honors, Research Year 4 MVIMG Graduate Research Forum 2000 American Society of Hematology Summer Medical Student Scholar Award 2000 Landacre Day Student Research Forum Oral Presentation, OSU 1999 Recipient ASH Travel Award, OSU 1999 Landacre Day Student Research Forum Poster Abstract Presentation, OSU 1996 Recipient of Howard Hughes Medical Student Fellowship Award 1995 First Honors at SUNY/Buffalo School of Medicine Student Research Forum
Aharon Freud, MD/PhD	2008 Phi Delta Epsilon Medical Fraternity Award, OSU 2008 College of Medicine MD/PhD Medical Scientist Program, OSU 2008 Emmerich von Haam Pathology Award, Dept of Pathology, OSU
Yoonhee Ha	2007 <i>USA Today</i> All-USA College Academic First Team 2007 Marshall Scholar, London School of Hygiene & Tropical Medicine, Univ of London 2006 Harry S. Truman Scholarship, US Government.
Nicholas Harrison	2011 First Place, Denman Undergraduate Research Award, OSU 2011 Brazil Research Exchange Travel Award
Michael Jaung	2006 Finalist, Denman Undergraduate Research Award, OSU
Chidimma Kalu	2009 NCI R01 Minority Supplement Award
Seth Karol, MD	2008 Phi Delta Epsilon Medical Fraternity Award, OSU 2008 Pediatrics Dept Chairman's Award, OSU
Kerry Katz	2004 OSU Honors Undergraduate Student Research Scholarship
Vijay Khatri, MD	1998 Best Research Paper, Oncology Fellowship Programs

	1997 Best Research Paper, Oncology Fellowship Programs
	1996 Best Research Paper, Oncology Fellowship Programs
Daniel Kim	2004 Honors Undergraduate Research Scholarship, OSU
Peter Kourlas, MD	2000 James V. Warren Award - Most Outstanding Research Fellow Dept.of Int. Med.
	1998-1999 National Cancer Institute Oncology Training Grant (T-32)
Teresa Lin	2004 Honors Undergraduate Research Scholarship, OSU
Patricia Lugar	1997 Third Honors at SUNY/Buffalo School of Medicine Student Research Forum
Guido Marcucci, MD	2001 NCI K08 Award
	1998 Recipient of American Cancer Society Cancer Research Fellowship
	1997 National Cancer Institute Oncology Training Grant (T-32)
Anjali Mishra, PhD	2011 Recipient of a Farber Travel Award for Young Investigators from the 60 <sup>th</sup> Annual Montagna Symposium on the Biology of the Skin
Maura Muñoz	2011 American Society of Hematology, Minority Medical Student Award
	2011 Recipient of Samuel J. Roessler Memorial Scholarship Fund, OSU
M. Nazareth, MD/PhD	1996 Roswell Park Cancer Institute Sidney Farber Award for Excellence
Myntee Ngangana	2010 American Society of Hematology, Minority Medical Student Award
Adam Oberkircher	1994 Roswell Park Graduate Research Forum Award
Il-Kyoo Park	OSU Award
Laura Rush, DVM/PhD	2002 NCI K08 Award
	2001 First Place, Molecular and Cellular Biology category, Veterinary Research Day
Mary E. Ross, PhD	1997 First Honors SUNY/Buffalo School of Medicine Student Research Forum
	1994-1995 Roswell Park Graduate Research Forum Award
	1994 American Women in Science Graduate Student Award
	1994 American Society of Clinical Oncology Merit Award
Susan Schmidt	2007-2008 University Fellowship, Ohio State University
	2008 Travel Award Recipient, OSUMC Research Day, Ohio State University
	2008 Medical Scientist Program Scholarship for Leadership, Ohio State University
	2009 MD/PhD Scientific Achievement Travel Award Recipient, Ohio State University
	2010 Travel Award Recipient, American Physician Scientist Association
	2011 Second place winner for Professional Biological Sciences Oral Presentations, Hayes Graduate Research Forum, Ohio State University
	2011-2012 Presidential Fellowship, Ohio State University
Ronald Siebenaler	2010-2011 Recipient of Pelotonia Undergraduate Research Award, OSU
Gregory L. Seidensticker	1998 Recipient of Samuel J. Roessler Memorial Scholarship Fund, OSU
Matthew Strout, MD/PhD	1999 Elected President of the Landacre Honor Society
	1999 Recipient of ASH Medical Student Scholarship Award, OSU
	1998 Recipient of Samuel J. Roessler Memorial Scholarship Fund, OSU
	1997 Recipient of ASH Travel Award, OSU
	1995-6 Recipient of Lady Tata Memorial Trust Resrch Intern. Award in Leukemia
Anna Tulchinsky	2006 Recipient of Samuel J. Roessler Memorial Scholarship Fund, OSU
Matthew Turner	1998 Recipient of the Undergraduate Research Scholarship, OSU
Katherine Tzou	2004 Best Poster, 3 <sup>rd</sup> Annual Graduate & Postgraduate Research Day, OSU
	2003 First Place, Denman Undergraduate Research Award, OSU
Jeff Vandeusen, MD/PhD	2001 American Society Hematology Summer Medical Student Scholar Award
	2000 Landacre Day Student Research Forum Poster Abstract Presentation, OSU
Srinu Vourganti	2001 Recipient of Samuel J. Roessler Memorial Scholarship Fund, OSU
Modi Wetzler	1998 Recipient of the Barry Goldwater Scholarship
Jackie Ward, MD/PhD	2000 National Cancer Institute Oncology Training Grant (T-32)
Susan Whitman, PhD	2002 NCI K01 Award
	2002 General Motors Junior Faculty Grant
	2001 James V. Warren Award - Most Outstanding Research Fellow Dept.of Int. Med.
	1999 & 2000 National Cancer Institute Oncology Training Grant (T-32)
	1998 Recipient of the Ladies Auxiliary to the Veterans of Foreign Wars
Daniel Yanes	2010-2012 Pelotonia Fellowship
Renuka Yeldandi	1999 Recipient of Samuel J. Roessler Memorial Scholarship Fund, OSU
Nicholas Zorko	2009-2010 Recipient for T32 NIH Predoctoral Fellowship, OSU



2011 Recipient Pelotonia Predoctoral Research Fellowship, OSU  
2010 Recipient of ASH Travel Award

**Former Caligiuri Laboratory Students:** (\* indicates M.A. Caligiuri as principal mentor for degree)

<b>Name</b>	<b>Position</b>	<b>Years</b>	<b>Subsequent Position</b>
Tiffan Hughes, PhD	Doctoral*	05-11	Postdoctoral Fellow
Takeki Mitsui, MD/PhD	Postdoctoral	06-09	Assistant Professor Gumna University, Japan
Jianhua Yu, PhD	Postdoctoral	05-08	Assistant Professor, OSU
Chiara Giovenzana	Visiting Doctoral	06-07	Postdoctoral Fellow, Unimore, Italy
Jessica Dal Col	Visiting Doctoral	06-07	Postdoctoral Fellow, Unimore, Italy
Don Benson, MD/PhD	Postdoctoral	04-06	Assistant Professor, OSU
Margaret Germain	Undergraduate	2008	OSU School of Medicine
Adrienne Dorrance	Doctoral*	2008	Postdoc, Harvard Boston Children's Hospital
M. Brian Becknell	Doctoral*	2006	Resident Columbus Children's (Pediatrics)
Aharon G. Freud	Doctoral*	2006	Resident Stanford (Pathology)
Bradley Blaser	Doctoral*	2006	Resident Harvard (Medicine)
Sameek Roychowdhury	Doctoral*	2005	Resident, University of Michigan (Medicine)
Jeff VanDeusen	Doctoral*	2005	Resident, Duke University (Medicine)
Akihiko Yokohama, MD/PhD	Postdoctoral	04-06	Assistant Prof Med, Gunma Univ, Japan
Wei Ding, MD/PhD	Postdoctoral	02-04	Resident, Mayo Clinic Rochester, MN (Medicine)
Rebecca Bruner, MD	Postdoctoral	01-04	Assistant Professor, OSU
Robert Baiocchi, MD/PhD	Postdoctoral	01-04	Assistant Professor, OSU
Martin Guimond, PhD	Postdoctoral	02-04	NIH Postdoctoral Fellow
Marta Calvacanti, MD/PhD	Postdoctoral	02-03	Assistant Prof, Univ of Rio de Janeiro
Megan Cooper MD/PhD	Doctoral*	98-02	Resident in Pediatrics, Wash U
Jackie Ward, MD/PhD	Postdoctoral	01-02	OSU Internal Medicine (Physician)
Susan Whitman, PhD	Postdoctoral	99-01	Research Scientist, OSU
Sorin Florea, MD	Postdoctoral	00-01	Resident, Kettering Medical Center
Charles Eisenbeis, MD/PhD	Postdoctoral	99-00	OSU Internal Medicine (Asst. Prof)
Peter Kourlas, MD	Postdoctoral	98-00	Riverside Methodist Hospital Private Practice
Maggie O'Brien, DVM	Doctoral	99-00	Practicing Veterinary Medicine
Ruoqi Peng, MD	Postdoctoral	97-00	Merck Pharmaceuticals (Research Associate)
Haixin Yu, MD	Postdoctoral	94-99	Schering Plough (Research Associate)
Kazuhiro Suzuki, MD	Postdoctoral	97-99	Professor & Chair of Urology, Gunma, Japan
Manisha Shah, MD	Postdoctoral	95-98	Assistant Professor, OSU
Guido Marcucci, MD	Postdoctoral	95-98	Assistant Professor, OSU
Li Yu, M.D., PhD	Postdoctoral	96-98	Prof & Dir, BMT General Hospital of PLA, Beijing
Vijay Khatri, MD	Postdoctoral	96-97	Assistant Professor Surgical Oncology UC/Davis
Feng Hua, MD	Postdoctoral	96-97	S.U.N.Y. at Buffalo, Res. in Neurology Prog.
Feng Yu, MD	Postdoctoral	96-97	Family Practice Residency, Maine
Michael Nazareth, MD/PhD	Postdoctoral	96-98	S.U.N.Y at Buffalo, Dermatology Resident
William Carson, MD	Postdoctoral	93-95	Assistant Professor, OSU
Jesper Jurlander, MD	Postdoctoral	94-96	Assistant Professor, Univ.of Copenhagen
Ewa Mrozek, MD	Postdoctoral	94-96	Assistant Professor, OSU
Gregory Schnier, MD	Postdoctoral	93-94	Univ. of Kentucky (Surgery Resident)
Mary Beth Ross	Ph.D.*	1996	Assistant Professor Children's Hospital Columbus
Eric Bluman	Ph.D.*	1996	Orthopedics Resident, Brown University
Robert Baiocchi	Ph.D.*	1995	Assistant Professor, OSU
Matthew Strout	Ph.D.*	1997	Yale Residency/Fellow in Heme/Onc
Todd Fehniger	Ph.D.*	2000	Wash U Residency/Fellow in Heme/Onc
Lan Feng	M.S.	2000-01	Scientist, Genentech, San Francisco
Julie Dierksheide	M.S.	1999	Medical School, Ohio
John Spindler	M.S.*	1997	Physician Asst. Program Applicant
Daryl Schiller	M.S.*	1997	Physician Asst. Program Applicant
Grace Barresi	M.S.*	1996	Physician Asst. MD Anderson Cancer Ctr
Patricia Lugar	M.S.*	1996	S.U.N.Y./Buffalo School of Medicine

Shilpi Tanden	M.S.*	1996	Roswell Park Cancer Institute
Adam Oberkircher	M.S.*	1996	Daemen College, Physician Asst. Program
Melanie Marien	M.S.*	1996	Daemen, Physician Asst. Program
Matthew P. Strout	M.S.*	1996	OSU School of Medicine
Michelle Porter	M.S.*	1995	Yale Univ., Physician Asst. Program
Joseph Loftus	M.S.*	1994	St. George School of Medicine
Florian Penetrante	M.S.*	1993	N.Y. School of Osteopathic Medicine
Robert Baiocchi	M.S.*	1993	OSU College of Medicine
Cheryl Russo	Honors Program	1996	S.U.N.Y./Syracuse School of Medicine
Seth Karol	B.S.	2006	Ohio State University College of Medicine
Jennifer Bush	B.S.*	2002	Toledo College of Medicine
Brian Carlson	B.S.	2001	Ohio State University
Matthew Turner	B.S.	1999	Univ of Cincinnati School of Medicine (MD/Ph.D)
Renuka Yeldandi	B.S.	1999	Ohio State University College of Medicine
Gregory L. Seidensticker	B.S.	1998	Ohio State University College of Medicine
Brian Ruiz de Luzuriaga	B.S.	1998	Duke University Medical School
Elizabeth Stover	B.S.	1998	Harvard Medical School (MD/PhD)
Ronnie Freud	B.S.	1998	University of Wisconsin, then OSU MD/PhD
Adertomi Ajayi	B.S.	1997	Meharry Medical College
Daniel Stover	Independent Study	1999	Princeton University
Joyce Anderson	Independent Study		S.U.N.Y./Buffalo School of Medicine
Heena Sultan	Independent Study		S.U.N.Y./School of Medicine
Thomas Caprio	Independent Study		S.U.N.Y./Buffalo School of Medicine
Anthony Caprio	Independent Study		S.U.N.Y./Buffalo School of Medicine
Lawrence Jacobs	Independent Study		Georgetown School of Medicine
Ravi Srivastava	Independent Study		Vanderbilt School of Medicine
Michael Matos	Independent Study		Johns Hopkins Medical School
Edward Trabulsi	Independent Study		S.U.N.Y./Buffalo School of Medicine
Mauritis Boon	Independent Study		S.U.N.Y./Buffalo School of Medicine
Gregory Nagel	Independent Study		S.U.N.Y./Buffalo School of Medicine
Joseph Marine	Independent Study		U.C.S.F. School of Medicine
Julie Beudet	Independent Study		Univ. of Montreal School of Medicine
Teresa Caligiuri	Independent Study		S.U.N.Y./Buffalo School of Medicine
Kenneth Eckhardt	Independent Study	1996	Newfoundland School of Medicine
Anand Ponnappan	Independent Study	1999	Residency in Otolaryngology, Univ. of Colorado
Srinu Vourganti	Independent Study	2000-02	MD, Ohio State University College of Medicine
Viswam Nair	Independent Study	2000-01	MD, Ohio State University College of Medicine
Andrew Khouri	Independent Study	2002	Harvard University
Chidimma Kalu	Independent Study	2009	MD, Ohio State University Collage of Medicine
Tatianna Witte	Independent Study	2006	DDS, UCLA School of Dentistry, second year student

## Publications

### Original Peer-Reviewed Reports

1. Lewiston N, Robin ED, Hance AJ, Simon LM, **Caligiuri MA**, Robin DA, Theodore J: Prolonged diving and recovery in the freshwater turtle, *Pseudemys Scripta*: III. The effect of acidosis on lactate generation and O<sub>2</sub> consumption in brain slices. **Comp. Biochem. Physiol.**70A:371-373, 1981.
2. Robin ED, Robin A, Ackerman R, Lewiston N, Hance AJ, **Caligiuri MA**, Theodore J: Prolonged diving and recovery in the freshwater turtle, *Pseudemys Scripta* I. Lung and blood gases, pH, lactate concentrations and the "cation" gap. **Comp. Biochem. Physiol.** 70A:359-364, 1981.
3. Hance AJ, Robin ED, Halter JB, Lewiston N, Robin DA, Cornell L, **Caligiuri M**, Theodore J. Hormonal changes and enforced diving in the harbor seal *Phoca vitulina*. II. Plasma catecholamines. **Am J Physiol.** 1982 May;242(5):R528-32. PubMed PMID: 7081478.
4. **Caligiuri MA**, Robin ED. Prolonged diving and recovery in the freshwater turtle, *Pseudemys scripta*--IV. Effects of profound acidosis on O<sub>2</sub> consumption in turtle vs rat (mammalian) brain and heart slices. **Comp Biochem Physiol A Comp Physiol.** 1985;81(3):603-5. PubMed PMID: 2863049.
5. **Caligiuri MA**, Early AP, Marinello MJ, Preisler HD. Acute nonlymphocytic leukemia in a glue sniffer. **Am J Hematol.** 1985 Sep;20(1):89-90. PubMed PMID: 3861092.
6. **Caligiuri M**, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, Komaroff AL, Ritz J. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. **J Immunol.** 1987 Nov 15;139(10):3306-13. PubMed PMID: 2824604.
7. Michon JM, **Caligiuri MA**, Hazanow SM, Levine H, Schlossman SF, Ritz J. Induction of natural killer effectors from human thymus with recombinant IL-2. **J Immunol.** 1988 May 15;140(10):3660-7. PubMed PMID: 3258886.
8. Anderson P, **Caligiuri M**, Ritz J, Schlossman SF. CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. **Nature.** 1989 Sep 14;341(6238):159-62. PubMed PMID: 2528695.
9. **Caligiuri MA**, Murray C, Levine H, Longtine JA, Ritz J. Clonal evidence for the induction of NKH1 on activated human thymocytes. Functional changes associated with antigen expression. **Eur J Immunol.** 1989 Sep;19(9):1735-9. PubMed PMID: 2477257.
10. Soiffer RJ, **Caligiuri MA**, Tondini C, Canellos GP. High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. **Cancer.** 1989 Nov 15;64(10):2014-8. PubMed PMID: 2553238.
11. Anderson P, **Caligiuri M**, O'Brien C, Manley T, Ritz J, Schlossman SF. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. **Proc Natl Acad Sci U S A.** 1990 Mar;87(6):2274-8. PubMed PMID: 2138330; PubMed Central PMCID: PMC53669.

12. **Caligiuri MA**, Zmuidzinis A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. *J Exp Med*. 1990 May 1;171(5):1509-26. PubMed PMID: 1692080; PubMed Central PMCID: PMC2187895.
13. Buchwald D, Freedman AS, Ablashi DV, Sullivan JL, **Caligiuri M**, Weinberg DS, Hall CG, Ashley RL, Saxinger C, Balachandran N, et al. A chronic "postinfectious" fatigue syndrome associated with benign lymphoproliferation, B-cell proliferation, and active replication of human herpesvirus-6. *J Clin Immunol*. 1990 Nov;10(6):335-44. PubMed PMID: 1964694.
14. Robertson MJ, **Caligiuri MA**, Manley TJ, Levine H, Ritz J. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. *J Immunol*. 1990 Nov 15;145(10):3194-201. PubMed PMID: 1700001.
15. Baume DM, **Caligiuri MA**, Manley TJ, Daley JF, Ritz J. Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. *Cell Immunol*. 1990 Dec;131(2):352-65. PubMed PMID: 2122925.
16. Klumpp TR, **Caligiuri MA**, Rabinowe SN, Soiffer RJ, Murray C, Ritz J. Autoimmune pancytopenia following allogeneic bone marrow transplantation. *Bone Marrow Transplant*. 1990 Dec;6(6):445-7. Erratum in: *Bone Marrow Transplant* 1992 Feb;9(2):150. Caligiuri MA [corrected to **Caligiuri MA**]. PubMed PMID: 1965793.
17. **Caligiuri MA**, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. *J Clin Oncol*. 1991 Dec;9(12):2110-9. PubMed PMID: 1960552.
18. **Caligiuri MA**, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. *J Clin Invest*. 1993 Jan;91(1):123-32. PubMed PMID: 7678599; PubMed Central PMCID: PMC330005.
19. Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, **Caligiuri MA**. Expression of a functional c-kit receptor on a subset of natural killer cells. *J Exp Med*. 1993 Sep 1;178(3):1079-84. PubMed PMID: 7688785; PubMed Central PMCID: PMC2191187.
20. **Caligiuri MA**, Schichman SA, Strout MP, Mrózek K, Baer MR, Frankel SR, Barcos M, Herzig GP, Croce CM, Bloomfield CD. Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. *Cancer Res*. 1994 Jan 15;54(2):370-3. PubMed PMID: 8275471.
21. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, **Caligiuri MA**, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature*. 1994 Feb 17;367(6464):645-8. PubMed PMID: 7509044.
22. Beecher MS, Baiocchi RA, Linett ML, Krajewski CA, **Caligiuri MA**. Expression of the zeta protein subunit in CD3- NK effectors derived from human thymus. *Cell Immunol*. 1994 May;155(2):508-16. PubMed PMID: 7514106.

23. Baiocchi RA, **Caligiuri MA**. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. *Proc Natl Acad Sci U S A*. 1994 Jun 7;91(12):5577-81. PubMed PMID: 7911241; PubMed Central PMCID: PMC44039.
24. Schichman SA, **Caligiuri MA**, Gu Y, Strout MP, Canaani E, Bloomfield CD, Croce CM. ALL-1 partial duplication in acute leukemia. *Proc Natl Acad Sci U S A*. 1994 Jun 21;91(13):6236-9. PubMed PMID: 8016145; PubMed Central PMCID: PMC44173.
25. Carson WE, Haldar S, Baiocchi RA, Croce CM, **Caligiuri MA**. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. *Proc Natl Acad Sci U S A*. 1994 Aug 2;91(16):7553-7. PubMed PMID: 7519782; PubMed Central PMCID: PMC44440.
26. Schichman SA, **Caligiuri MA**, Strout MP, Carter SL, Gu Y, Canaani E, Bloomfield CD, Croce CM. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. *Cancer Res*. 1994 Aug 15;54(16):4277-80. PubMed PMID: 8044771.
27. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, **Caligiuri MA**. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. *J Exp Med*. 1994 Oct 1;180(4):1395-403. PubMed PMID: 7523571; PubMed Central PMCID: PMC2191697.
28. Gruss HJ, Hirschstein D, Wright B, Ulrich D, **Caligiuri MA**, Barcos M, Strockbine L, Armitage RJ, Dower SK. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. *Blood*. 1994 Oct 1;84(7):2305-14. PubMed PMID: 7522624.
29. Carson WE, Lindemann MJ, Baiocchi R, Linett M, Tan JC, Chou CC, Narula S, **Caligiuri MA**. The functional characterization of interleukin-10 receptor expression on human natural killer cells. *Blood*. 1995 Jun 15;85(12):3577-85. PubMed PMID: 7540068.
30. Oberkircher AR, Strout MP, Herzig GP, Fritz PD, **Caligiuri MA**. Description of an efficient and highly informative method for the evaluation of hematopoietic chimerism following allogeneic bone marrow transplantation. *Bone Marrow Transplant*. 1995 Nov;16(5):695-702. PubMed PMID: 8547867.
31. Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Poiesz B, **Caligiuri MA**. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. *Blood*. 1995 Nov 1;86(9):3287-94. PubMed PMID: 7579429.
32. Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Haldar S, Monne M, Seiden MV, Narula SK, Sklar J, Croce CM, **Caligiuri MA**. Lymphomagenesis in the SCID-human mouse involves abundant production of human interleukin-10. *Blood*. 1995 Feb 15;85(4):1063-74. PubMed PMID:7849294.
33. Carson WE, Ross ME, Baiocchi RA, Marien MJ, Boiani N, Grabstein K, **Caligiuri MA**. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. *J Clin Invest*. 1995 Dec;96(6):2578-82. PubMed PMID: 8675621; PubMed Central PMCID: PMC185961.

34. **Caligiuri MA**, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP, Baer MR, Schiffer CA, Heinonen K, Knuutila S, Nousiainen T, Ruutu T, Block AW, Schulman P, Pedersen-Bjergaard J, Croce CM, Bloomfield CD. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. **Cancer Res**. 1996 Mar 15;56(6):1418-25. PubMed PMID: 8640834.
35. Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, **Caligiuri MA**. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. **Clin Cancer Res**. 1996 Apr;2(4):669-77. PubMed PMID: 9816217.
36. Mrózek E, Anderson P, **Caligiuri MA**. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. **Blood**. 1996 Apr 1;87(7):2632-40. PubMed PMID: 8639878.
37. Lai CF, Ripperger J, Morella KK, Jurlander J, Hawley TS, Carson WE, Kordula T, **Caligiuri MA**, Hawley RG, Fey GH, Baumann H. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. **J Biol Chem**. 1996 Jun 14;271(24):13968-75. PubMed PMID: 8662928.
38. Bluman EM, Bartynski KJ, Avalos BR, **Caligiuri MA**. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. **J Clin Invest**. 1996 Jun 15;97(12):2722-7. PubMed PMID: 8675682; PubMed Central PMCID: PMC507364.
39. Soni N, Meropol NJ, Porter M, **Caligiuri MA**. Diabetes mellitus induced by low-dose interleukin-2. **Cancer Immunol Immunother**. 1996 Sep;43(1):59-62. PubMed PMID: 8917637.
40. Jurlander J, **Caligiuri MA**, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffmann L, Ball ED, Frei-Lahr DA, Christiansen NP, Block AM, Knuutila S, Herzig GP, Bloomfield CD. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. **Blood**. 1996 Sep 15;88(6):2183-91. PubMed PMID: 8822938.
41. Bullrich F, Veronese ML, Kitada S, Jurlander J, **Caligiuri MA**, Reed JC, Croce CM. Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. **Blood**. 1996 Oct 15;88(8):3109-15. PubMed PMID: 8874210.
42. Bluman EM, Schnier GS, Avalos BR, Strout MP, Sultan H, Jacobson FW, Williams DE, Carson WE, **Caligiuri MA**. The c-kit ligand potentiates the allogeneic mixed lymphocyte reaction. **Blood**. 1996 Nov 15;88(10):3887-93. PubMed PMID: 8916954.
43. Carson WE, Fehniger TA, **Caligiuri MA**. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. **Eur J Immunol**. 1997 Feb;27(2):354-60. PubMed PMID: 9045904.
44. Ross ME, **Caligiuri MA**. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. **Blood**. 1997 Feb 1;89(3):910-8. PubMed PMID: 9028322.

45. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, **Caligiuri MA**. A potential role for interleukin-15 in the regulation of human natural killer cell survival. *J Clin Invest*. 1997 Mar 1;99(5):937-43. PubMed PMID: 9062351; PubMed Central PMCID: PMC507901.
46. **Caligiuri MA**, Strout MP, Oberkircher AR, Yu F, de la Chapelle A, Bloomfield CD. The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. *Proc Natl Acad Sci U S A*. 1997 Apr 15;94(8):3899-902. PubMed PMID: 9108076; PubMed Central PMCID: PMC20539.
47. Jurlander J, Lai CF, Tan J, Chou CC, Geisler CH, Schriber J, Blumenson LE, Narula SK, Baumann H, **Caligiuri MA**. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. *Blood*. 1997 Jun 1;89(11):4146-52. PubMed PMID: 9166857.
48. Plass C, Weichenhan D, Catanese J, Costello JF, Yu F, Yu L, Smiraglia D, Cavenee WK, **Caligiuri MA**, deJong P, Held WA. An arrayed human not I-EcoRV boundary library as a tool for RLGS spot analysis. *DNA Res*. 1997 Jun 30;4(3):253-5. PubMed PMID: 9330914.
49. Baiocchi RA, Khatri VP, Lindemann MJ, Ross ME, Papoff G, Caprio AJ, Caprio TV, Fenstermaker R, Ruberti G, Bernstein ZP, **Caligiuri MA**. Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. *Blood*. 1997 Sep 1;90(5):1737-46. PubMed PMID: 9292506.
50. Fehniger TA, Carson WE, Mrózek E, **Caligiuri MA**. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo. *Blood*. 1997 Nov 1;90(9):3647-53. PubMed PMID: 9345049.
51. **Caligiuri MA**, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrózek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN, Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield CD. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. *Cancer Res*. 1998 Jan 1;58(1):55-9. PubMed PMID: 9426057.
52. Marcucci G, Strout MP, Bloomfield CD, **Caligiuri MA**. Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. *Cancer Res*. 1998 Feb 15;58(4):790-3. PubMed PMID: 9485036.
53. Strout MP, Marcucci G, Bloomfield CD, **Caligiuri MA**. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. *Proc Natl Acad Sci U S A*. 1998 Mar 3;95(5):2390-5. PubMed PMID: 9482895; PubMed Central PMCID: PMC19353.
54. Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, **Caligiuri MA**. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. *J Clin Invest*. 1998 Mar 15;101(6):1373-8. PubMed PMID: 9502779; PubMed Central PMCID: PMC508692.
55. Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, **Caligiuri MA**, Evans SS. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. *J Immunol*. 1998 Jul 1;161(1):400-8. PubMed PMID: 9647249.

56. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, **Caligiuri MA**. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. *Cancer Immunol Immunother*. 1998 Aug;46(6):318-26. PubMed PMID: 9756416.
57. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, **Caligiuri MA**. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. *Leukemia*. 1998 Sep;12(9):1482-9. PubMed PMID: 9737700.
58. Burd R, Dziedzic TS, Xu Y, **Caligiuri MA**, Subjeck JR, Repasky EA. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. *J Cell Physiol*. 1998 Oct;177(1):137-47. PubMed PMID: 9731754.
59. Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, **Caligiuri MA**. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. *Blood*. 1998 Nov 15;92(10):3647-57. PubMed PMID: 9808558.
60. Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, **Caligiuri MA**. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. *J Immunol*. 1998 Dec 1;161(11):6433-8. PubMed PMID: 9834136.
61. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechsler M, Goodsaid F, **Caligiuri MA**. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. *J Immunol*. 1999 Apr 15;162(8):4511-20. PubMed PMID: 10201989.
62. Carson WE, Yu H, Dierksheide J, Pfeffer K, Bouchard P, Clark R, Durbin J, Baldwin AS, Peschon J, Johnson PR, Ku G, Baumann H, **Caligiuri MA**. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. *J Immunol*. 1999 Apr 15;162(8):4943-51. PubMed PMID: 10202041.
63. Plass C, Yu F, Yu L, Strout MP, El-Rifai W, Elonen E, Knuutila S, Marcucci G, Young DC, Held WA, Bloomfield CD, **Caligiuri MA**. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. *Oncogene*. 1999 May 20;18(20):3159-65. PubMed PMID: 10340388.
64. Khatri VP, Baiocchi RA, Peng R, Oberkircher AR, Dolce JM, Ward PM, Herzig GP, **Caligiuri MA**. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. *J Immunol*. 1999 Jul 1;163(1):500-6. PubMed PMID: 10384154.
65. Lee EJ, George SL, **Caligiuri M**, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. *J Clin Oncol*. 1999 Sep;17(9):2831-9. PubMed PMID: 10561359.



66. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, **Caligiuri MA**, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science*. 1999 Oct 15;286(5439):531-7. PubMed PMID: 10521349.
67. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, **Caligiuri MA**, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. *Nat Genet*. 2000 Feb;24(2):132-8. PubMed PMID: 10655057.
68. Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, **Caligiuri MA**. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. *J Immunol*. 2000 Feb 15;164(4):1643-7. PubMed PMID: 10657604.
69. Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Ruutu T, Knuutila S, Bloomfield CD, **Caligiuri MA**. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. *Proc Natl Acad Sci U S A*. 2000 Feb 29;97(5):2145-50. PubMed PMID: 10681437; PubMed Central PMCID: PMC15768.
70. Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Issa JJ, Michler RE, **Caligiuri M**, Plass C, Goldschmidt-Clermont PJ. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. *Cardiovasc Res*. 2000 Apr;46(1):172-9. PubMed PMID: 10727665.
71. Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, **Caligiuri MA**. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. *J Clin Invest*. 2000 Jul;106(1):117-24. PubMed PMID: 10880055; PubMed Central PMCID: PMC314354.
72. Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G, Yu H, Baumann H, Shah MH, Cooper MA, Durbin J, **Caligiuri MA**. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. *Blood*. 2000 Aug 15;96(4):1465-73. PubMed PMID: 10942393.
73. Reuther GW, Lambert QT, **Caligiuri MA**, Der CJ. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. *Mol Cell Biol*. 2000 Dec;20(23):8655-66. PubMed PMID: 11073967; PubMed Central PMCID: PMC86471.
74. Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, **Caligiuri MA**, Ambinder RF. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. *Blood*. 2000 Dec 15;96(13):4055-63. PubMed PMID: 11110673.
75. Whitman SP, Strout MP, Marcucci G, Freud AG, Culley LL, Zeleznik-Le NJ, Mrózek K, Theil KS, Kees UR, Bloomfield CD, **Caligiuri MA**. The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. *Cancer Res*. 2001 Jan 1;61(1):59-63. PubMed PMID: 11196198.

76. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, **Caligiuri MA**. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. *J Exp Med*. 2001 Jan 15;193(2):219-31. PubMed PMID: 11208862; PubMed Central PMCID: PMC2193336.
77. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, **Caligiuri MA**, Bloomfield CD, de La Chapelle A, Krahe R. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. *Proc Natl Acad Sci U S A*. 2001 Jan 30;98(3):1124-9. PubMed PMID: 11158605; PubMed Central PMCID: PMC14719.
78. Nuovo GJ, Morrison C, Porcu P, **Caligiuri MA**, Suster S. In situ determination of T-cell receptor beta expression patterns. *J Histochem Cytochem*. 2001 Feb;49(2):139-45. PubMed PMID: 11156682.
79. Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, **Caligiuri MA**. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. *Eur J Immunol*. 2001 Mar;31(3):792-801. PubMed PMID: 11241284.
80. Mrózek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PR, Theil KS, Pettenati MJ, Archer KJ, **Caligiuri MA**, Vardiman JW, Koltz JE, Larson RA, Bloomfield CD. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. *J Clin Oncol*. 2001 May 1;19(9):2482-92. PubMed PMID: 11331327.
81. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaehri BA, Ghayur T, Carson WE, **Caligiuri MA**. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. *Blood*. 2001 May 15;97(10):3146-51. PubMed PMID: 11342442.
82. Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Frühwald M, Costello JF, Held WA, Yu L, Krahe R, Koltz JE, Bloomfield CD, **Caligiuri MA**, Plass C. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. *Blood*. 2001 May 15;97(10):3226-33. PubMed PMID: 11342453.
83. Smiraglia DJ, Rush LJ, Frühwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, **Caligiuri MA**, Plass C. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. *Hum Mol Genet*. 2001 Jun 15;10(13):1413-9. PubMed PMID: 11440994.
84. Marcucci G, **Caligiuri MA**, Döhner H, Archer KJ, Schlenk RF, Döhner K, Maghaby EA, Bloomfield CD. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. *Leukemia*. 2001 Jul;15(7):1072-80. PubMed PMID: 11455976.
85. Reuther GW, Lambert QT, Booden MA, Wennerberg K, Becknell B, Marcucci G, Sondak J, **Caligiuri MA**, Der CJ. Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA. *J Biol Chem*. 2001 Jul 20;276(29):27145-51. Epub 2001 May 23. PubMed PMID: 11373293.

86. Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M, **Caligiuri MA**. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. *J Clin Invest*. 2001 Sep;108(6):887-94. PubMed PMID: 11560958; PubMed Central PMCID: PMC200931.
87. Morrison C, Porcu P, **Caligiuri MA**, Nuovo GJ. In situ determination of B-cell heavy chain and kappa/lambda light chain expression patterns: methodology and clinical utility. *Diagn Mol Pathol*. 2001 Sep;10(3):171-8. PubMed PMID: 11552720.
88. Alexander RL, Ramage J, Kucera GL, **Caligiuri MA**, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. *Leuk Res*. 2001 Oct;25(10):875-81. PubMed PMID: 11532521.
89. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, **Caligiuri MA**. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. *Eur J Immunol*. 2001 Oct;31(10):3016-25. PubMed PMID: 11592078.
90. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrózek K, Vardiman JW, George SL, Koltz JE, Larson RA, Bloomfield CD, Caligiuri MA. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. *Cancer Res*. 2001 Oct 1;61(19):7233-9. PubMed PMID: 11585760.
91. Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, Mrózek K, Sill H, Knuutila S, Koltz JE, Archer KJ, **Caligiuri MA**, Bloomfield CD, de La Chapelle A. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. *Proc Natl Acad Sci U S A*. 2001 Nov 20;98(24):13901-6. Epub 2001 Nov 13. PubMed PMID: 11707601; PubMed Central PMCID: PMC61139.
92. Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, **Caligiuri MA**, Chalmers JJ. Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system. *Cytometry*. 2001 Dec 1;45(4):285-93. PubMed PMID: 11746098.
93. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, **Caligiuri MA**, Calabretta B. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. *Nat Genet*. 2002 Jan;30(1):48-58. Epub 2001 Dec 20. PubMed PMID: 11753385.
94. Biber JL, Jabbour S, Parihar R, Dierksheide J, Hu Y, Baumann H, Bouchard P, **Caligiuri MA**, Carson W. Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gamma. *Cell Immunol*. 2002 Mar-Apr;216(1-2):31-42. PubMed PMID: 12381348.
95. Kurooka M, Nuovo GJ, **Caligiuri MA**, Nabel GJ. Cellular localization and function of Fas ligand (CD95L) in tumors. *Cancer Res*. 2002 Mar 1;62(5):1261-5. PubMed PMID: 11888887.

96. Schilsky RL, Dressler LM, Bucci D, Monovich L, Jewell S, Suster S, **Caligiuri MA**, Kantoff PW, Compton C. Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. *Clin Cancer Res*. 2002 May;8(5):943-8. PubMed PMID: 12006505.
97. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, **Caligiuri MA**, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. *Blood*. 2002 Aug 15;100(4):1224-32. PubMed PMID: 12149202.
98. Reuther GW, Lambert QT, Rebhun JF, **Caligiuri MA**, Quilliam LA, Der CJ. RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. *J Biol Chem*. 2002 Aug 23;277(34):30508-14. Epub 2002 Mar 5. PubMed PMID: 11880369.
99. Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, **Caligiuri MA**. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. *Clin Cancer Res*. 2002 Sep;8(9):2812-9. Erratum in: Clin Cancer Res. 2002 Nov;8(11):3639. PubMed PMID: 12231521.
100. Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, **Caligiuri MA**. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. *Blood*. 2002 Oct 1;100(7):2341-8. PubMed PMID: 12239141.
101. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, **Caligiuri MA**, Durbin JE, Biron CA. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. *J Immunol*. 2002 Oct 15;169(8):4279-87. PubMed PMID: 12370359.
102. Yang W, Barth RF, Adams DM, Ciesielski MJ, Fenstermaker RA, Shukla S, Tjarks W, **Caligiuri MA**. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. *Cancer Res*. 2002 Nov 15;62(22):6552-8. PubMed PMID: 12438250.
103. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, **Caligiuri MA**. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. *Blood*. 2002 Nov 15;100(10):3633-8. Epub 2002 Jul 5. PubMed PMID: 12393617.
104. Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, **Caligiuri MA**. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. *Blood*. 2003 Jan 15;101(2):425-32. Epub 2002 Aug 22. PubMed PMID: 12393493.
105. Ladner KJ, **Caligiuri MA**, Guttridge DC. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. *J Biol Chem*. 2003 Jan 24;278(4):2294-303. Epub 2002 Nov 12. PubMed PMID: 12431991.

106. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE 3rd, **Caligiuri M**, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. *Clin Cancer Res*. 2002 Dec;8(12):3718-27. Erratum in: *Clin Cancer Res*. 2003 Apr;9(4):1573. PubMed PMID: 12473581.
107. Jilani I, Estey E, Manshuri T, **Caligiuri M**, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. *Leukemia*. 2003 Jan;17(1):114-9. PubMed PMID: 12529667.
108. Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, Santilli G, Byrom MW, Goldoni S, Ford LP, **Caligiuri MA**, Maraia RJ, Perrotti D, Calabretta B. BCR/ABL activates mdm2 mRNA translation via the La antigen. *Cancer Cell*. 2003 Feb;3(2):145-60. PubMed PMID: 12620409.
109. Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, **Caligiuri MA**. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. *Cancer Res*. 2003 Mar 1;63(5):965-71. PubMed PMID: 12615710.
110. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, **Caligiuri MA**. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. *Blood*. 2003 Apr 15;101(8):3052-7. Epub 2002 Dec 12. PubMed PMID: 12480696.
111. Tridandapani S, Wardrop R, Baran CP, Wang Y, Opalek JM, **Caligiuri MA**, Marsh CB. TGF-beta 1 suppresses [correction of suppresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. *J Immunol*. 2003 May 1;170(9):4572-7. PubMed PMID: 12707335.
112. Griffin JH, Leung J, Bruner RJ, **Caligiuri MA**, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. *Proc Natl Acad Sci U S A*. 2003 Jun 24;100(13):7830-5. Epub 2003 Jun 13. PubMed PMID: 12808148; PubMed Central PMCID: PMC164673.
113. Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, **Caligiuri MA**, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. *Blood*. 2003 Sep 1;102(5):1613-8. Epub 2003 May 15. PubMed PMID: 12750167.
114. Baldus CD, Tanner SM, Kusewitt DF, Liyanarachchi S, Choi C, **Caligiuri MA**, Bloomfield CD, de la Chapelle A. BAALC, a novel marker of human hematopoietic progenitor cells. *Exp Hematol*. 2003 Nov;31(11):1051-6. PubMed PMID: 14585369.
115. Ley TJ, Minx PJ, Walter MJ, Ries RE, Sun H, McLellan M, DiPersio JF, Link DC, Tomasson MH, Graubert TA, McLeod H, Khoury H, Watson M, Shannon W, Trinkaus K, Heath S, Vardiman JW, **Caligiuri MA**, Bloomfield CD, Milbrandt JD, Mardis ER, Wilson RK. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. *Proc Natl Acad Sci U S A*. 2003 Nov 25;100(24):14275-80. Epub 2003 Nov 12. PubMed PMID: 14614138; PubMed Central PMCID: PMC283582.

116. Eisenbeis CF, **Caligiuri MA**, Byrd JC. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? *Clin Cancer Res*. 2003 Dec 1;9(16 Pt 1):5810-2. PubMed PMID: 14676100.
117. Cosio FG, Nuovo M, Delgado L, Yearsley M, Porcu P, **Caligiuri M**, Pelletier RP, Nuovo GJ. EBV kidney allograft infection: possible relationship with a peri-graft localization of PTLD. *Am J Transplant*. 2004 Jan;4(1):116-23. PubMed PMID: 14678042.
118. Becknell B, Shen T, Maghraby E, Taya S, Kaibuchi K, **Caligiuri MA**, Marcucci G. Characterization of leukemia-associated Rho guanine nucleotide exchange factor (LARG) expression during murine development. *Cell Tissue Res*. 2003 Dec;314(3):361-6. Epub 2003 Sep 26. PubMed PMID: 14513355.
119. Gao JX, Liu X, Wen J, **Caligiuri MA**, Stroynowski I, Zheng P, Liu Y. Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. *Blood*. 2003 Dec 15;102(13):4456-63. Epub 2003 Aug 21. PubMed PMID: 12933569.
120. Yu L, Liu C, Bennett K, Wu YZ, Dai Z, Vandeusen J, Opavsky R, Raval A, Trikha P, Rodriguez B, Becknell B, Mao C, Lee S, Davuluri RV, Leone G, Van den Veyver IB, **Caligiuri MA**, Plass C. A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies. *Genomics*. 2004 Oct;84(4):647-60. PubMed PMID: 15475242.
121. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, **Caligiuri MA**, Bloomfield CD, Look AT. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. *Lancet*. 2004 Feb 14;363(9408):535-6. PubMed PMID: 14975618.
122. Perrotti D, Marcucci G, **Caligiuri MA**. Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox. *J Clin Oncol*. 2004 Feb 15;22(4):582-4. Epub 2004 Jan 15. PubMed PMID: 14726508.
123. Baldus CD, Liyanarachchi S, Mrózek K, Auer H, Tanner SM, Guimond M, Ruppert AS, Mohamed N, Davuluri RV, **Caligiuri MA**, Bloomfield CD, de la Chapelle A. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. *Proc Natl Acad Sci U S A*. 2004 Mar 16;101(11):3915-20. Epub 2004 Mar 8. PubMed PMID: 15007164; PubMed Central PMCID: PMC374344.
124. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, **Caligiuri MA**, Childs RW. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. *Blood*. 2004 Jul 1;104(1):170-7. Epub 2004 Mar 11. PubMed PMID: 15016654.
125. Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodegua L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, **Caligiuri MA**, Porcu P. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. *Clin Cancer Res*. 2004 Sep 15;10(18 Pt 1):6101-10. PubMed PMID: 15447996.
126. Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, **Caligiuri MA**. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive

- lymphoproliferative disorder. *J Natl Cancer Inst.* 2004 Oct 6;96(19):1447-57. PubMed PMID: 15467034.
127. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, **Caligiuri MA**, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. *J Clin Oncol.* 2004 Nov 1;22(21):4290-301. PubMed PMID: 15514371.
128. Roychowdhury S, May KF Jr, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, **Caligiuri MA**. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. *Cancer Res.* 2004 Nov 1;64(21):8062-7. PubMed PMID: 15520217.
129. Becknell B, Trotta R, Yu J, Ding W, Mao HC, Hughes T, Marburger T, **Caligiuri MA**. Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector. *J Immunol Methods.* 2005 Jan;296(1-2):115-23. Epub 2004 Dec 8. PubMed PMID: 15680156.
130. Blaser BW, Roychowdhury S, Kim DJ, Schwind NR, Bhatt D, Yuan W, Kusewitt DF, Ferketich AK, **Caligiuri MA**, Guimond M. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. *Blood.* 2005 Jan 15;105(2):894-901. Epub 2004 Sep 16. PubMed PMID: 15374888.
131. May KF Jr, Roychowdhury S, Bhatt D, Kocak E, Bai XF, Liu JQ, Ferketich AK, Martin EW Jr, **Caligiuri MA**, Zheng P, Liu Y. Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. *Blood.* 2005 Feb 1;105(3):1114-20. Epub 2004 Oct 14. PubMed PMID: 15486062.
132. Dierksheide JE, Baiocchi RA, Ferketich AK, Roychowdhury S, Pelletier RP, Eisenbeis CF, **Caligiuri MA**, VanBuskirk AM. IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. *Blood.* 2005 Feb 15;105(4):1558-65. Epub 2004 Oct 21. PubMed PMID: 15498860.
133. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, **Caligiuri MA**, Plass C. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. *Nat Genet.* 2005 Mar;37(3):265-74. Epub 2005 Feb 20. PubMed PMID: 15723065.
134. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, **Caligiuri MA**. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. *Immunity.* 2005 Mar;22(3):295-304. PubMed PMID: 15780987.
135. Fröhling S, Schlenk RF, Krauter J, Thiede C, Ehninger G, Haase D, Harder L, Kreitmeier S, Scholl C, **Caligiuri MA**, Bloomfield CD, Döhner H, Döhner K. Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. *Genes Chromosomes Cancer.* 2005 Apr;42(4):427-32. PubMed PMID: 15645492.

136. Dai G, Chan KK, Liu S, Hoyt D, Whitman S, Klisovic M, Shen T, **Caligiuri MA**, Byrd J, Grever M, Marcucci G. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. *Clin Cancer Res*. 2005 Apr 15;11(8):2998-3008. PubMed PMID: 15837754.
137. Trotta R, Parihar R, Yu J, Becknell B, Allard J 2nd, Wen J, Ding W, Mao H, Tridandapani S, Carson WE, **Caligiuri MA**. Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. *Blood*. 2005 Apr 15;105(8):3011-8. Epub 2004 Dec 16. PubMed PMID: 15604218.
138. Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, Klisovic MI, Maharry K, Guimond M, Strout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD, Marcucci G, **Caligiuri MA**. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. *Blood*. 2005 Jul 1;106(1):345-52. Epub 2005 Mar 17. PubMed PMID: 15774615; PubMed Central PMCID: PMC1895129.
139. Parihar R, Trotta R, Roda JM, Ferketich AK, Tridandapani S, **Caligiuri MA**, Carson WE 3rd. Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12. *Cancer Res*. 2005 Oct 1;65(19):9099-107. PubMed PMID: 16204085.
140. Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, **Caligiuri MA**. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. *Blood*. 2005 Oct 1;106(7):2433-5. Epub 2005 Jun 23. PubMed PMID: 15976176; PubMed Central PMCID: PMC1895258.
141. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galiotta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, **Caligiuri MA**, Bloomfield CD, Marcucci G, Perrotti D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. *Cancer Cell*. 2005 Nov;8(5):355-68. PubMed PMID: 16286244.
142. Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, **Caligiuri MA**, Zheng P, Liu Y. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. *Blood*. 2005 Nov 1;106(9):3127-33. Epub 2005 Jul 21. PubMed PMID: 16037385; PubMed Central PMCID: PMC1895337.
143. Mone A, Puhalla S, Whitman S, Baiocchi RA, Cruz J, Vukosavljevic T, Banks A, Eisenbeis CF, Byrd JC, **Caligiuri MA**, Porcu P. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN- $\alpha$ -refractory adult T-cell leukemia. *Blood*. 2005 Nov 15;106(10):3380-2. Epub 2005 Aug 2. PubMed PMID: 16076875; PubMed Central PMCID: PMC1895052.
144. Wang L, Baiocchi RA, Pal S, Mosialos G, **Caligiuri M**, Sif S. The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. *Mol Cell Biol*. 2005 Sep;25(18):7953-65. PubMed PMID: 16135788; PubMed Central PMCID: PMC1234311.
145. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ,



- Larson RA, de la Chapelle A, Bloomfield CD. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2005 Dec 20;23(36):9234-42. Epub 2005 Nov 7. PubMed PMID: 16275934.
146. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, **Caligiuri MA**, Heerema NA. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. *J Clin Oncol*. 2006 Jan 20;24(3):437-43. Epub 2005 Dec 12. PubMed PMID: 16344317.
147. Mikhailkevich N, Becknell B, **Caligiuri MA**, Bates MD, Harvey R, Zheng WP. Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation. *J Immunol*. 2006 Feb 1;176(3):1553-60. PubMed PMID: 16424184.
148. Glaser R, Litsky ML, Padgett DA, Baiocchi RA, Yang EV, Chen M, Yeh PE, Green-Church KB, **Caligiuri MA**, Williams MV. EBV-encoded dUTPase induces immune dysregulation: Implications for the pathophysiology of EBV-associated disease. *Virology*. 2006 Mar 1;346(1):205-18. PubMed PMID: 16321417.
149. Zelenetz AD, Advani RH, Buadi F, Cabanillas F, **Caligiuri MA**, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J; National Comprehensive Cancer Network. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2006 Mar;4(3):258-310. PubMed PMID: 16507273.
150. VanDeusen JB, Shah MH, Becknell B, Blaser BW, Ferketich AK, Nuovo GJ, Ahmer BM, Durbin J, **Caligiuri MA**. STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo. *Eur J Immunol*. 2006 Mar;36(3):623-30. PubMed PMID: 16482512.
151. Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, **Caligiuri MA**, Marcucci G, Perrotti D. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. *Blood*. 2006 Mar 15;107(6):2507-16. Epub 2005 Nov 17. PubMed PMID: 16293596; PubMed Central PMCID: PMC1895740.
152. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, **Caligiuri MA**. Evidence for discrete stages of human natural killer cell differentiation in vivo. *J Exp Med*. 2006 Apr 17;203(4):1033-43. Epub 2006 Apr 10. PubMed PMID: 16606675; PubMed Central PMCID: PMC2118285.
153. Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, **Caligiuri MA**, Villalona-Calero MA. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. *J Clin Oncol*. 2006 Apr 20;24(12):1852-9. PubMed PMID: 16622259.
154. Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM Jr, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein M, Marcucci G, **Caligiuri MA**. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. *Immunity*. 2006 May;24(5):575-90. PubMed PMID: 16713975.

155. Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, Iliopoulos D, **Caligiuri MA**, Huebner K, Croce CM. Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. *Clin Cancer Res*. 2006 Jun 1;12(11 Pt 1):3494-501. PubMed PMID: 16740775.
156. Shah MH, Freud AG, Benson DM Jr, Ferkitich AK, Dezube BJ, Bernstein ZP, **Caligiuri MA**. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. *Clin Cancer Res*. 2006 Jul 1;12(13):3993-6. PubMed PMID: 16818697.
157. Richards JO, Chang X, Blaser BW, **Caligiuri MA**, Zheng P, Liu Y. Tumor growth impedes natural-killer-cell maturation in the bone marrow. *Blood*. 2006 Jul 1;108(1):246-52. Epub 2006 Mar 23. PubMed PMID: 16556890; PubMed Central PMCID: PMC1895835.
158. Ganesan LP, Joshi T, Fang H, Kutala VK, Roda J, Trotta R, Lehman A, Kuppusamy P, Byrd JC, Carson WE, **Caligiuri MA**, Tridandapani S. FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. *Blood*. 2006 Jul 15;108(2):718-25. Epub 2006 Mar 16. PubMed PMID: 16543474; PubMed Central PMCID: PMC1895481.
159. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, **Caligiuri MA**, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Weisdorf D, Davies SM; KIR Study Group, Center for International Blood and Marrow Transplantation Research. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. *Biol Blood Marrow Transplant*. 2006 Aug;12(8):876-84. PubMed PMID: 16864058.
160. Fulci G, Breyman L, Gianni D, Kurozumi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, **Caligiuri MA**, Chiocca EA. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. *Proc Natl Acad Sci U S A*. 2006 Aug 22;103(34):12873-8. Epub 2006 Aug 14. PubMed PMID: 16908838; PubMed Central PMCID: PMC1568940.
161. Radmacher MD, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Baldus CD, Kolitz JE, **Caligiuri MA**, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. *Blood*. 2006 Sep 1;108(5):1677-83. Epub 2006 May 2. PubMed PMID: 16670265; PubMed Central PMCID: PMC1895508.
162. Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, Guimond M, Strout MP, Feng L, Nakamura T, Yu L, Rush LJ, Weinstein M, Leone G, Wu L, Ferkitich A, Whitman SP, Marcucci G, **Caligiuri MA**. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. *J Clin Invest*. 2006 Oct;116(10):2707-16. Epub 2006 Sep 14. PubMed PMID: 16981007; PubMed Central PMCID: PMC1564428.
163. Blaser BW, Schwind NR, Karol S, Chang D, Shin S, Roychowdhury S, Becknell B, Ferkitich AK, Kusewitt DF, Blazar BR, **Caligiuri MA**. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. *Blood*. 2006 Oct 1;108(7):2463-9. Epub 2006 Jun 6. PubMed PMID: 16757683; PubMed Central PMCID: PMC1895554.

164. Palomero T, McKenna K, O-Neil J, Galinsky I, Stone R, Suzukawa K, Stiakaki E, Kalmanti M, Fox EA, **Caligiuri MA**, Aster JC, Look AT, Ferrando AA. Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. *Leukemia*. 2006 Nov;20(11):1963-6. Epub 2006 Sep 28. PubMed PMID: 17008890.
165. Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, **Caligiuri MA**. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. *Clin Cancer Res*. 2006 Dec 1;12(23):7046-53. PubMed PMID: 17145827.
166. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, **Caligiuri MA**, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. *Blood*. 2006 Dec 1;108(12):3674-81. Epub 2006 Aug 10. PubMed PMID: 16902153; PubMed Central PMCID: PMC1895460.
167. Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesús ML, Alghothani M, Benson DM Jr, Lehman A, Jarjoura D, Perrotti D, Bates MD, **Caligiuri MA**. Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells. *Blood*. 2007 Mar 15;109(6):2481-7. Epub 2006 Nov 16. PubMed PMID: 17110450; PubMed Central PMCID: PMC1852195.
168. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, **Caligiuri MA**, Lucas DM, Byrd JC. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. *Clin Cancer Res*. 2007 Apr 1;13(7):2144-50. PubMed PMID: 17404098.
169. Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Koltz JE, Larson RA, **Caligiuri MA**, Bloomfield CD. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. *Blood*. 2007 Jun 15;109(12):5164-7. Epub 2007 Mar 6. PubMed PMID: 17341662; PubMed Central PMCID: PMC1890839.
170. Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, **Caligiuri MA**, Perrotti D. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. *Blood*. 2007 Aug 1;110(3):994-1003. Epub 2007 May 2. PubMed PMID: 17475908; PubMed Central PMCID: PMC1924762.
171. **Caligiuri MA**, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky KJ, Marburger TB, Wen J, Perrotti D, Bloomfield CD, Whitman SP. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. *Blood*. 2007 Aug 1;110(3):1022-4. Epub 2007 May 2. PubMed PMID: 17475912; PubMed Central PMCID: PMC1924768.
172. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, **Caligiuri MA**, Bloomfield CD, Byrd JC, Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic

- leukemia. *J Clin Invest*. 2007 Sep;117(9):2408-21. PubMed PMID: 17717597; PubMed Central PMCID: PMC1950458.
173. Yu J, Wei M, Boyd Z, Lehmann EB, Trotta R, Mao H, Liu S, Becknell B, Jaung MS, Jarjoura D, Marcucci G, Wu LC, **Caligiuri MA**. Transcriptional control of human T-BET expression: the role of Sp1. *Eur J Immunol*. 2007 Sep;37(9):2549-61. PubMed PMID: 17705132.
174. Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanné-Chantelot C, Vardiman JW, **Caligiuri MA**, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. *Blood*. 2007 Sep 1;110(5):1648-55. Epub 2007 May 9. PubMed PMID: 17494858; PubMed Central PMCID: PMC1975847.
175. Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, **Caligiuri MA**, Briesewitz R. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. *Blood*. 2007 Sep 15;110(6):2075-83. Epub 2007 May 30. PubMed PMID: 17537993.
176. Opavsky R, Tsai SY, Guimond M, Arora A, Opavska J, Becknell B, Kaufmann M, Walton NA, Stephens JA, Fernandez SA, Muthusamy N, Felsher DW, Porcu P, **Caligiuri MA**, Leone G. Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis. *Proc Natl Acad Sci U S A*. 2007 Sep 25;104(39):15400-5. Epub 2007 Sep 19. PubMed PMID: 17881568; PubMed Central PMCID: PMC2000495.
177. Trotta R, Ciarlariello D, Dal Col J, Allard J 2nd, Neviani P, Santhanam R, Mao H, Becknell B, Yu J, Ferketich AK, Thomas B, Modi A, Blaser BW, Perrotti D, **Caligiuri MA**. The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. *J Exp Med*. 2007 Oct 1;204(10):2397-405. Epub 2007 Sep 17. PubMed PMID: 17875674; PubMed Central PMCID: PMC2118465.
178. French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, **Caligiuri MA**, Yokoyama WM. Chronic lymphocytosis of functionally immature natural killer cells. *J Allergy Clin Immunol*. 2007 Oct;120(4):924-31. Epub 2007 Jul 2. PubMed PMID: 17604094.
179. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kusewitt D, Lee RJ, **Caligiuri MA**, Tridandapani S, Muthusamy N, Byrd JC. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. *Blood*. 2007 Oct 1;110(7):2569-77. Epub 2007 Apr 17. PubMed PMID: 17440052; PubMed Central PMCID: PMC1988922.
180. Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, **Caligiuri MA**, Muthusamy N, Byrd JC. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. *Clin Cancer Res*. 2008 Jan 15;14(2):569-78. PubMed PMID: 18223233.
181. Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, **Caligiuri MA**, Leone GW, Perrotti D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for

- BCR/ABL leukemogenesis. *Blood*. 2008 Jan 15;111(2):816-28. Epub 2007 Oct 9. PubMed PMID: 17925491; PubMed Central PMCID: PMC2200861.
182. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, **Caligiuri MA**, Marcucci G, Bloomfield CD. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. *Blood*. 2008 Feb 1;111(3):1552-9. Epub 2007 Oct 16. PubMed PMID: 17940205; PubMed Central PMCID: PMC2214747.
183. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, **Caligiuri MA**, Chan KK, Wu LC, Marcucci G. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. *Blood*. 2008 Feb 15;111(4):2364-73. Epub 2007 Dec 14. PubMed PMID: 18083845; PubMed Central PMCID: PMC2234064.
184. Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, Grewal R, Hruban RH, Yeo CJ, Yassin Y, Iartchouk O, Montgomery K, Whitman SP, **Caligiuri MA**, Loh ML, Gilliland DG, Look AT, Kucherlapati R, Kern SE, Meyerson M, Neel BG. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. *Genes Chromosomes Cancer*. 2008 Mar;47(3):253-9. PubMed PMID: 18064648.
185. Kondadasula SV, Roda JM, Parihar R, Yu J, Lehman A, **Caligiuri MA**, Tridandapani S, Burry RW, Carson WE 3rd. Colocalization of the IL-12 receptor and Fc gamma RIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. *Blood*. 2008 Apr 15;111(8):4173-83. Epub 2008 Jan 3. PubMed PMID: 18174382; PubMed Central PMCID: PMC2288725.
186. Gowda A, Ramanunni A, Cheney C, Rozewski D, Kindsvogel W, Lehman A, Jarjoura D, **Caligiuri M**, Byrd JC, Muthusamy N. Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia. *MAbs*. 2010 Jan-Feb;2(1):35-41. Epub 2010 Jan 8. PubMed PMID: 20081380; PubMed Central PMCID: PMC2828576.
187. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, **Caligiuri MA**, Larson RA, Bloomfield CD. MicroRNA expression in cytogenetically normal acute myeloid leukemia. *N Engl J Med*. 2008 May 1;358(18):1919-28. PubMed PMID: 18450603.
188. Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, **Caligiuri MA**, Tridandapani S, Muthusamy N, Byrd JC. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. *Blood*. 2008 May 1;111(9):4723-30. Epub 2008 Jan 8. PubMed PMID: 18182577; PubMed Central PMCID: PMC2343602.
189. Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, **Caligiuri MA**. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute

- myeloid leukemia with the MLL partial tandem duplication. *Blood*. 2008 Sep 1;112(5):2013-6. Epub 2008 Jun 19. PubMed PMID: 18566324; PubMed Central PMCID: PMC2518901.
190. Richards J, McNally B, Fang X, **Caligiuri MA**, Zheng P, Liu Y. Tumor growth decreases NK and B cells as well as common lymphoid progenitor. *PLoS One*. 2008 Sep 11;3(9):e3180. PubMed PMID: 18784839; PubMed Central PMCID: PMC2527520.
191. Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, **Caligiuri MA**. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. *J Immunol*. 2008 Sep 15;181(6):3784-92. PubMed PMID: 18768831; PubMed Central PMCID: PMC2924753.
192. Dorrance AM, Liu S, Chong A, Pulley B, Nemer D, Guimond M, Yuan W, Chang D, Whitman SP, Marcucci G, **Caligiuri MA**. The MLL partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. *Blood*. 2008 Sep 15;112(6):2508-11. Epub 2008 Jul 10. PubMed PMID: 18617636; PubMed Central PMCID: PMC2532816.
193. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, **Caligiuri MA**, Kolitz JE, Larson RA, Bloomfield CD. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. *J Clin Oncol*. 2008 Oct 1;26(28):4595-602. Epub 2008 Jun 16. PubMed PMID: 18559874; PubMed Central PMCID: PMC2653131.
194. Baer MR, George SL, **Caligiuri MA**, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. *J Clin Oncol*. 2008 Oct 20;26(30):4934-9. Epub 2008 Jun 30. PubMed PMID: 18591543; PubMed Central PMCID: PMC2652081.
195. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, **Caligiuri MA**, Kolitz JE, Larson RA, Bloomfield CD. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. *J Clin Oncol*. 2008 Nov 1;26(31):5078-87. Epub 2008 Sep 22. Erratum in: *J Clin Oncol*. 2008 Dec 20;26(36):6021. PubMed PMID: 18809607; PubMed Central PMCID: PMC2652095.
196. Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, **Caligiuri MA**, Tridandapani S, Muthusamy N, Byrd JC. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. *Br J Haematol*. 2009 Mar;144(6):848-55. Epub 2009 Jan 12. PubMed PMID: 19183192; PubMed Central PMCID: PMC2776067.
197. Park IK, Giovenzana C, Hughes TL, Yu J, Trotta R, **Caligiuri MA**. The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. *Blood*. 2009 Mar 12;113(11):2470-7. Epub 2008 Oct 7. PubMed PMID: 18840707; PubMed Central PMCID: PMC2656272.

198. Benson DM Jr, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, **Caligiuri MA**. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. *Blood*. 2009 Mar 19;113(12):2706-14. Epub 2008 Dec 5. PubMed PMID: 19060242; PubMed Central PMCID: PMC2661858.
199. Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo G, Yu J, **Caligiuri MA**. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. *Blood*. 2009 Apr 23;113(17):4008-10. Epub 2009 Feb 24. PubMed PMID: 19244159; PubMed Central PMCID: PMC2673127.
200. Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, **Caligiuri MA**, Byrd JC. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. *Leukemia*. 2009 May;23(5):912-8. Epub 2009 Feb 19. PubMed PMID: 19225537.
201. Yu J, Ershler M, Yu L, Wei M, Hackanson B, Yokohama A, Mitsui T, Liu C, Mao H, Liu S, Liu Z, Trotta R, Liu CG, Liu X, Huang K, Visser J, Marcucci G, Plass C, Belyavsky AV, **Caligiuri MA**. TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. *Blood*. 2009 May 28;113(22):5558-67. Epub 2009 Mar 27. PubMed PMID: 19329776; PubMed Central PMCID: PMC2689053.
202. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, **Caligiuri MA**, Larson RA, Bloomfield CD. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. *J Clin Oncol*. 2009 Jul 1;27(19):3198-204. Epub 2009 May 18. PubMed PMID: 19451432; PubMed Central PMCID: PMC2716941.
203. Mani A, Roda J, Young D, **Caligiuri MA**, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE 3rd, Shapiro CL. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. *Breast Cancer Res Treat*. 2009 Sep;117(1):83-9. Epub 2008 Dec 3. PubMed PMID: 19051009; PubMed Central PMCID: PMC2997435.
204. Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, **Caligiuri MA**, Velardi A, Wagtmann N. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. *Blood*. 2009 Sep 24;114(13):2667-77. Epub 2009 Jun 24. PubMed PMID: 19553639; PubMed Central PMCID: PMC2756126.
205. Yu J, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park IK, Hwang C, Liu S, Marcucci G, Trotta R, Benson DM Jr, **Caligiuri MA**. CD94 defines phenotypically and functionally distinct mouse NK cell subsets. *J Immunol*. 2009 Oct 15;183(8):4968-74. PubMed PMID: 19801519; PubMed Central PMCID: PMC2924742.
206. Freud AG, **Caligiuri MA**. Purification of human NK cell developmental intermediates from lymph nodes and tonsils. *Methods Mol Biol*. 2010;612:1-14. PubMed PMID: 20033630.
207. Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, **Caligiuri MA**. CD94 surface density identifies a functional intermediary between the CD56bright

- and CD56dim human NK-cell subsets. *Blood*. 2010 Jan 14;115(2):274-81. Epub 2009 Nov 6. PubMed PMID: 19897577; PubMed Central PMCID: PMC2808153.
208. Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J, Curphey D, Blaser BW, Vandeusen JB, Mao H, Yu J, **Caligiuri MA**. A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. *Leuk Res*. 2010 Feb;34(2):203-9. Epub 2009 Aug 5. PubMed PMID: 19660811; PubMed Central PMCID: PMC2814907.
209. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Koltz JE, Wetzler M, Carroll AJ, Baer MR, **Caligiuri MA**, Larson RA, Bloomfield CD. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2010 Feb 1;28(4):596-604. Epub 2009 Dec 21. PubMed PMID: 20026798; PubMed Central PMCID: PMC2815994.
210. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, **Caligiuri MA**, Muthusamy N, Byrd JC. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. *Blood*. 2010 Feb 11;115(6):1204-13. Epub 2009 Dec 2. PubMed PMID: 19965644; PubMed Central PMCID: PMC2826232.
211. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, **Caligiuri MA**, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. *Cell*. 2010 Mar 5;140(5):652-65. PubMed PMID: 20211135; PubMed Central PMCID: PMC2924756.
212. Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, **Caligiuri MA**. In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. *J Immunol*. 2010 Mar 15;184(6):2769-75. Epub 2010 Feb 8. PubMed PMID: 20142363; PubMed Central PMCID: PMC2924750.
213. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, **Caligiuri MA**, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. *Cancer Cell*. 2010 Apr 13;17(4):333-47. PubMed PMID: 20385359; PubMed Central PMCID: PMC2917066.
214. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Koltz JE, Wetzler M, Carroll AJ, Baer MR, **Caligiuri MA**, Larson RA, Bloomfield CD. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2010 May 10;28(14):2348-55. Epub 2010 Apr 5. PubMed PMID: 20368543; PubMed Central PMCID: PMC2881719.
215. Hughes T, Becknell B, Freud AG, McClory S, Briercheck E, Yu J, Mao C, Giovenzana C, Nuovo G, Wei L, Zhang X, Gavrillin MA, Wewers MD, **Caligiuri MA**. Interleukin-1beta selectively expands



- and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. *Immunity*. 2010 Jun 25;32(6):803-14. PubMed PMID: 20620944.
216. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, **Caligiuri MA**, Larson RA, Bloomfield CD. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Blood*. 2010 Aug 5;116(5):788-92. Epub 2010 May 4. PubMed PMID: 20442368; PubMed Central PMCID: PMC2918333.
217. Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, **Caligiuri MA**. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. *Blood*. 2010 Sep 30;116(13):2286-94. Epub 2010 May 11. PubMed PMID: 20460501.
218. Male V, Hughes T, McClory S, Colucci F, **Caligiuri MA**, Moffett A. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. *J Immunol*. 2010 Oct 1;185(7):3913-8. Epub 2010 Aug 27. PubMed PMID: 20802153.
219. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, **Caligiuri MA**, Marcucci G, Bloomfield CD. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Blood*. 2010 Nov 4;116(18):3622-6. Epub 2010 Jul 23. PubMed PMID: 20656931; PubMed Central PMCID: PMC2981481.
220. Smith MA, Maurin M, Cho HI, Becknell B, Freud AG, Yu J, Wei S, Djeu J, Celis E, **Caligiuri MA**, Wright KL. PRDM1/Blimp-1 controls effector cytokine production in human NK cells. *J Immunol*. 2010 Nov 15;185(10):6058-67. Epub 2010 Oct 13. PubMed PMID: 20944005.
221. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, **Caligiuri MA**, Larson RA, Bloomfield CD. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Blood*. 2010 Dec 16;116(25):5660-9. Epub 2010 Sep 14. PubMed PMID: 20841507; PubMed Central PMCID: PMC3031412.
222. Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, **Caligiuri MA**, Larson RA, Marcucci G, Bloomfield CD. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2010 Dec 20;28(36):5257-64. Epub 2010 Nov 15. PubMed PMID: 21079133; PubMed Central PMCID: PMC3018359.
223. Trotta R, Ciarlariello D, Dal Col J, Mao H, Chen L, Briercheck E, Yu J, Zhang J, Perrotti D, **Caligiuri MA**. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. *Blood*. 2011 Feb 24;117(8):2378-84. Epub 2010 Dec 14. PubMed PMID: 21156847; PubMed Central PMCID: PMC3062407.

224. Kannan Y, Yu J, Raices RM, Seshadri S, Wei M, **Caligiuri MA**, Wewers MD. IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells. *Blood*. 2011 Mar 10;117(10):2855-63. Epub 2011 Jan 11. PubMed PMID: 21224476; PubMed Central PMCID: PMC3062297.
225. Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, **Caligiuri MA**, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. *Leukemia*. 2011 May;25(5):800-7. Epub 2011 Feb 15. PubMed PMID: 21321569.
226. Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, **Caligiuri MA**, Marcucci G, Bloomfield CD. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. *J Clin Oncol*. 2011 Apr 1;29(10):1373-81. Epub 2011 Feb 22. PubMed PMID: 21343549; PubMed Central PMCID: PMC3084003.
227. Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G Jr, Benson DM, Loughran TP Jr, Tridandapani S, **Caligiuri MA**. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. *J Clin Invest*. 2011 Apr 1;121(4):1456-70. PubMed PMID: 21364281; PubMed Central PMCID: PMC3069763.
228. Liu S, Madiari F, Hackshaw KV, Allen CE, Carl J, Huschart E, Karanfilov C, Litsky A, Hickey CJ, Marcucci G, Huja S, Agarwal S, Yu J, **Caligiuri MA**, Wu LC. The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis. *PLoS One*. 2011 Mar 3;6(3):e17161. PubMed PMID: 21390242; PubMed Central PMCID: PMC3048431.
229. Becker H, Maharry K, Radmacher M, Mrozek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, **Caligiuri MA**, Larson RA, Marcucci G, Bloomfield CD. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *Haematologica*. 2011 Jun 9. [Epub ahead of print] PubMed PMID: 21659357.
230. Mehta P, Wavreille AS, Justiniano SE, Marsh RL, Yu J, Burry RW, Jarjoura D, Eubank T, **Caligiuri MA**, Butchar JP, Tridandapani S. LyGDI, a Novel SHIP-Interacting Protein, Is a Negative Regulator of FcγR-Mediated Phagocytosis. *PLoS One*. 2011;6(6):e21175. Epub 2011 Jun 14. PubMed PMID: 21695085; PubMed Central PMCID: PMC3114867.
231. Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrózek K, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu YZ, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA, **Caligiuri MA**, Bloomfield CD. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. *Blood*. 2011 Aug 9. [Epub ahead of print] PubMed PMID: 21828125.
232. Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, **Caligiuri MA**, Farag SS. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural

- killer cell versus multiple myeloma effect. *Blood*. 2011 Oct 26. [Epub ahead of print] PMID: 22031859
233. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, **Caligiuri MA**, Marcucci G, Bloomfield CD. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN "favorable" genetic category. *Blood*. 2011 Oct 26. [Epub ahead of print] PMID:22031865
234. McClory S, Hughes, T, Freud AG, Briercheck E, Martin C, Trimboli AJ, Yu J, Zhang X, Leone G, Nuovo G, **Caligiuri MA**. Evidence for a stepwise program of extrathymic T cell development within human tonsil. *J Clin Invest* 2012, *in press*
235. **Trotta R**, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM, **Caligiuri MA**. MiR-155 regulates IFN- $\gamma$  production in natural killer cells. *Blood*. 2012 *in press*

### Patents:

**Caligiuri MA**, Freud AG, Becknell MB: US Patent **7,915,043** CD34(+) cells and their methods of use. Issued March 29, 2011.

**Caligiuri MA**, Meropol NJ, Schilsky RJ: U.S. Patent **7,306,801** Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein. Issued: December 11, 2007.

**Caligiuri MA** and Baiocchi RA: U.S. Patent **6,042,826**: Method for inducing apoptosis of primary central nervous system B cell lymphomas. Issued March 28, 2000.

**Caligiuri MA**, Meropol NJ, Schilsky RJ: European Patent **01935476.0-2402-US0115525** Cancer treatments by using a combination of an antibody against HER2 and Interleukin 2. Issued: December 27, 2002.

**Caligiuri, MA**, Trotta R, Yu J, Becknell B: US Patent Application **20080299660** - Methods for Transfecting Natural Killer Cells. Filed on March 21, 2005

**Caligiuri MA**, Baiocchi RA: US Patent Application **20070196389** – Viral gene products and methods for vaccination to prevent viral associated diseases. Filed on November 17, 2006

### Letters to the Editor/Editorials:

1. Jurlander J, **Caligiuri MA**, Bloomfield CD: Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation. *Blood* 90: 3230-3236, 1997.
2. Bloomfield CD, Herzig GP, **Caligiuri MA** (Guest Editors): Acute Leukemias: recent advances. *Seminars in Oncology* 24: 1-2, 1997.
3. Marcucci G, **Caligiuri MA**, Bloomfield CD: Defining the "absence of the CBF $\beta$ /MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long term complete remission. A call for definitions. *Blood* 90: 5022-5024, 1997.

4. Shah MH, Hackshaw KV, **Caligiuri MA**: Rheumatoid arthritis and the role of interleukin-15. Letter to Editor. **Nature Medicine** 4: 6, 1998.
5. Rush LJ, Heinonen K, Mrozek K, Wolf BJ, Abdel-Rahman M, Szymanska J, Peltomaki P, Kapadia F, Bloomfield CD, **Caligiuri MA**, Plass C. Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line. **Blood** 99; 5 1874-76, 2002.

**Books Edited:**

1. Cytokines in the Genesis and Treatment of Cancer. **Caligiuri MA** and Lotze ML, Editors. Humana Press, 2007.

**Reviews:**

1. **Caligiuri MA**, Mayer RJ: Pregnancy and Leukemia. **Seminars in Oncology** 16:338-396, 1989.
2. **Caligiuri MA**, Ritz J: Immunology. In: **Leukemia**. Henderson, ES, and Lister TA, eds. W B Saunders, 105-115, 1989.
3. **Caligiuri MA**, Manley TJ, Wang ES, Levine H, Smith KA, and Ritz J: Constitutive expression of the high affinity IL-2 receptor in a subpopulation of resting peripheral blood NK cells. In **Natural Killer Cells: Biology and Clinical Application**, Schmidt, RE, ed. Karger, New York. 166-171, 1990.
4. **Caligiuri MA**: Cancer and Pregnancy. In: **Medical Oncology. Basic Principles and Clinical Management of Cancer**. Calabresi P & Schein PS, eds. Macmillan Publishing Co., New York. Chapter 58: 1203-1218, 1993.
5. **Caligiuri MA**: Leukemia and Pregnancy. **Advances in Oncology**. 8:10-17, 1992.
6. **Caligiuri MA**: Low dose IL-2 therapy: rationale and clinical approaches. **Seminars in Oncology**. 20:3-10, Suppl 6, 1993.
7. Carson WE, **Caligiuri, MA**: Cellular adoptive immunotherapy with natural killer Cells. In **Cell Therapy**. Morstyn G, Sheridan B, eds. Cambridge University Press. Chapter 25: 451-474, 1996.
8. Baiocchi RA, Bernstein ZP, **Caligiuri MA**: Lymphomagenesis in the HU-PBL-SCID mouse model: clues towards the pathogenesis and treatment of AIDS lymphoma. **Sangre** 40: 245-252, 1995.
9. Carson WE and **Caligiuri MA**: Natural Killer Cell Subsets and Development. In **Methods: A Companion to Methods in Enzymology**. Academic Press: 9: 327-343, 1996.
10. Carson WE and **Caligiuri MA**: Interleukin 15: A potential player during the innate immune response to infection. **Experimental Parasitology**: 84: 291-294, 1996.
11. Daley JP, **Caligiuri MA**, Biddle WC: *Ex vivo* expansion of human hematopoietic progenitor cells in serum-free stem pro<sup>tm</sup> -34 medium. **Focus** 15: 62-67, 1996.
12. Khatri VJ, Baiocchi RA, Bernstein ZP, **Caligiuri MA**: Lymphomagenesis in the severe combined immune deficient mouse engrafted with human lymphocytes: clues towards the pathogenesis and treatment of AIDS lymphoma. **International Journal of Oncology** 4: 241-246, 1997.

13. **Caligiuri, MA**, Strout MP, Gilliland DG: Molecular Biology of Acute Myeloid Leukemia. **Seminars in Oncology** 24: 32-44, 1997.
14. Strout MP and **Caligiuri MA**: Developments in Cytogenetics and Oncogenes in Acute Leukemia. **Current Opinion in Oncology** 9: 8-17, 1997.
15. Carson WE and **Caligiuri MA**: Interleukin 15: In: **Cytokines, Health and Disease** 15: 209-221,1997.
16. Khatri VP, Baiocchi RA, Bernstein ZP and **Caligiuri MA**: Immunotherapy with low-dose interleukin 2: rationale for prevention of immune-deficiency-associated cancer. **The Cancer Journal From Scientific American** 3: 128-136, 1997.
17. Carson WE and **Caligiuri MA**: Interleukin-15 as a potential regulator of the innate immune response. **Brazilian Journal of Medical and Biological Research** 31: 1-9, 1998.
18. Marcucci G, Strout MP, **Caligiuri MA**, Bloomfield CD: Core Binding Factor (CBF) and *ALL1* (*MLL*)-associated adult primary acute myeloid leukemia. Biology and Clinical Implications of Two major genetic subtypes. **ASCO Educational Book**, Chestnut Hill, MA. 36-47, 1998.
19. Khatri VP and **Caligiuri MA**: Interleukin 10 and its receptor: In: **Encyclopedia of Immunology**. 1997.
20. Baiocchi RA, Khatri VP and **Caligiuri MA**: Immunotherapy strategies for immunodeficiency associated lymphomas. IN: Classification, Biology and Treatment of Lymphoma (Armitage JO and Lister TA, Eds) **International Proceedings Journal**. Volume V:11-33, 1998
21. Khatri VP and **Caligiuri MA**: A review of the association between interleukin-10 and human malignancies. **Cancer Immunol and Immunother**. 46:239-244, 1998
22. Strout MP, **Caligiuri MA**: Developments in cytogenetics and oncogenes in acute leukemia. **Current Opinion in Oncology**. 9:8-17, 1998.
23. Baiocchi RA, **Caligiuri MA**. Cytokines in the evolution and treatment of AIDS-lymphoma. **Current Opinion in Oncology** 11:516-521, 1999.
24. Strout MP, **Caligiuri MA**, Bloomfield CD. Recent advances in the biology and management of primary acute myeloid leukemia with rearrangements of the MLL gene. **Medscape Oncology** 3 (3), 2000  
<http://www.medscape.com/medscape/oncology/journal/2000/v03.n03/mo5283.stro/mo5283.stro-01.html>
25. Marcucci G, **Caligiuri MA**, Bloomfield CD. Core binding factor (CBF) primary acute myeloid leukemia: biology and clinical implications. **Medscape Oncology** 3(2), 2000  
<http://www.medscape.com/medscape/oncology/journal/2000/v03.n02/mo5095.marc/mo5095.marc-01.html>
26. Marcucci G, **Caligiuri MA**, Bloomfield CD. Molecular and clinical advances in core binding factor (CBF) primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. **Cancer Investigation** 18(8):768-80, 2000
27. Porcu P and **Caligiuri MA**. AIDS-related lymphomas: Future Directions. **Seminars in Oncology** 27:454-62, 2000

28. **Caligiuri MA**, Bloomfield: The Molecular Biology of Leukemia. In: **Cancer: Principles and Practice of Oncology**. DeVita VT Jr, Hellman S, Rosenberg SA, eds. J.B. Lippincott Co, Philadelphia, December 2000, 2389-2404
29. Byrd JC, Carroll AJ, **Caligiuri MA**, Larson RA, Bloomfield CD: Recent genetic studies of adult patients with acute myeloid leukemia performed by the Cancer and Leukemia Group B. In: **Acute Leukemias VIII – Prognostic Factors and Treatment Strategies**. Springer-Verlag, Heidelberg, Germany. pp. 449-456, 2001.
30. Marcucci G and **Caligiuri MA** Antisense and Gene Transfer Strategies in Leukemia. In **Leukemia**. Henderson, ES, and Lister TA, eds. W B Saunders. 7<sup>th</sup> Edition 449-457, 2002.
31. Fehniger TA, Caligiuri MA. Ontogeny and expansion of human natural killer cells: clinical implications. **Int. Rev. Immunol.** 20, 495-526, 2001.
32. Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, **Caligiuri MA**. Fatal Leukemia in Interleukin-15 Transgenic Mice. **Blood Cells, Molecules and Diseases** 27:1, 223-230, 2001.
33. Fehniger TA, Cooper MA, **Caligiuri MA**. Interleukin-2 and Interleukin-15: Immunotherapy for Cancer. **Cytokine and Growth Factors** 20(3), 503-534, 2001.
34. Byrd JC, Carroll AJ, **Caligiuri MA**, Larson RA, Bloomfield CD: Recent genetic studies of adult patients with acute myeloid leukemia performed by the Cancer and Leukemia Group B. In: **Acute Leukemias VIII – Prognostic Factors and Treatment Strategies**. Springer-Verlag, Heidelberg, Germany. pp. 449-456, 2001.
35. Cataland SR, **Caligiuri MA**, Bloomfield CD: Genetic subtyping of adult acute leukemias and their implications for treatment. **Oncology Spectrums** 2(9):617-625, 2001.
36. Bloomfield CD, Archer KJ, Mrózek K, Byrd JC, Whitman SP, Dodge RK, Carroll AJ, Larson RA, **Caligiuri MA**: Cytogenetics for treatment stratification in *de novo* adult acute myeloid leukemia. **Acute Leukemias IX**, Springer-Verlag, Berlin-Heidelberg-New York-Tokyo. November 2001.
37. Fehniger TA, Cooper MA, **Caligiuri MA**. Interleukin-2 and Interleukin-15: Immunotherapy for Cancer. **Cytokine and Growth Factor Reviews** 13, 169-183, 2002.
38. Cooper MA, **Caligiuri MA**. Immunologic manipulation in AML: from bench to bedside. **Leukemia**. 4:736-7, 2002.
39. Shah MH, Porcu P, Mallery SR, **Caligiuri MA**. AIDS-associated Malignancies. **Cancer Chemotherapy and Biological Response Modifiers, Annual** 20: 31, 633-664, 2002.
40. Farag SS, Fehniger TA, Ruggeri L, Velardi A, **Caligiuri MA**. Natural killer cells: biology and application in stem-cell transplantation. **Cytotherapy**. 4(5):445-6, 2002.
41. VanDeusen JB, **Caligiuri, MA**. New developments in anti-tumor efficacy and malignant transformation of human natural killer cells. **Current Opinions in Hematology**. 10: 55-59, 2003.
42. Marcucci G, Perrotti D, **Caligiuri MA**. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. (Clin. Cancer Res., 9: 1333-1337, 2003). **Clin. Cancer Res.** 9(4):1248-52, 2003.

43. Bloomfield CD, Archer KJ, Mrózek K, Byrd JC, Whitman SP, Dodge RK, Carroll AJ, Larson RA, **Caligiuri MA**: Cytogenetics for treatment stratification in *de novo* adult acute myeloid leukemia. In: **Acute Leukemias IX-Basic Research, Experimental Approaches and Novel Therapies**. Springer-Verlag, Berlin-Heidelberg, Germany. pp. 366-376, 2003.
44. Colucci F, **Caligiuri MA**, Di Santo JP. What does it take to make a natural killer? **Nat Rev Immunol**. 3(5):413-25, 2003.
45. Farag SS, Fehniger TA, Becknell B, Blaser BW, **Caligiuri MA**. New directions in natural killer cell-based immunotherapy of human cancer. **Expert Opin Biol Ther**. 3(2):237-50, 2003.
46. Farag SS, VanDeusen JB, Fehniger TA, **Caligiuri MA**. Biology and clinical impact of human natural killer cells. **Int J Hematol**. 78(1):7-17, 2003.
47. Marcucci G, **Caligiuri MA**, Bloomfield CD. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically? **Eur J Haematol**. 71(3):143-54, 2003.
48. Becknell B, **Caligiuri MA**. Cancer T cell therapy expands. **Nat Med**. 9(3):257-8, 2003.
49. VanDeusen JB, **Caligiuri MA**. New developments in anti-tumor efficacy and malignant transformation of human natural killer cells. **Curr Opin Hematol**. 10(1):55-9, 2003.
50. Cooper MA, **Caligiuri MA**. Cytokines and cancer. **The Cytokine Handbook, 4<sup>th</sup> Edition**. Chapter 53: 1213-1232, 2003.
51. Farag SS, **Caligiuri MA**. Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma. **Advances in Pharmacology**, 51:281-303, 2004.
52. Cataland S, **Caligiuri MA**, Shannon K. Myelodysplastic Syndromes. **American Society of Hematology Self Assessment Program (ASH-SAP)**. 2004
53. Cooper MA, **Caligiuri MA**, Max E, Powell J. Lymphocyte Biology. **Clinical Hematology 1<sup>st</sup> Edition**, Chapter 6, 2004.
54. Roychowdhury S, **Caligiuri MA**. Cytokine therapy for cancer: Antigen presentation. **Tumor Immunology and Cancer Vaccines**. 123:249-66, 2004.
55. **Caligiuri MA**, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. **Hematology (Am Soc Hematol Educ Program)**. 337-53, 2004.
56. Shah MH, Porcu P, Mallery SR, **Caligiuri MA**. AIDS-associated malignancies. **Cancer Chemother Biol Response Modif**. 21:717-46, 2003.
57. Cooper MA, **Caligiuri MA**. Isolation and characterization of human natural killer cell subsets. **Curr Protoc Immunol**. May;Chapter 7:Unit 7.34, 2004.
58. Becknell B, **Caligiuri MA**. Interleukin-2, interleukin-15, and their roles in human natural killer cells. **Adv Immunol**. 86:209-39, 2005.
59. Roychowdhury S, **Caligiuri MA**. Cytokine therapy for cancer: antigen presentation. **Cancer Treat Res**. 123:249-66, 2005.
60. Farag SS, **Caligiuri MA**. Human natural killer cell development and biology. **Blood Rev**. 20:123-37, 2006.

61. **Caligiuri MA.** Recent advances in the treatment of transplant-related lymphoma. *Clin Adv Hematol Oncol.* Jan;4(1):32-3. 2006.
62. Farag SS, **Caligiuri MA.** Immunologic approaches to acute leukemia in the elderly. *Semin Hematol.* Apr;43(2):118-25, 2006.
63. Blaser BW, **Caligiuri MA.** Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15. *Best Pract Res Clin Haematol.* 19(2):281-92, 2006.
64. Bloomfield CD, Mrozek K, **Caligiuri MA.** Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions. *Clin Cancer Res.* 12(11 Pt 2):3564s-71s, 2006.
65. Freud AG, **Caligiuri MA.** Human natural killer cell development. *Immunological Reviews* Vol 214:56-72, Dec 2006.
66. Becknell B, **Caligiuri MA.** NK Cells in Innate Immunity and Cancer *PPO Focus* Vol 1, 3:1-8, 2007.
67. Becknell B, **Caligiuri MA.** Natural killer cells in innate immunity and cancer. *J Immunother.* Oct;31(8):685-92, 2008.
68. **Caligiuri MA.** Human natural killer cells. *Blood* Aug 1;112(3):461-9, 2008.
69. Vivier E, Raulet DH, Moretta A, **Caligiuri MA,** Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. *Science.* 2011 Jan 7;331(6013):44-9. PubMed PMID: 21212348; PubMed CentralPMCID: PMC3089969.
70. Vasu S, **Caligiuri MA.** Targeted immunotherapy for acute myeloid leukemia. *Best Pract Res Clin Haematol.* 24:533-40, 2011. PMID: 22127317 [PubMed - in process]

#### **Presented Abstracts (since 1990):**

1. Anderson P, **Caligiuri MA,** O'Brien C, Manley T, Ritz J, Schlossman SF: FcgRIII (CD16) is included in the NK receptor complex expressed by human natural killer cells. *The FASEB Journal* 4:A2028, Abstr # 1935, 1990.
2. **Caligiuri MA,** Zmuidzinis A, Manley T, Levine H, Smith KA, Ritz J: Identification of a novel subset of lymphocytes with constitutive expression of a functional high affinity IL-2 receptor in resting human peripheral blood. *American Association for Cancer Research* 31:246, Abstr # 1456, 1990.
3. Soiffer R, Murray C, **Caligiuri MA,** Ritz J: Selective expansion of NK cells following bone marrow transplantation. The VIIth International Workshop on Natural Killer Cells, June 4-7, Stockholm, Sweden. *Nat. Immun. Cell Growth Regul.* 10:171, 1991.
4. **Caligiuri MA,** Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, Smith K, Ritz J: Phase 1 study of a 3 month low dose continuous infusion of IL-2 in advanced cancer: Significant immune modulation without toxicity. *American Association for Cancer Research:* 32:1463, 1991.



5. **Caligiuri MA**, Manley T, Delage R, Ritz, J: The alternate (CD2) pathway of activation mediates selective depletion of non MHC restricted thymocytes. The VIIIth International Workshop on Natural Killer Cells, June 4-7, 1991. Stockholm, Sweden. **Nat. Immun.**
6. **Caligiuri MA**, Beecher MS, Anderson PA: Expression of TCR- $\zeta$  in CD3-negative effectors derived from human thymus. The VIIIth International Workshop on Natural Killer Cells, June 4-7, 1991. Stockholm, Sweden. (Poster and Presentation). **Nat. Immun. Cell Growth Regul.** 10:173, 1991.
7. Matos ME, Schnier GS, Beecher MS, Ashman LK, Williams DE, **Caligiuri MA**: c-Kit ligand (Mast Cell Growth Factor) differentially augments effects of IL-2 on human natural killer cells. American Society of Hematology. **Blood** 80:729, Suppl 1, 1992.
8. Oberkircher A, Strout M, Herzig GP, **Caligiuri, MA**: PCR amplification of minisatellites for the evaluation of hematopoietic chimerism following allogeneic BMT: description of an efficient and highly informative method. American Society of Hematology. **Blood** 82:1694, Suppl. 1, 1993.
9. Baiocchi RA, **Caligiuri MA**: Low dose IL-2 prevents the development of Epstein-Barr Virus-associated lymphoproliferative disorder in the human-SCID mouse. **American Society of Hematology**
10. Biddle W, Wysocki M, Pancook J, **Caligiuri MA**: Selective in vitro expansion and differentiation of an isolated CD34<sup>+</sup> fraction into early myeloid progenitor cells under serum-free culture conditions. **American Association of Cancer Research** 34:216, 1993.
11. Frankel SR, Nagel GS, **Caligiuri MA**: Low-dose IL-2: A novel strategy for immunotherapy. **Cancer Invest.** 11:26, Suppl 1, 1993.
12. Laughlin MJ, Loftus J, Herzig GP, Nagel G, Caligiuri T, **Caligiuri, MA**: Natural killer cell activity following dose intensive chemotherapy. American Society of Hematology. **Blood.** 82:953, Suppl 1, 1993.
13. Baiocchi R, Haldar S, Sullivan L, Tan J, Seiden M, Sklar J, Narula S, **Caligiuri MA**: Human IL-10 and BCL-2 are aberrantly expressed in severe combined immune deficient mouse/human chimeras with Epstein-Barr virus lymphoproliferative disease. **American Association for Cancer Research** 35:2817, 1994.
14. Carson WE, Haldar S, Baiocchi RA, **Caligiuri, MA**: The c-kit ligand suppresses apoptosis of human natural killer cells in serum-free media through the upregulation of BCL-2. **American Association for Cancer Research** 35:15, 1994.
15. Carson WE, Lindemann MJ, Sullivan L, Narula S, **Caligiuri MA**: Interleukin-10 activates human natural killer cells. American Association for Cancer Research 35:2855, 1994. Carson WE, Schnier G, Jacobsen R, Martin FH, **Caligiuri MA**: c-Kit ligand potentiates the mixed lymphocyte reaction. **American Association for Cancer Research** 35:2944, 1994.
16. Frankel SR, Pixlie L, Porter M, Herzig GP, **Caligiuri, MA**: Low dose IL-2 in first remission acute myeloid leukemia. **American Association for Cancer Research** 35:1344, 1994.
17. Baiocchi R, Sullivan L, Tan J, Narula S, **Caligiuri MA**: Epstein-Barr virus associated lymphoproliferative disease (EBV-LPD) in the severe combined immune deficient human/mouse model: prevention with low dose interleukin-2 suppresses production of human interleukin-6 and interleukin-10. **Proc. ASCO** 13:969, 1994.

18. Krajewski CA, Mrozek E, **Caligiuri MA**: Generation and expansion of CD3-CD56+ non-MHC-restricted cytotoxic effectors from human hematopoietic precursors: requirement for c-kit ligand and interleukin 2. *Proc. ASCO* 13:954, 1994.
19. Meropol NJ, Porter MM, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, **Caligiuri MA**: Low dose interleukin-2 (IL-2): daily subcutaneous injection results in selective in vivo expansion of natural killer (NK) cells with minimal toxicity. *Proc. ASCO* 13:965, 1994.
20. Carson WE, Grabstein K, Giri JG, Lindemann MJ, Linett ML, **Caligiuri MA**: Interleukin-15 is a novel cytokine which activates human natural killer cells using components of the interleukin-2 receptor. *Proc. ASCO* 13:962, 1994.
21. Strout MP, Oberkircher AR, Herzig GP, Fritz PD, Baer MR, Frankel SR, Christiansen NP, **Caligiuri MA**: Molecular evaluation of engraftment following non-T cell depleted allogeneic bone marrow transplantation (BMT): evidence for mixed chimerism in specific leukocyte subpopulations. *Proc. ASCO* 13:999, 1994.
22. Ross ME, Tomasi TB, **Caligiuri MA**: Immunomodulation of human natural killer cells by transforming growth factor beta 2. *Proc ASCO* 13:970, 1994.
23. Bluman EM, Lindemann MJ, Porter MM, Pixley L, Frankel SR, **Caligiuri MA**: Low dose interleukin-2 (IL-2) expands natural killer (NK) cell populations *in vivo* by selective prevention of apoptosis. *Blood*. (Suppl 1): 84:288A, 1994.
24. Bernstein ZP, Porter M, Grimes P, Gould M, Poiesz B, Fyfe G, **Caligiuri MA**: Phase I study of daily subcutaneous (SQ) low dose interleukin-2 (IL-2) in HIV-associated malignancies. *Blood*. 84:10:483A, 1994.
25. Ross ME, Kono Y, Carson WE, Tomasi TB, **Caligiuri MA**: Transforming growth factor-B (TGF-B) suppresses IFN production by IL12 & IL15 activated natural killer (NK) cells. *Proceedings of the American Association of Cancer Research*. Volume 36: 2795, 1995.
26. Carson WE, Fehniger TA, Penetrante FB, **Caligiuri MA**: Characterization of a high affinity interleukin-2 receptor on a CD16+ natural killer cell subset. *Proceedings of the American Association of Cancer Research*. Volume 36: 2789, 1995.
27. Jurlander J, **Caligiuri MA**, Strout MP, Ball ED, Frei-Lahr DA, Hoffmann L, Oberkircher AR, Christiansen NP, Block AW, Herzig GP, Bloomfield CD: Persistence of the t(8;21) fusion transcript following allogeneic (Allo) bone marrow transplantation (BMT) for acute myeloid leukemia (AML). *Blood* (Suppl 1). 86: 2262, 1995.
28. Jurlander J, Lai CF, Tan J, Chou CC, Geisler CH, Narula SK, Baumann H, **Caligiuri MA**: Interleukin-10 (IL-10) is a survival factor for B cell chronic lymphocytic leukemia (B-CLL). *Blood* (Suppl 1) 86: 1371, 1995.
29. Strout MP, **Caligiuri MA**, Schichman SA, Mrozek K, Herzig GP, Arthur DC, Heinonen AK, Knuutila S, Nousiainen T, Ruutu T, Block AW, Croce CM, Bloomfield CD: The partial tandem duplication of *ALL1* is a recurrent novel molecular defect in acute myeloid leukemia (AML) with trisomy 11. *Blood* (Suppl 1) 86: 1702, 1995.
30. Carson WE, Ross ME, Baiocchi RA, Marien MJ, Boiani N, Grabstein K, **Caligiuri MA**: Endogenous production of interleukin 15 by activated monocytes is critical for optimal production of interferon-gamma by human natural killer cells in vitro. Third International Workshop of the Society for Natural Immunity, Oxnard, CA, December, 1995. *Natural Immunity* 14:79.

31. Mrózek E, Wetzler M, Anderson P, **Caligiuri MA**: Interleukin 15 induces CD56+ large granular lymphocytes from CD34+ progenitor cells. *American Association for Cancer Research* 37: 3098, 1996.
32. Bluman EM, **Caligiuri MA**: Human natural killer cells are potent producers of macrophage inflammatory protein-1 $\alpha$ . *American Association for Cancer Research* 37: 3110, 1996.
33. Strout MP, Bloomfield CD, Oberkircher AR, Herzig GP, **Caligiuri MA**: The partial tandem duplication of *ALL1* or normal cytogenetics involves only one allele of chromosome 11. *American Association for Cancer Research* 37: 3910, 1996.
34. **Caligiuri MA**, Strout MP, Arthur DC, Baer MR, Shah MH, Block AW, Mrozek K, Yu F, Oberkircher A, Lawrence D, Knuutila S, Ruutu T, Herzig GP, Schiffer CA, Bloomfield CD: Rearrangement of *ALL1* is a recurrent molecular defect in adult acute myeloid leukemia (AML) with normal cytogenetics that predicts a short complete remission (CR) duration. *Proc. ASCO* 15: 1060, 1996.
35. Baiocchi RA, Khatri V, Lindemann ML, Ross ME, Caprio AI, Caprio TV, Fenstermaker R, Bernstein ZP, **Caligiuri MA**: Analysis of FAS/CD95 expression and function in Epstein-Barr virus (EBV)-associated human B cell tumors. *Blood* (Supp 1) 88: 1509, 1996.
36. Khatri VP, Baiocchi RA, Herzig GP, Oberkircher A, Dolce J, Ward P, **Caligiuri MA**: A successful endogenous immune response to Epstein-Barr virus-associated monoclonal B-cell lymphoma. *Annual Society of Surgical Oncology Meeting*, 1997.
37. Khatri VP, Baiocchi RA, Herzig GP, Oberkircher A, Dolce J, Ward P, **Caligiuri MA**: A successful endogenous immune response to Epstein-Barr virus-associated monoclonal B-cell lymphoma. *The National AIDS Malignancy Conference*, 1997.
38. Khatri VP, Yu F, Baiocchi RA, Shah MH, Zwering BH, Gould M, Bernstein ZP, **Caligiuri MA**: Analysis of T<sub>H</sub>1 T<sub>H</sub>2 cytokine gene profile during low dose IL-2 therapy in patients with AIDS or AIDS lymphoma. *The National AIDS Malignancy Conference*, 1997.
39. Yu H, Carson WE and **Caligiuri MA**: The Flt3 ligand combines with interleukin-15 for natural killer cell expansion from CD34+ progenitor cells: evidence for redundancy with c-kit ligand. IV International Workshop of the Society for Natural Immunity. Helsinki, Finland. *Natural Immunity* 15, 170-171, 1997.
40. Khatri VP, Yu F, Baiocchi RA, Shah MH, Zwering BH, Gould M, Bernstein ZP, **Caligiuri MA**: Low-dose IL-2 therapy enhances the innate immunity and restores the protective TH1 cytokine profile in patients with AIDS/AIDS lymphoma. IV International Workshop of the Society for Natural Immunity. Helsinki, Finland. *Natural Immunity* 15, 203-204, 1997.
41. Khatri VP, Yu F, Baiocchi RA, Shah MH, Zwering BH, Gould M, Bernstein ZP, **Caligiuri MA**: Low dose IL-2 therapy enhances the innate immunity and restores the protective TH1 cytokine profile in patients with AIDS/ AIDS lymphoma. *Natural Immunity*, Vol 5 (4), 203, 1997.
42. Khatri VP, Yu F, Baiocchi RA, Shah MH, Zwering BH, Gould M, Bernstein ZP, **Caligiuri MA**: Analysis of Th1/Th2 cytokine gene expression profile during low dose IL-2 therapy in patients with AIDS or AIDS lymphoma. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*: Vol 14 (4), Abstract #99, A41, 1997.
43. Khatri VP, Baiocchi RA, Herzig GP, Oberkircher AM, Dolce JM, Ward PM, **Caligiuri MA**. A successful endogenous human immune response to transplantation associated monoclonal

- lymphoma. **Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology**, Vol 14 (4), Abstract #122, A47, 1997.
44. Bernstein ZP, Khatri VP, Barresi G, Gould M, Jacobs S, Poiesz B, **Caligiuri MA**: A Phase II study of daily subcutaneous (SQ) low dose interleukin-2 (IL-2) in HIV-associated malignancies. **Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology**, Vol 14 (4), Abstract #96, A40, 1997.
  45. Burd R, Dziedzic TS, Xu Y, **Caligiuri MA**, Subjectk JR, Repasky EA: Tumor cell apoptosis, NK cell recruitment and tumor vascular changes are induced by low temperature, long duration whole body hyperthermia. **Society of Biological Therapy**. Pasadena, CA. October 23, 1997.
  46. Strout MP, Marcucci G, Bloomfield CD, **Caligiuri MA**: ALU-mediated homologous recombination in somatic cells is a consistent mechanism responsible for the partial tandem duplication of *ALL1* in acute myeloid leukemia (AML). **Blood**. (Suppl 1) 90: 317, 1997.
  47. Marcucci G, Livak KJ, Bi WL, Strout MP, Bloomfield CD, **Caligiuri MA**: Detection of *AML1/ETO* Transcript in patients (pts) with t(8;21) associated AML using a novel "real time" quantitative RT-PCR assay. **Blood**. (Suppl 1) 90: 390, 1997.
  48. Marcucci G, Strout MP, Bloomfield CD, **Caligiuri MA**: Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemia ALL1 fusion transcripts. **Blood**. (Suppl 1) 90: 317, 1997.
  49. Marcucci G, **Caligiuri MA**, Oberkircher AR, Bloomfield CD: Absence of minimal residual disease (MRD) by reverse transcription polymerase chain reaction (RT-PCR) in CBF $\alpha$ /MYH11-associated acute myeloid leukemia. **Blood**. (Suppl 1) 90: 62, 1997.
  50. Plass C, Yu F, Yu L, Strout MP, Held WA, **Caligiuri MA**: Genomic scanning for aberrant methylation in acute myeloid leukemia: involvement of WIT-1 methylation at relapse. **Blood**. (Suppl 1) 90: 254, 1997.
  51. Baiocchi RA, Lindemann MJ, Nordone P, **Caligiuri MA**: Combination cytokine therapy prevents human EBV-associated lymphoproliferative disease in the human-PBL-SCID mouse model: critical role of human natural killer cells. **Blood**. (Suppl 1) 90: 512, 1997.
  52. Lee E, George S, **Caligiuri MA**, Dodge R, Smith R, Szatrowski T, Schiffer C: A phase I study of induction chemotherapy for older patients with acute myeloid leukemia using Ara-C, daunorubicin, and etoposide with and without the MDR modulator PSC-8333: Cancer and Leukemia Group B study 9420. **Blood**. (Suppl 1) 90: 506, 1997.
  53. Fehniger TA, Carson WE, **Caligiuri MA**: The CD56 bright NK cell subset is the most potent producer of macrophage activating factors. **Proceedings of the American Association for Cancer Research** 38: 32, 212, 1997.
  54. Whitman SP, Strout MP, Freud RG, Mrozek K, Theil K, Kees UR, Bloomfield CD, **Caligiuri MA**. A novel, partial, non-tandem duplication of *MLL* in a B-acute lymphoblastic leukemia (B-ALL) cell line. **Blood**. (Suppl 1) 92, 287, 1998
  55. Mrozek K, Prior TW, Edwards C, Snyder PJ, Carroll AJ, Koduru PRK, Pettenati MJ, Archer KJ, **Caligiuri MA**, Kolitz J, Larson RA, Bloomfield CD. A comparison of cytogenetic and molecular genetic *de novo* acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study. **Blood**. (Suppl 1) 92, 313, 1998
  56. Stock W., Sher D., Dodge R, Muriano E, **Caligiuri MA**, Frankel S, Larson RA, Bloomfield CD. High level of wilms tumor gene (*WT1*) expression is detected in the majority of newly diagnosed

- acute lymphoblastic leukemia (ALL) of adults: Implications for prognosis and monitoring of minimal residual disease (MRD). **Blood**. (Suppl 1) 92, 915, 1998
57. Fehniger TA, Shah MH, Turner MJ, VanDeusen J, **Caligiuri MA**. Human natural killer (NK) cells show differential cytokine and chemokine production following activation by IL-18 and/or IL-15 in combination with IL-12. **Blood**. (Suppl 1) 92, 1398, 1998
  58. Yu H, Fehniger TA, Fuchshuber P, Theil KS, Viver E, Carson WE, **Caligiuri MA**. FLT3 ligand promotes the generation of a distinct CD34<sup>+</sup> human natural killer cell progenitor that responds to IL-15. **Blood**. (Suppl 1) 92, 1511, 1998.
  59. Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, **Caligiuri MA**. Natural killer cells from HIV-1<sup>+</sup> patients produce C-C chemokines and inhibit HIV-1 infection. **Blood**. (Suppl 1) 92, 2237, 1998.
  60. Shah MH, Yu H, Stover EH, VanDeusen J, **Caligiuri MA**. Simultaneous quantification of cytokine gene expression in multiple organs during endotoxic shock. **Blood**. (Suppl 1) 92, 2238, 1998.
  61. Baer MR, Pixley LA, Schriber JR, Frankel SR, Fehniger TA, Herzig GP, **Caligiuri MA**. Prolonged administration of low-dose interleukin-2 (IL-2) to patients (PTS) with acute myeloid leukemia (AML) in remission (CR) expands natural killer (NK) cells without significant clinical toxicity. **Blood**. (Suppl 1) 92, 2534, 1998
  62. Bernstein ZP, Khatri V, Poiesz B, Gould M, Jacob S, Kunkel LA, **Caligiuri MA**. Phase I/II study of daily subcutaneous (SC) low dose interleukin-2 (IL-2) in AIDS-associated lymphomas (AIDS-NHL). **Blood**. (Suppl 1) 92, 2576, 1998
  63. Schriber JR, Wetzler M, Herzig GP, Slack JL, Alvarnas JC, Abramowski C, Tucker GM, Fay JW, Fehniger TA, **Caligiuri MA**. Outpatient interleukin 2 (IL-2) following stem cell transplantation (SCT) increases NK cell number and cytotoxicity. **Blood**. (Suppl 1) 92, 2700, 1998
  64. Tanner SM, Virtaneva K, Rush L, Bloomfield CD, Plass C, Krahe R, de la Chapelle A, **Caligiuri MA**. Gene expression in acute myeloid leukemia with trisomy 8. **European Journal of Human Genetics**. Vol. 7(Suppl 1)92, 300, 1999
  65. Ruoqi P, Baiocchi R, Schmalbrock P, Moeschberger M, Yang W, Barth RF, **Caligiuri MA**. Combination antiviral therapy for treatment of primary central nervous system lymphoma associated with the Epstein-Barr virus: In vivo evaluation in an animal model. **Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology**. 1999
  66. Tanner SM, Virtaneva K, Rush L, **Caligiuri MA**, Bloomfield CD, Mrózek K, Plass C, Krahe R, de la Chapelle. A novel genes in acute myeloid leukemia with trisomy 8. Poster presentation: ASHG meeting, San Francisco, USA, October, 1999. **American Journal of Human Genetics** 1999; 65(4): Suppl: A325 (1834).
  67. Fehniger TA, Cooper MA, Cella M, Ponnappan A, Carson WE, **Caligiuri MA**. T Cell-Derived IL-2 Costimulates CD56<sup>bright</sup> Human Natural Killer (NK) Cell Interferon Gamma (IFN- $\gamma$ ) Production: In Vitro Evidence That Antigen-Specific Immune Response. Poster Presentation: ASH 41<sup>st</sup> Annual Meeting, New Orleans, USA, December 1999. **Blood** (Suppl 1) 94, 7a, 1999.
  68. Cooper MA, Fehniger TA, Ghaheri BA, Ponnappan A, Chen K, **Caligiuri MA**. IL-1 $\beta$  Costimulates Cytokine Production By CD56<sup>bright</sup> Human Natural Killer (NK) Cells. Annual Meeting, New Orleans, USA, December 1999. **Blood** (Suppl 1) 94, 8a, 1999.

69. Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Knuutila S, Bloomfield CD, **Caligiuri MA**. Identification Of A New Gene At 11q23 Encoding A Guanine Nucleotide Exchange In Factor: Evidence For Its Rearrangement In Acute Myeloid Leukemia (AML). Annual Meeting, New Orleans, USA, December 1999. *Blood* (Suppl 1) 94, 52a, 1999.
70. Whitman SP, Strout MP, Maghraby EA, Marcucci G, Bloomfield CD, **Caligiuri MA**. Partial Tandem Duplication of MLL (MLL PTD): Quantitative Assessment Of Transcript Copy Number In Acute Myeloid Leukemia (AML) With And Without Evidence Of MLL Gene Rearrangement. Annual Meeting, New Orleans, USA, December 1999. *Blood* (Suppl 1) 94, 53a, 1999.
71. **Caligiuri MA**, Lee EJ, Baer MR, Dodge R, Cooke K, Szatrowski T, Schiffer CA, Bloomfield, CD, Larson RA. Daily Low Dose Interleukin 2 (IL-2) Therapy With Or Without Intermediate Dose Pulsing in Acute Myeloid Leukemia (AML) Patients (PTS) > 60 Years Old In First Complete Remission (CRI): A Feasibility Study (CALGB 9420). Annual Meeting, New Orleans, USA, December 1999. *Blood* (Suppl 1) 94, 76a, 1999.
72. Stock W, Sher D, Dodge R, **Caligiuri MA**, Frankel S, Larson RA, Bloomfield CD. Quantitative Molecular Monitoring Of BCR/ABL Transcripts In Adult Acute Lymphoblastic Leukemia (ALL) Using A Real-Time PCR Assay: Pilot Study From The Cancer And Leukemia Group B (CALGB 8762). Annual Meeting, New Orleans, USA, December 1999. *Blood* (Suppl 1) 94, 287a, 1999.
73. Willhauck M, Marcucci G, Döhner K, Schlenk RF, Lichter P, Bloomfield CD, **Caligiuri MA**, Döhner H. Quantitative Detection Of AML1/ETO Transcripts In Patients With t(8;21) Associated AML By Real Time RT-PCR. Annual Meeting, New Orleans, USA, December 1999. ***Blood*** (Suppl 1) 94, 287a, 1999
74. Baer MR, George SL, Dodge RK, Cooke K, **Caligiuri MA**, Powell BL, Kolitz JE, Schiffer CA, Larson RA. Phase III Study of PSC-833 Modulation of Multidrug Resistance (MDR) In Previously Untreated Acute Myeloid Leukemia (AML) Patients (PTS) ≥60 Years (CALGB 9720). Annual Meeting, New Orleans, USA, December 1999. ***Blood*** (Suppl 1) 94, 383a, 1999
75. Kolitz JE, George SL, Hurd D, Hoke E, Dodge RK, Velez-Garcia E, Powell BL, Moore J, **Caligiuri MA**, Vardiman JW, Bloomfield CD, Larson RA. Parallel Phase I Trials Of Multi-Drug Resistance (MDR) Modulation With PSC-833 (PSC) In Untreated Patients (PTS) With Acute Myeloid Leukemia (AML) < 60 Years Old Preliminary Results Of CALGB 9621. Annual Meeting, New Orleans, USA, December 1999. ***Blood*** (Suppl 1) 94, 384a, 1999.
76. Yang J, Flinn I, Ma H, **Caligiuri MA**, Ambinder R. Dramatic Fall In Epstein-Barr Virus (EBV) Load In Lymphoproliferative Disease In Organ Transplant Recipients Does Not Correlate With Response to Rituximab. Annual Meeting, New Orleans, USA, December 1999. ***Blood*** (Suppl 1) 94, 524a, 1999.
77. Kolitz JE, George SL, Hurd D, Hoke E, Dodge RK, **Caligiuri MA**, Velez-Garcia E, Powell BL, Moore J, Vardiman JW, Bloomfield CD, Larson RA. Cytogenetic Risk-Adapted Intensification Followed By Immunotherapy With Recombinant Interleukin-2 (rIL-2) In Patients (PTS) < 60 Years Old With Acute Myeloid Leukemia (AML) In First Complete Remission (CR): Preliminary Results OF CALGB 9621. Annual Meeting, New Orleans, USA, December 1999. ***Blood*** (Suppl 1) 94, 579a, 1999.
78. Marcucci G, **Caligiuri MA**, Maghraby EA, Archer KJ, Döhner K, Schlenk RF, Döhner H, Bloomfield CD. Quantification Of CBFβ/MYH11 Transcripts In inv(16) Acute Myeloid Leukemia (AML) By Real Time RT-PCR. Annual Meeting, New Orleans, USA, December 1999. ***Blood*** (Suppl 1) 94, 625a, 1999.
79. Golub TR, Slonim D, Tamayo P, Huard C, Gaasenbeek M, Mesirov J, Coller H, Loh M, Downing JR, **Caligiuri MA**, Bloomfield CD, Lander ES. Gene Expression Pattern Recognition For Cancer

- Classification. Annual Meeting, New Orleans, USA, December 1999. **Blood** (Suppl 1) 94, 656a, 1999.
80. Fleming GF, Meropol NJ, Hollis DR, Rosner GL, Fracasso PM, Sosman JA, Tkaczuk L, Levine EG, Rhoades C, **Caligiuri MA**, Carson WE, Ratain MJ. Phase I trial of recombinant human anti-Her2 monoclonal antibody (H) plus low-dose interleukin-2 (IL-2) in patients with solid tumors. **Proceedings ASCO** 18:710, 1999.
  81. Peng R, Baiocchi RA, Carrodegua L, Grecula J, Gupta N, Barth R, Chan K, Schmalbrock P, Moeschberger M, **Caligiuri MA**. Combination Therapy with Antiviral Agents (GCV + AZT) plus Radiation Prolongs Survival in an Animal Model of EBV+ Primary Central Nervous System Lymphoma Associated with the Epstein-Barr Virus. **AACR** 2000.
  82. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen J, Cooper MA, Robinson ML, Durbin J, **Caligiuri MA**. Fatal T/NK cell leukemia in IL-15 transgenic mice. **FASEB J.** 14:A1024, No. 90.22, 2000.
  83. Eisterer W, Jiang X, Glimm H, Lambie K, Shaw G, Lee K, Petzer A, Auewarakul Y, **Caligiuri MA**, Barnett m, Eaves C, Eaves A. Regeneration of CD34 BCR-ABL IL-3 G-CSF cells in nod/SCID L) cells. **Blood** 96:11 Abstract 1506, ASH, San Francisco, CA, 2000.
  84. Marcucci G, Bloomfield CD, Balcerzak SP, Kourlas PJ, Stanley HR, Fingert H, Maghraby EA, Lucas D, Chen K, Byrd JC, Kraut EH, Grever MR, **Caligiuri MA**. Phase I trial of Genasense (G3139, Genta, Inc.), a BCL-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL). **Blood** 96:11 Abstract 513. ASH, San Francisco, CA, 2000.
  85. Rush LJ, Gao X, Wright FA, Kolitz JE, Bloomfield CD, **Caligiuri MA**, Plass C. DNA hypermethylation in acute myeloid leukemia (AML): nonrandom patterns with preferential involvement of chromosome 11. **Blood** 96:11 Abstract 2156. ASH, San Francisco, CA, 2000.
  86. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Carson WE, **Caligiuri MA**. Human natural killer cells: A unique innate immunoregulatory role for the CD56BRIGHT subset. **Blood** 96:11 Abstract 3830. ASH, San Francisco, CA, 2000.
  87. Alexander RL, Ramage J, Klein B, Kucera GL, **Caligiuri MA**, Bloomfield CD, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. **Blood** 96:11 Abstract 1312. ASH, San Francisco, CA, 2000.
  88. Virtaneva KI, Wright FA, Tanner SM, Yuan B, Lemon WJ, **Caligiuri MA**, Bloomfield CD, de la Chapelle A, Krahe R: Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics. **Nature Genetics**, 2001.
  89. Bloomfield CD, Byrd JC, Farag SS, Mrózek K, Dodge RK, Archer KJ, Whitman S, Larson RA, Carroll AJ, **Caligiuri MA**. Cytogenetics for treatment stratification in adult acute myeloid leukemia (AML). **Annals of Hematology** 80:S37, 2001.
  90. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, **Caligiuri MA**. Interleukin 15 Is Required for Natural Killer Cell Survival In Vivo. **Blood**, 96: 2001.
  91. Rush LJ, Gao X, Wright FA, Kolitz JE, Bloomfield CD, **Caligiuri MA**, Plass C: DNA hypermethylation in acute myeloid leukemia (AML): nonrandom patterns with preferential involvement of chromosome 11. **Blood** 96:501a, 2001.

92. Virtaneva KI, Wright FA, Tanner SM, Yuan B, Lemon WJ, **Caligiuri MA**, Bloomfield CD, de la Chapelle A, Krahe R: Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics. **Nature Genetics**, 2001.
93. Bloomfield CD, Byrd JC, Farag SS, Mrózek K, Dodge RK, Archer KJ, Whitman S, Larson RA, Carroll AJ, **Caligiuri MA**. Cytogenetics for treatment stratification in adult acute myeloid leukemia (AML). **Annals of Hematology** 80:S37, 2001.
94. Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Lucas D, Chen KK, Byrd JC, Kraut EH, Grever MR, **Caligiuri MA**: Biologic activity and pharmacokinetics of Genasense™ (G3139, Genta, Inc.), a BCL-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL). **Proceedings of American Society of Clinical Oncology** 20:288a (abstract no. 1149), 2001.
95. Rush LJ, Mrózek K, Heinonen K, Abdel-Rahman M, Symanuska J, Bloomfield CD, **Caligiuri MA**, Plass C: Cytogenetic and molecular genetic characterization the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562. **Blood** 98(11):154b, 2001.
96. Tanner SM, Baldus CD, Austin JL, Leone G, Rush LJ, Archer KJ, **Caligiuri MA**, Bloomfield CD, de la Chapelle A: Involvement of BAALC, a novel human gene, in hematopoiesis and acute leukemia. **Blood** 98(11):800a, 2001.
97. Kolitz JE, George SL, Dodge RK, Hoke E, Hurd D, Powell B, Velez-Garcia E, **Caligiuri MA**, Moore JO, Vardiman JW, Bloomfield CD, Larson RA: Dose escalation studies of Ara-C (A), Daunorubicin (D) and Etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 in untreated adults with acute myeloid leukemia (AML) < 60 years: final induction results of CALGB 9621. **Blood** 98(11):461a, 2001.
98. Kolitz JE, George SL, Dodge RK, Hoke E, Hurd D, Powell B, Velez-Garcia E, **Caligiuri MA**, Moore J, Vardiman JW, Linker CA, Bloomfield CD, Larson RA: Consolidation therapy by cytogenetic risk in adults with acute myeloid leukemia (AML) < 60 years in first complete remission (CR): Results of CALGB 9621. **Blood** 98(11):688a, 2001.
99. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, **Caligiuri MA**, Anastasi J, Powell BL, Kolitz JE, Sciffer CA, Bloomfield CD, Larson RA: Phase III study of the multidrug resistance (MDR) modulator PSC-833 in previously untreated acute myeloid leukemia (AML) patients ≥ 60 years old: correlation of outcome with functional MDR (CALGB studies 9720 and 9760). **Blood** 98(11):461a, 2001.
100. Stock W, Dodge RK, Vardiman JW, Bloomfield CD, **Caligiuri MA**, Frankel S, Stone RM, Larson RA: Treatment of adult acute lymphoblastic leukemia (ALL): Phase II trial of dose intensification of daunorubicin and cytarabine followed by high-dose methotrexate and intrathecal methotrexate in place of cranial irradiation (CALGB 19802). **Blood** 98(11):590a, 2001.
101. Marcucci G, Byrd JC, Cataland SR, Fisher DB, Lucas D, Chan KK, Klisovic M, Young DC, Didier LA, Balcerzak SP, Frankel SR, Kraut EH, Bloomfield CD, Grever MR, **Caligiuri MA**: Clinical and biological activity of Genasense™ (G3139, Genta, Inc.)(GS), a BCL-2 antisense, in refractory (REF) or relapsed (REL) acute leukemia (AL): A Phase I Study. **Blood** 98(11):216b, 2001.
102. Marcucci G, Byrd JC, Cataland SR, Fisher DB, Lucas D, Chen KK, Young D, Didier LA, Bloomfield CD, Balcerzak SP, Frankel SR, Kraut EH, Grever MR, **Caligiuri MA**: Significant disease response to Genasense™ (Genta Inc)(GS), a BCL-2 antisense, in combination with chemotherapy in refractory (REF) or relapsed (REL) acute leukemia (AL). **Clinical Cancer Research** 7(11):3681s (abstract #139), 2001.



103. Whitman SP, Archer KJ, Feng L, Baldus C, Becknel B, Carlson BD, Carroll AJ, Mrózek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, **Caligiuri MA**: The FLT3 internal tandem duplication in normal karyotype adult *de novo* AML lacking the wildtype FLT3 gene predicts poor prognosis: A Cancer and Leukemia Group B study. **Clinical Cancer Research** 7(11):3767s (abstract #564), 2001.
104. Virtaneva KI, Wright FA, Tanner SM, Yuan B, Lemon WJ, **Caligiuri MA**, Bloomfield CD, de la Chapelle A, Krahe R: Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics. **Abstracts of the Nature Genetics and American Association for Cancer Research Conference**, Oncogenomics: Dissecting Cancer through Genome Research, p.65 (abstract 30), 2001.
105. Tanner SM, Baldus CD, Austin JL, Whitman SP, Marcucci G, **Caligiuri MA**, de la Chapelle A, Archer KJ, Bloomfield, CD: Expression of BAALC predicts adverse prognosis in adult *de novo* acute myeloid leukemia (AML) with normal cytogenetics: a Cancer and Leukemia Group B (CALGB) study. **Proc Amer Assoc Cancer Res**. Suppl: (late-breaking abstract LB-138), 2002.
106. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, **Caligiuri MA**. In Vivo Evidence for a Dependence on Interleukin-15 for Natural Killer Cell Survival. **Society for Natural Immunity, International Natural Killer Cell Workshop**, p.91, 2002.
107. Sher D, Dodge RK, Bloomfield CD, Larson RA, **Caligiuri MA**, Stock W: Clone-Specific Quantitative Real-Time PCR of IgH or TCR Gene Rearrangements in Adult Acute Lymphoblastic Leukemia (ALL) Following Induction Chemotherapy Identifies Patients with a Poor Prognosis: Pilot Study from the Cancer and Leukemia Group B (CALGB 20101). **Blood** 100 (11): 153a (abstract# 574), 2002.
108. Baldus CD, Tanner SM, Guimond M, Mao C, **Caligiuri MA**, Bloomfield C, de la Chapelle A. Overexpression of BAALC Suppresses Normal Hematopoiesis. **Blood** 100 (11): 164b (abstract# 4147), 2002.
109. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Bloomfield CD, **Caligiuri MA**, Look AT: Adult T-cell ALL Patients Whose Lymphoblasts Express the HOX11 Oncogene Have an Excellent Prognosis When Treated With Chemotherapy And Are Not Candidates for Allogeneic Bone Marrow Transplantation in First Remission. **Blood** 100 (11): 154a (abstract# 578), 2002.
110. Baldus CD, Tanner S, Ruppert A, Whitman SP, Marcucci G, **Caligiuri MA**, Kolitz JE, Larson RA, de la Chapelle A, and Bloomfield CD: High BAALC expression identifies a new risk group of *de novo* Acute Myeloid Leukemia (AML) patients: A Cancer and Leukemia Group B (CALGB) Study. **Proc Amer Soc Clin Oncol** 22: 563 (Abstract 2266), 2003.
111. Baldus CD, Liyanarachchi S, Mrozek K, Auer H, Guimond M, Davuluri R, Ruppert AS, Mohamed N, Vardiman JW, **Caligiuri MA**, Bloomfield C, de la Chapelle A: High Resolution Mapping of Chromosome 21 Genomic Dosage and Gene Expression Studies Reveal Frequent Amplification of the 25-30 MB Region in 21q21 and Overexpression of the APP Gene in Acute Myeloid Leukemia (AML) Subsets. **Blood**, 102 (11): 363a (abstract #1319), 2003.
112. Kolitz JE, George SL, Barrier R, Hoke E, Hurd DD, Velez-Garcia E, Powell BL, Marcucci G, Brooks PL, Carroll AJ, **Caligiuri MA**, Vardiman JW, Bloomfield CD, Larson RA: A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) <60 years old with normal or unfavorable cytogenetics: results from CALGB 9621. **Blood**, 102 (11):175a (abstract #609), 2003.
113. Kolitz JE, George SL, Barrier R, Hoke E, Hurd DD, Velez-Garcia E, Powell BL, Marcucci G, Baer MR, Hohl RJ, Mrozek K, Carroll AJ, Edwards CG, **Caligiuri MA**, Vardiman JW, Bloomfield C,

- Larson RA: Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): results from CALGB 9621. **Blood**, 102 (11):176a (abstract #612), 2003.
114. Whitman SP, Liu S, Klisovic MI, Vukosavljevic T, Guimond M, Rush LJ, Ruppert AS, Strout MP, Becknell B, Dorrance AM, Bruner RJ, Plass C, Bloomfield CD, Marcucci G, **Caligiuri MA**: Activation of the silenced MLL (ALL-1) wild-type allele in acute myeloid leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death. **Blood**, 102 (11):221a (abstract #775), 2003.
115. DeAngelo DJ, Stone RM, Bruner RJ, **Caligiuri MA**, Heaney ML, Nimer SD, Paquette R, Sawyers CL, Lambing JL, Lokker NA, Giese NA, Sinha V, Cooper MR, Druker BJ, Heinrich MC. Phase I Clinical Results with MLN518, a Novel FTL3 Antagonist: Tolerability, Pharmacokinetics, and Pharmacodynamics. **Blood**, 102(11): (abstract 219), 2003
116. Dorrance AM, Yuan W, Becknell B, Guimond M, Strout MP, Feng L, Yu L, Liu S, Shen T, Whitman SP, Marcucci G, **Caligiuri MA**. Homeotic Transformations and Aberrant Hox Gene Expression in Mice with a Partial Tandem Duplication of the Mll Gene: Evidence for a Gain-of-Function. **Blood**, 102,(11): (abstract #453), 2003.
117. VanDeusen JB, Yu L, Blaser BW, Mao C, Guimond M, LeBeau MM, Klisovic MI, Marcucci G, Plass C, **Caligiuri MA**. Characterization and DNA Methyltransferase Inhibitor Treatment of Primary Murine T/NK Acute Lymphoblastic Leukemia (ALL). **Blood**, 102 (11): (abstract #2315), 2003.
118. Yu L, Liu C, VanDeusen JB, Wu Y, Dai Z, Becknell B, Mao C, Lee S, **Caligiuri MA**, Plass C. Aberrant Methylation across the Genome is specific for Malignant Transformation in a Murine Model of T/NK Acute Lymphoblastic Leukemia (ALL). **Blood**, 102 (11): (abstract #3187), 2003.
119. Baldus CD, Tanner SM, Ruppert A, Whitman SP, Marcucci G, **Caligiuri MA**, Kolitz JE, Larson RA, de la Chapelle A, Bloomfield CD: High BAALC expression predicts adverse outcome in *de novo* acute myeloid leukemia (AML) patients: a CALGB study update. **Ann Hematol** 83 Suppl 1: 2004.
120. Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel A, Larson RA, **Caligiuri MA**, Bloomfield CD, Chan KK, Grever MR, Byrd JC. G3139, a BCL-2 antisense oligo-nucleotide, in AML. **Ann Hematol**. 83 Suppl 1:S93-4, 2004.
121. Paolo Neviani, Ramasamy Santhanam, Rossana Trotta, Mario Notari, Bradley W. Blaser, Ji-Suk Chang, Shujun Liu, Hsiaoyin Mao, Joshua J. Oaks, Denis C. Roy, Mauro Valtieri, Rebecca Bruner-Klisovic, Michael A. Caligiuri, Clara D. Bloomfield, Guido Marcucci, Danilo Perrotti. ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. **Blood** (Abstract #1992) 2005
122. Maria R. Baer, Nicholas W. Cuvillo, Jennifer S. Shoemaker, Robert C. Barrier, Jr., Michael A. Caligiuri, Jonathan E. Kolitz, Bayard L. Powell, Richard A. Larson, Clara D. Bloomfield. Treatment Failure Is Strongly Predicted by P-Glycoprotein (Pgp) Function but Not by Multidrug Resistance Protein (MRP-1), Breast Cancer Resistance Protein (BCRP) or Lung Resistance Protein (LRP) in Acute Myeloid Leukemia (AML) Patients 60 Years and Older Receiving Intensive Chemotherapy (CALGB 9720/9760). **Blood** (Abstract #2349) 2005
123. Guido Marcucci, C.D. Baldus, A.S. Ruppert, M.D. Radmacher, K. Mrózek, S.P. Whitman, J.E. Kolitz, C.G. Edwards, J.W. Vardiman, B.L. Powell, M.R. Baer, J.O. Moore, D. Perrotti, M.A. Caligiuri, A.J. Carroll, R.A. Larson, A. de la Chapelle, C.D. Bloomfield. Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal

- Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB). **Blood** (Abstract #335) 2005
124. Guido Marcucci, M. D. Radmacher, A. S. Ruppert, K. Mrózek, J. E. Kolitz, S. P. Whitman, C. G. Edwards, J. W. Vardiman, M. A. Caligiuri, A. J. Carroll, R. A. Larson, C. D. Bloomfield. Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study. **Blood** (Abstract #755) 2005
  125. Kristy J. Arnoczky, Trent B. Marburger, Tamara Vukosavljevic, Michael A. Caligiuri, Susan P. Whitman. Aberrant Pre-mRNA Processing Due to Novel Splicing Mutations in the CBL Proto-Oncogene in Acute Myeloid Leukemia. **Blood** (Abstract #4400) 2005.
  126. Lin TS, L MS, Heerema NA, Matkovich JJ, Moran ME, Cheney C, Lucas DM, Young DC, **Caligiuri MA**, Grever MR, Byrd JC. A Phase II Study of the TNF- $\alpha$  Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities. **Blood** 108, No. 11, abstract 2841, p 804a, 2006.
  127. Yu, J, Yu Li, Hackanson B, Wei M, Boyd Z, Yokohama A, Liu C, Trotta R, Mao HC, Becknell B, Jaung MS, Liu S, Byrd JC, Marcucci G, Plass C, **Caligiuri MA**. In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia. **Blood** 108, No. 11, abstract 2211, p 627a, 2006.
  128. Zhao XB, Trupti Ji, Lapalombella R, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Lee RJ, **Caligiuri MA**, Tridandapani S, Muthusamy N, Byrd JC. NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL. **Blood** 108, No. 11, abstract 135, p 138, 2006.
  129. Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy DC, **Caligiuri MA**, Bloomfield CD, Chen CS, Byrd JC, Perrotti D. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. **Blood** 108, No. 11, abstract 288, p 151, 2006.
  130. Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Kolitz JE, Larson RA, **Caligiuri MA**, and Bloomfield CD. Improved clinical outcome of cytogenetically normal acute myeloid leukemia with the *MLL* partial tandem duplication: A Cancer and Leukemia Group B (CALGB) study. One Hundredth Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007. **Proc. Am. Assoc. Cancer Res.**
  131. Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Kolitz JE, Larson RA, **Caligiuri MA**, Marcucci G, and Bloomfield CD. FLT3 D835/I836 mutations predict worse disease free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without *FLT3* internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study. Forty-Third Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2007. **J Clin Oncol.**
  132. Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Gambacorti-Passerini C, Volinia S, Marcucci G, **Caligiuri MA**, Leone GW, Perrotti D. Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis. **Blood** 110, No. 11, abstract 33, 2007.
  133. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Ruppert AS, Powell BL, Carroll AJ, **Caligiuri MA**, Kolitz JE, Larson RA, Bloomfield CD. Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML)

- with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study. **Blood** 110, No. 11, abstract 104, 2007.
134. Kolitz JE, Hars V, DeAngelo DJ, Allen SL, Shea TC, Vij R, Hoke E, Bloomfield CD, **Caligiuri MA**, George SL, Larson RA. Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. **Blood** 110, No. 11, abstract 157, 2007.
135. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Maharry K, Langer C, Baldus CD, Powell BL, Baer MR, Carroll AJ, **Caligiuri MA**, Kolitz JE, Larson RA, Bloomfield CD. Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study. **Blood** 110, No. 11, abstract 362, 2007.
136. Wagtmann N, Andre P, Zahn S, Spee P, Anfossi N, Gauthier L, Blaser BW, **Caligiuri MA**, Capanni M, Ruggeri L, Velardi A, Romagne F. Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, -2 and -3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo. **Blood** 110, No. 11, abstract 582, 2007.
137. Corbacioglu A, Fröhling S, Paschka P, Marcucci G, Anhalt A, Urlbauer K, Krauter J, Larson R, Mrózek K, Ruppert AS, Ganser A, **Caligiuri MA**, Döhner H, Schlenk RF, Bloomfield CD, Döhner K. Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations –A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB). **Blood** 110, No. 11, abstract 762, 2007.
138. Park I-K, Giovenzana C, Hughes TL, Yu J, Trotta R, **Caligiuri MA**. The Axl/Gas6 Pathway Is Required for Human Natural Killer Cell Development. **Blood** 110, No. 11, abstract 2305, 2007.
139. Guimond M, Freud AG, Mao HC, Blaser BW, Lagemann G, Vandeusen JB, Dorrance A, Ferketich AK, Cavalcanti M, Mackall CL, **Caligiuri MA**. Mechanism by Which Exogenous Administration of Flt3 Ligand (FL) Expands Natural Killer Cells *In Vivo*. **Blood** 110, No. 11, abstract 2310, 2007.
140. Kondadasula SV, Roda JM, Parihar R, Yu J, **Caligiuri MA**, Tridandapani S, Burry RW, Carson WE. Co-localization of the IL-12 receptor and FcγRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-γ. One Hundred and First Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 12-16, 2008. **Proc. Am. Assoc. Cancer Res.**
141. Mitsui T, Yu J, Yokohama A, Hughes TL, Shah MV, Loughran TP, **Caligiuri MA**. Characterization of An NKp46<sup>+</sup> NKT Subset Which Is Susceptible to Malignant Transformation *in Vivo*. **Blood** 112, No.11, abstract 1546, 2008.
142. Neviani P, Santhanam R, Ma Y, Marcucci G, Byrd JC, Chen CS, Cortes J, **Caligiuri MA**, Huettner C, Bhatia R, Roy DC, Perrotti D. Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34<sup>+</sup>/CD38<sup>-</sup> Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals. **Blood** 112, No.11, abstract 189, 2008.
143. Hughes TL, Becknell MB, Freud A, Schmidt SE, Yu J, Mao C, Gavrilin M, Wewers M, **Caligiuri MA**. The Stage-Specific Effect of Interleukin-1 Beta (IL-1β) during Human Natural Killer Cell Development. **Blood** 112, No.11, abstract 3746, 2008.

144. Neviani P, Santhanam R, Ma Y, Bin Zhang B, Mao HC, Volinia S, Marcucci G, Chen CS, Cortes J, Huettner CS, Koschmieder S, Hokland P, Bhatia R, Roy DC, Caligiuri MA, Perrotti D. PP2A induction by FTY720 inhibits survival and self-renewal of CD34+/CD38- CML stem cell through the simultaneous suppression of BCR/ABL and BCR/ABL-independent signals. One Hundredth Annual Meeting of the American Association for Cancer Research, Denver, CO, April 18-22, 2009. **Proc. Am. Assoc. Cancer Res.**
145. Schmidt SE, Freud AG, Hughes TL, Mao C, Caligiuri MA. Phenotypic identification of five distinct CD34+ subsets of hematopoietic progenitor cells in human secondary lymphoid tissue with evidence for divergent pathways of differentiation. One Hundredth Annual Meeting of the American Association for Cancer Research, Denver, CO, April 18-22, 2009. **Proc. Am. Assoc. Cancer Res.**
146. Yu J, Wei M, Mao H, Hughes T, Trotta R, Park IK, Mitsui T, Hwang C, Liu S, Jarjoura D, Benson DM, Caligiuri MA. CD94 defines distinct NK1.1 mouse and CD56dim human natural killer cell subsets. One Hundredth Annual Meeting of the American Association for Cancer Research, Denver, CO, April 18-22, 2009. **Proc. Am. Assoc. Cancer Res.**
147. Benson DM, Chandler J, Mishra A, Baiocchi R, Yu J, Liu T, Lozanski G, Porcu P, Devine S, Rotem-Yehudar R, Caligiuri M. CT-011, a monoclonal PD-1 blocking antibody, enhances natural killer cell activation and cytotoxicity against multiple myeloma. One Hundredth Annual Meeting of the American Association for Cancer Research, Denver, CO, April 18-22, 2009. **Proc. Am. Assoc. Cancer Res.**
148. Benson DM, Romagne F, Squiban P, Wagtmann N, Farag S, Mita A, Hofmeister C, Smith M, Bakan C, Caligiuri M. Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results. **Proceedings of American Society of Clinical Oncology** 27:15S abstract 3032, 2009.
149. Schwind S, Marcucci G, Maharry K, Mrózek K, Radmacher MD, Holland KB, Becker H, Whitman SP, Wu YZ, Baer MR, Powell BL, Carroll AJ, **Caligiuri MA**, Larson RA, Bloomfield CD. Aberrant Gene Expression of *BAALC* and *ERG* in Older [ $\geq 60$  Years (y)] *De Novo* Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study. **Blood** 114, abstract 214, 2009.
150. Benson D, Hofmeister CC, Padmanabhan S, Abonour R, Suvannasankha A, Mita A, Squiban P, Smith MK, Bakan CE, Marzetto M, Andre P, Tollier J, **Caligiuri MA**, Farag S. Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results. **Blood** 114, abstract 2880, 2009.
151. Benson D, Bakan CE, Zhang S, Alghothani L, Liang J, Hofmeister C, Srivastava S, Smith MK, Greenfield CN, Andre P, Squiban P, Romagne F, **Caligiuri MA**, Farag S. IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect. **Blood** 114, abstract 3870, 2009.
152. Benson D, Bakan CE, Alghothani L, Hofmeister CC, Efebera YA, Smith MK, Greenfield CN, Andre P, Squiban P, Romagne F, **Caligiuri MA**, Devine SM. Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma. **Blood** 114, abstract 4641, 2009.
153. Yip BH, **Caligiuri MA**, So CWE. Amplification of Histone Methyltransferase, Mixed-Lineage Leukemia (MLL), Perturbs Normal Hematopoiesis and Induces Hematological Disorder. **Blood** 114, abstract 1965, 2009.

154. Eiring AM, Harb J, Neviani P, Oaks J, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner C, Bhatia R, Roy DC, Liebhaber S, **Caligiuri MA**, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D. Suppression of RISC-Independent *Decoy* and RISC-Mediated mRNA *Base-Pairing* Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors. **Blood** 114, abstract 855, 2009.
155. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey C, Yu J, Mishra A, Becker H, Li C, Briesewitz R, Baiocchi RA, Chan KK, **Caligiuri MA**, Byrd JC, Perrotti D, Garzon R, Marcucci G. Evidence of MicroRNA-29b and Sp1/NF- $\kappa$ B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications. **Blood** 114, abstract 938, 2009.
156. Oaks J, Neviani P, Mukhopadhyay A, Santhanam R, Ma Y, Mao C, Marcucci G, Chen CS, Cortes J, **Caligiuri MA**, Hokland P, Huettner C, Koschmieder S, Cancelas J, Briesewitz R, Bhatia R, Roy DC, Ogretmen B, Perrotti D. FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(-) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor. **Blood** 114, abstract 3259, 2009.
157. Awan F, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson D, Cheney C, Mo X, Lehman A, Jones JA, Flynn JM, Jarjoura D, Baiocchi RA, Desjarlais J, Tridandapani S, **Caligiuri MA**, Muthusamy N, Byrd JC. CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody. **Blood** 114, abstract 3725, 2009.
158. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Whitman SP, Paschka P, Margeson D, Wu YZ, Schwind S, Langer C, Baer MR, Carroll AJ, **Caligiuri MA**, Koltz JE, Larson RA, Bloomfield CD. Comparison of Clinical and Biologic Significance of *WT1* Mutations in Populations of Older ( $\geq 60$  years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) *De Novo* Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study. **Blood** 114, abstract 326, 2009.
159. Whitman SP, Maharry K, Radmacher MD, Mrózek K, Margeson D, Holland KB, Becker H, Wu YZ, Schwind S, Baer MR, Powell BL, Stone RM, Carroll AJ, Larson RA, **Caligiuri MA**, Marcucci G, Bloomfield CD. Adverse Prognostic Impact of *FLT3* Internal Tandem Duplication (ITD) Is Age-Associated in Older [ $\geq 60$  Years (Y)] *De Novo* cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. **Blood** 114, abstract 1579, 2009.
160. Schwind S, Marcucci G, Holland KB, Mrózek K, Michael RD, Maharry K, Becker H, Whitman SP, Wu YZ, Carter TH, Powell BL, **Caligiuri MA**, Baer MR, Larson RA, Bloomfield CD. Higher MN1 expression is an unfavorable prognosticator in older patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A CALGB study. One Hundred and First Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010. **Proc. Am. Assoc. Cancer Res.**
161. Eiring AM, Harb J, Neviani P, Oaks JJ, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber S, **Caligiuri MA**, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D. Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors. One Hundred and First Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010. **Proc. Am. Assoc. Cancer Res.**
162. Alvarez-Breckenridge CA, Yu J, Pradarelli J, Liu T, Kaur B, **Caligiuri M**, Chiocca EA. Oncolytic viral therapy for glioblastoma induces robust natural killer cell activation. One Hundred and First

- Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010. **Proc. Am. Assoc. Cancer Res.**
163. Benson DM, Padmanabhan S, Hofmeister CC, Bakan CE, Abonour R, Suvannasankha A, Efebera YA, Squiban PJ, **Caligiuri MA**, Farag S. A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma. **Proceedings of American Society of Clinical Oncology** 27:15S abstract 8139, 2010.
  164. Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, **Caligiuri MA**, Marcucci G, Bloomfield CD. Mutations In the *Tet Oncogene Family Member 2 (TET2)* Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study. **Blood** 116, abstract 98, 2010.
  165. Zorko N, Whitman SP, Bernot K, Ngangana MT, Siebenaler R, Liu S, Wu YZ, Kalu C, Zhang X, Jarjoura D, Xie Z, Chan KK, Dorrance AM, Lee BH, Briesewitz R, Perrotti D, Marcucci G, **Caligiuri MA**. The *Mll* PTD and *Ft3* ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia. **Blood** 116, abstract 150, 2010.
  166. Park IK, Mishra A, Chandler JC, **Caligiuri MA**. Effective Targeting of Acute Myeloid Leukemia (AML) Harboring the FLT3 ITD Mutation through the Axl/Gas6 Pathway. **Blood** 116, abstract 500, 2010.
  167. Neviani P, Harb JG, Oaks JJ, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Ma Y, Mao C, Marcucci G, Holyoake TL, Volinia S, Cortes JE, **Caligiuri MA**, Huettner C, Bittman R, Chen CS, Arlinghaus RB, Hokland P, Roy DC, Bhatia R, Perrotti D. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment. **Blood** 116, abstract 515, 2010.
  168. Becker H, Maharry K, Radmacher MD, Margeson D, Mrózek K, Whitman SP, Wu YZ, Metzeler KH, Schwind S, Holland KB, Kolitz JE, Carroll AJ, **Caligiuri MA**, Baer MR, Larson RA, Marcucci G, Bloomfield CD. Sole Trisomy 8 In Patients (pts) with *De Novo* Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and MicroRNA (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study. **Blood** 116, abstract 577, 2010.
  169. Benson DM, Bakan CE, Padmanaban S, Abonour R, Suvannasankha A, Jagannath S, Chari A, Clever D, Kalu C, Collins S, Alghothani Y, Hofmeister CC, Efebera Y, Blanchet S, **Caligiuri MA**, Farag S. IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. **Blood** 116, abstract 1966, 2010.
  170. Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Zou X, Fisk H, Labanowska J, Caserta E, Wu LC, Becker H, Schwind S, Chandler HC, Wu YZ, Heerema NA, Porcu P, Garzon R, Marcucci G, **Caligiuri MA**. Interleukin-15 Is a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia. **Blood** 116, abstract 704, 2010.
  171. Mishra A, Sams GH, Johns J, Curphey DP, Sullivan LA, Falkenberg LG, Gibson H, Liu S, Jaroncyk L, Carson WE, Kulp SK, Chen CS, Wong HK, La Perle K, Porcu P, Garzon R, Marcucci G, **Caligiuri MA**. A novel mouse model for cutaneous T-cell lymphoma reveals a role for IL-15 and activity of a new oral HDAC inhibitor. One Hundred and Second Annual Meeting of the American Association for Cancer Research, Orlando, FL, April 2-6, 2011. **Proc. Am. Assoc. Cancer Res.**

172. Neviani P, Harb J, Oaks J, Walker C, Santhanam R, Paisie C, Eiring A, Zhang B, Perazzona B, Y Ma, Mao C, Marcucci G, Holyoake T, Volinia S, Cortes J, **Caligiuri M**, Huettner C, Bittman R, Chen CS, Arlinghaus R, Hokland P, Roy DC, Bhatia R, Perrotti D. BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment. One Hundred and Second Annual Meeting of the American Association for Cancer Research, Orlando, FL, April 2-6, 2011. *Proc. Am. Assoc. Cancer Res.*

**Invited Lectures:**

**On line video presentations:**

1. Caligiuri, M. (2009), "Natural killer cells: development, diversity and applications to human disease", in Lanier, L. (ed.), *Natural Killer Cell Biology: Natural killer cell-mediated immunity to pathogens and cancer*, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at <http://www.hstalks.com/bio>)

**National/International:**

1. International Congress of Chemotherapy, Taormina, Italy. The use of monoclonal antibodies in autologous bone marrow transplantation. May 1988.
2. Medical Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY. The use of anti-CD6 monoclonal antibody for the prevention of GVHD in allogeneic bone marrow transplantation. March, 1989.
3. Puerto Rican Society of Hematology, Puerto Rico. Hematopoietic growth factors: Biology and clinical significance. Oct. 12-13, 1990.
4. NIH/National Institute of Allergy and Infectious Disease. Research workshop on chronic fatigue syndrome. The role of NK cells in viral infection. March 18, 1991.
5. National Cancer Institute-INSERM Workshop on the use of interleukin-2 in hematologic malignancies. September 12-13, 1991 (Invited Participant).
6. Chiron Corporation. Low dose IL-2: Clinical trial and basic observations. September 9, 1992.
7. The CALGB Leukemia Core Meeting. The use of low dose IL-2 for AML. Baltimore, MD. October 17, 1992.
8. Chemotherapy Foundation Symposium X. Innovative cancer chemotherapy for tomorrow. The Page and William Black Post-Graduate School of the Mount Sinai School of Medicine. Ezra M. Greenspan, M.D., Chairman. Low Dose IL-2: A Novel Strategy for Immunotherapy. November 12, 1992.
9. The University of Rochester Medical Center. Hematology Research Seminar. IL-2/IL-2R: Novel clinical approaches from a basic observation. November 24, 1992.
10. The Egypt International Hospital Corp. Cairo, Egypt. International symposium on advances in the diagnosis and treatment of lymphoma, leukemia and breast cancer: Laboratory and clinical advances. (1) Recent advances in the treatment of acute myelogenous leukemia and, (2) Bone marrow transplantation. Cairo, Egypt. January 13-15, 1993.



11. Cancer Therapy Evaluation Program of the NCI on Intergroup Trial of Autologous Marrow Transplant with IL-2 in AML and IL-2 therapy for first remission AML. February 9, 1993.
12. The Princess Margaret Hospital & and the University of Toronto. Medical Grand Rounds. Low dose IL-2 therapy: clinical approaches from basic observations. June 16, 1993.
13. The Proleukin User's Registry Meeting. Colorado Springs, CO. Clinical applications of interleukin 2. June 30, 1993.
14. Clinical Research Education Series Seminar. Amgen Inc. The role of SCF in NK cell biology. September 3, 1993.
15. The CALGB Leukemia Core Meeting. The use of low dose IL-2 for AML. Raleigh-Durham, NC. October 2, 1993.
16. The CALGB National Meeting. Low dose IL-2 therapy for HIV-associated lymphoma. Chicago, IL. November 4, 1993.
17. Chemotherapy Foundation Symposium XI. Innovative Cancer Chemotherapy for Tomorrow. The Page and William Black Post-Graduate School of the Mount Sinai School of Medicine. Ezra M. Greenspan, M.D., Chairman. Low dose IL-2 in ambulatory treatment of AML and solid tumors. November 10, 1993.
18. New York Hospital/Cornell Medical School. IL-2 therapy for first remission AML. November 23, 1993.
19. Memorial Sloan Kettering Cancer Center. IL-2 therapy for first remission AML. November 23, 1993.
20. National Cancer Institute, Task Force on AIDS Malignancies. Invited Speaker. Low dose IL-2 in AIDS lymphoma: Murine model and early clinical results. December 8, 1993.
21. Schering-Plough Research Institute. Human IL-10 in the SCID-hu chimeric mouse. February 16, 1994.
22. M.D. Anderson Cancer Center. Low Dose IL-2 therapy: rationale and potential clinical applications. February 17, 1994.
23. Georgetown University. The Lombardi Cancer Center. Hematology Research Conference. Cytokine therapies in the SCID-human chimeric mouse model. March 11, 1994.
24. Upstate Medical Center. Medical Oncology Grand Rounds: Immune strategies in AIDS lymphoma. March 25, 1994.
25. The CALGB National Meeting. Molecular rearrangement of the *ALL-1* gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Washington, DC. April 28, 1994.
26. Task Force on AIDS Malignancies (NCI). Invited Speaker. Update of recent IL-2 results in preclinical mode, preliminary data on clinical trial, and discussion of potential clinical trial in AIDS lymphoma. Dallas TX. May 14, 1994.
27. The Pezcoller Foundation Symposia. Invited Speaker. Normal and malignant hematopoiesis: new advances. Co-Chairperson, Session V, Molecular Approaches to Therapeutics. Roverto Italy. June 30-July 1, 1994.

28. The H. Lee Moffitt Cancer Center. Medical Grand Rounds. The use of cytokine therapy in AIDS lymphoma. Tampa, FL. July 15, 1994.
29. The Austrian and German Society of Hematology and Oncology. Interleukin 15. Vienna, Austria. October 12, 1994.
30. National Cancer Institute. AIDS Malignancy Working Group (Host: J. Karp, MD). Invited Speaker. Lymphomagenesis in SCID-human mouse. Potential insight into AIDS lymphoma. Bethesda, Maryland. October 24, 1994.
31. The University of Miami School of Medicine. Medical Grand Rounds. Clues to the pathogenesis and treatment of AIDS lymphoma. November 3, 1994.
32. The CALGB National Meeting. Molecular rearrangement of the *ALL-1* gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Update on IL-2 in AIDS Lymphoma. Atlanta, GA. November 6, 1994.
33. Wayne State University Medical School. Medical Grand Rounds. Low dose IL-2 in AIDS related lymphoma. Detroit, Michigan. December 7, 1994.
34. Hoffmann-LaRoche, Inc. Functional effects of IL-15 on human NK cells. Nutley, New Jersey. January 11, 1995.
35. Chiron Therapeutics. Clues to understanding pathogenesis and treatment of AIDS lymphoma. Emeryville, California. January 24, 1995.
36. National Cancer Institute. Workshop on Secondary Leukemia. Invited Speaker. 11q23 as a target for gene directed interventions. Bethesda, Maryland. January 29, 1995.
37. University of Pittsburgh. Lymphomagenesis in the SCID - human mouse model: Role of cytokines and clinical implications. Pittsburgh, Pennsylvania. February 8, 1995.
38. University of Pittsburgh. The Role of the c-kit ligand in human natural killer cell biology. Pittsburgh, Pennsylvania. February 9, 1995.
39. City of Hope. Lymphoma in AIDS: Clues to pathogenesis and treatment. Medical Grand Rounds. Los Angeles, California. March 30, 1995.
40. Lenox Hill Hospital. AIDS Lymphoma: A role for cytokine therapy. New York, New York. April 25, 1995.
41. Cancer and Leukemia Group B. New biologics (potential applications in lymphoma trials). Providence, Rhode Island. May 4, 1995.
42. Cancer and Leukemia Group B. Interleukin 15: A promising new cytokine. Providence, Rhode Island. May 5, 1995.
43. Christiana Hospital. Clues to understanding pathogenesis and treatment of AIDS lymphoma. Newark, Delaware. May 17, 1995.
44. Graduate Hospital. The University of Pennsylvania at Philadelphia. Lymphoma in AIDS: Clues to pathogenesis and treatment. Philadelphia, Pennsylvania. May 24, 1995.
45. American Society for Microbiology. Immunotherapy with IL-2 in hematologic malignancies. Washington, D.C. May 25, 1995.

46. University of Arkansas. AIDS and lymphoma. Little Rock, Arkansas. June 5, 1995.
47. National Cancer Institute. President's Cancer Panel on AIDS Neoplasms. Lymphoma. Bethesda, Maryland. June 6, 1995.
48. Albany Medical Center. AIDS Clinical Research Conference. AIDS lymphoma: Clues to pathogenesis. Albany, New York. June 22, 1995.
49. Albany Medical Center. Medical Grand Rounds. Cytokine imbalance - lymphoma. Albany, New York. June 22, 1995.
50. Medical Center of Delaware Cancer Center. 1995 Annual Hematology/Oncology Conference. HIV associated lymphomas. Wilmington, Delaware. September 21, 1995.
51. M. D. Anderson Cancer Center. Lymphoma...the next questions. Rationale and results of adjuvant IL-2 in AIDS lymphomas. San Antonio, Texas. October 21, 1995.
52. Hospital Universitario De Salamanca. Spanish Society of Hematology Annual Symposium. The role of interleukins in the pathogenesis and treatment of AIDS lymphoma. Zaragoza, Spain. November 14, 1995.
53. St. Michael's Hospital. Clues to understanding pathogenesis and treatment of AIDS lymphoma. Newark, New Jersey. December 15, 1995.
54. CTCRC Burton & Mariam Grossman Cancer Center. Clues to understanding the pathogenesis and treatment of AIDS lymphoma. San Antonio, Texas. February 20, 1996.
55. New Jersey School of Medicine and Dentistry: Tumor Board Conference. Rationale for the use of IL-2 in the treatment of AIDS. Newark, New Jersey. March 11, 1996.
56. Bowman-Gray School of Medicine: Cancer Center Grand Rounds. Immunomodulation in Cancer Therapy. Winston-Salem, North Carolina. March 15, 1996.
57. Cancer and Leukemia Group B Spring Meeting. Invited Speaker for the Pharmacy Committee Meeting. Cytokines, the great communicator. Miami, Florida. May 5, 1996.
58. University of Palermo: Minicourse in Immunology. Invited instructor and speaker. Erice, Italy. May 21-27, 1996.
59. University of North Carolina at Chapel Hill: Clues to the pathogenesis and treatment of AIDS lymphoma. Chapel Hill, North Carolina. June 18, 1996.
60. Medical College of Wisconsin. Clues to the pathogenesis and treatment of AIDS lymphoma. Milwaukee, Wisconsin. September 11, 1996.
61. Leukemia Society of America's Translational Research Program. Update on the partial tandem duplication of *ALL1*. Molecular Session. Washington, D.C. October 3-4, 1996.
62. ASBMT/AACR Meeting. Novel approaches in blood and marrow transplantation. The partial tandem duplication of *ALL1*-a common molecular defect in AML. San Diego, California. October 5, 1996.
63. Berlex Oncology Foundation. Clinical Pharmacology of Anticancer Drugs Course. Growth factors and cytokines. Lansdowne, Virginia. October 7, 1996.

64. Hematology Board Review. The George Washington University Medical Center. I. Chromosomal abnormalities and oncogenes in hematologic malignancies. II. Acute leukemia's of adults. Washington, D.C. October 11, 1996.
65. Baylor College of Medicine. Medical Grand Rounds. AIDS-related lymphoma. Houston, Texas. October 16, 1996.
66. CALGB Fall Group Meeting. Invited Speaker at the Clinical Research Associates Meeting. The CALGB Leukemia Tissue Bank. Pittsburgh, PA. November 2, 1996.
67. Brown University. Guest Immunology Seminar. The role of IL-15 in innate immunity. Providence, RI. November 14, 1996.
68. 4th International Conference on Clinical Applications of Growth Factors and Cytokines in Hematology and Oncology. The role of cytokines in the pathogenesis of EBV lymphoma. Atlanta, GA. November 15, 1996.
69. The Brazilian Society of Immunology. The International Meeting on Cytokines. IL-15: a new regulator of IFN- $\gamma$ . Angra dos Reis, Brazil. November 25, 1996.
70. The American Society of Hematology Meeting. The development of new immunotherapeutic agents. Orlando, FL. December 5, 1996.
71. Genetics Institute. Co-stimulation of human natural killer cells and regulation of the innate immune response. Andover, MA. January 23, 1997.
72. The New York Hospital-Cornell University of Medicine Medical Grand Rounds. Clues to the pathogenesis and treatment of AIDS lymphomas. New York, NY. February 20, 1997.
73. SCF/AIDS Preclinical Meeting. IL-2 and SCF trials in patients with AIDS cancer. Los Angeles, CA. March 4, 1997.
74. Biology of AIDS Lymphoma Workshop. Cytokine gene expression during in vivo therapy with IL-2. Washington, D. C. March 9, 1997.
75. American Association of Cancer Research. Demystifying the role of cytokines in tumor immunobiology: status and future utility. San Diego, CA. April 14, 1997.
76. Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Research Institute. Keynote Speaker for the Second Annual Cancer Research Day. Advances in understanding the molecular basis of cancer. Columbus, Ohio. April 23, 1997.
77. University of Maryland Director's Conference. Clues to the pathogenesis and treatment of AIDS Lymphoma. Baltimore, MD. April 29, 1997.
78. The Paulo Foundation X11 International Symposium-IV Meeting of the Society of Natural Immunity. Low dose IL-2 in AIDS-associated malignancies: rationale and results. Helsinki, Finland. May 30, 1997.
79. Cancer and Leukemia Group B Spring Meeting. Leukemia Tissue Bank. Molecular Biology of AML. AIDS Lymphoma protocols. Montreal, Canada. June 21, 1997
80. First Proleukin International Congress. Immunomodulation mediated by low-dose rIL-2: applications in immunodeficiency-related malignancies. San Francisco, CA. July 12, 1997.

81. Third Pan-Pacific Lymphoma Conference. Treatment of HIV Associated Lymphomas. Lanai, Hawaii. July 16, 1997.
82. 10<sup>th</sup> Annual Brazilian Congress on Clinical Oncology. Cytogenetics in Leukemia. ALL Treatment. Sao Paulo, Brazil. August 16-17, 1997.
83. Fifth Basic Sciences Symposium of the Transplantation Society. Co-stimulation is required for effective NK cell interferon gamma secretion. Chautauqua, New York. September 7, 1997.
84. The Cleveland Clinic/Ohio State University Symposium. Co-stimulatory signals are required for natural killer cell gamma interferon production. Columbus, Ohio. October 3, 1997.
85. Berlex Oncology Foundation. Growth Factors and Cytokines. Leesburg, Virginia. October 6, 1997.
86. Roswell Park Cancer Institute Seminar on Cell Cycle: Molecular targets for diagnosis and therapy, tumor suppressor genes and cell cycle progression. Bcl-2/Bax in drug induced apoptosis: role of cytokines. Buffalo, New York. November 8, 1997.
87. University of Minnesota Cancer Center. Acute myeloid leukemia: molecular mechanisms and clinical implications. Minneapolis, Minnesota. November 11, 1997.
88. CALGB Fall Group Meeting. Invited Speaker at the Oncology Nurses Meeting. IL-2 in hematologic malignancies. Orlando, Florida. November 21, 1997.
89. University of California, San Diego Hematology/Oncology Seminar. Clues to the pathogenesis and treatment of immunodeficiency related lymphoma. San Diego, CA. January 12, 1998.
90. City of Hope National Medical Center. The molecular biology of acute myeloid leukemia: a novel defect and its clinical significance. La Jolla, CA. January 13, 1998.
91. Dana Farber Cancer Institute. Acute myeloid leukemia: a novel defect and its clinical significance. Boston, MA. January 27, 1998.
92. Regional Cancer Center Consortium for Biological Therapy of Cancer. Cytokine Immunotherapy in Post-Implant EBV Lymphoma. Buffalo, NY. February 21, 1998.
93. The Cleveland Clinic Foundation, The Lerner Research Institute, Department of Cancer Biology. Acute myeloid leukemia: molecular mechanisms and their clinical significance. Cleveland, OH. March 24, 1998.
94. Annual scientific meeting of the American Society for Blood and Marrow Transplantation. Molecular biology of AML. Miami, FL. March 27, 1998.
95. Genzyme Corp., EBV Lymphoma, Framington, MA. August 11, 1998
96. International Union Against Cancer Conference, New Cytokines. Rio de Janeiro, Brazil. August 26, 1998
97. Amgen Lecturing Faculty Update Meeting. The Role of Stem Cell Factor in Human Natural Killer Cell Development and Expansion. Phoenix, AZ. August 28, 1998.
98. Berlex Oncology Foundation. Growth Factors and Cytokines. Leesburg, Virginia. October 5, 1998.

99. Case Western Reserve University – Blood Club Seminar. Pathogenesis and treatment strategies for immunodeficiency-related lymphoma. Cleveland, OH. March 19, 1999.
100. MD Anderson Cancer Center – 2<sup>nd</sup> Foundations of Clinical Cancer Research Symposium. 1) EBV-Associated Lymphoma Following BMT: Molecular Biology and Mother Nature Solve the Case. 2) Clues to the Pathogenesis and Treatment of Lymphoma Associated with Immunodeficiency. Houston, TX. March 26, 1999
101. American Association for Cancer Research Scientist Survivor Program. Guest Speaker; Workshop for Immunology/Biological Therapy and Ask the Experts Session. Philadelphia, PA. April 10, 1999
102. International Symposium on HIV, Leukemia, and Opportunistic Cancers. Variations in the Partial Duplication of MLL in Acute Leukemia. Marrakech, Morocco. May 24, 1999
103. VII International Conference on Malignant Lymphoma. Biology of CNS Lymphoma. Lugano, Switzerland. June 4, 1999
104. Proleukin 2<sup>nd</sup> International Congress. Cytokine Replacement Therapy in Patients with HIV Non-Hodgkins Lymphoma: The Rationale for Low Dose IL-2 Therapy. San Francisco, CA. July 29, 1999
105. Rituxan Investigator's Meeting. Presentation of Posttransplant Lymphoproliferative Disorder. Seattle, WA. August 6, 1999
106. Collegium Oto-Rhino-Laryngologicum Amicitiae Sacrum (ORLAS). New Strategies for Immunotherapy. Lyon, France. August 24, 1999
107. Acute Leukaemia Forum. Vaccines: Where are they? Toronto, Canada. August 28, 1999
108. Cleveland Clinic Cancer Center. AIDS Related Malignancies – Lymphomas. Cleveland, OH. September 24, 1999
109. Berlex Oncology Foundation Clinical Pharmacology of Anticancer Drugs. Growth Factors and Cytokines. Lansdowne, VA. October 4, 1999
110. 14<sup>th</sup> Annual Scientific Meeting of the Society for Biological Therapy. Combination Humanized-Monoclonal Antibody and Cytokine Therapy for Treatment of Human Malignancy. Boston, MA October 28, 1999.
111. Lymphoma Research Foundation of America and The Wellness Community of Columbus, Ohio. Ask the Doctor about Lymphoma. November 6, 1999.
112. Cancer Center Grand Rounds Karmanos Cancer Center, Wayne State University: Cancer and Immune Deficiency: laboratory and clinical investigations. December 16, 1999
113. University of California Irvine Chao Family Comprehensive Cancer Center Grand Rounds. Irvine, CA. Clues to the pathogenesis and treatment of cancer in association with immune deficiency; Development and function of human natural killer cells; and Molecular mechanisms of leukemia and it's impact on clinical management. January 24, 2000.
114. McGill University, University de Montreal, Canada. Clues to the pathogenesis and treatment of immune deficiency lymphoma. Acute myeloid leukemia-molecular mechanisms and clinical impact. March 9, 2000.

115. Case Western University Grand Rounds, Cleveland, OH. Clues to the pathogenesis and treatment viral-associated malignancies. June 13, 2000.
116. Brazilian Society of Immunology, Santa Catarina, Brazil. IL-15 as a regulator of the innate immune response. August 14, 2000.
117. Leukemia 2000, Houston, Texas. Immune modulation in AML. September 8, 2000.
118. Mouse Models of Hematopoietic Malignancies Workshop, New York, NY. Fatal lymphocytic leukemia in interleukin-15 transgenic mice follows early expansions in natural killer and CD8+ t-cells. September 19, 2000.
119. 2000 Rituxan Investigators Meeting, Washington, D.C. Use of IL-2 + Rituxan to increase ADCC. September 22, 2000.
120. BioMEMS & Biomedical Nanotechnology World 2000, Columbus, OH. Nanotechnology: Potential Roles in Oncology. September 25, 2000.
121. New Molecular Targets in Cancer Therapy, St. Petersburg, FL. NEED TITLE. October 16, 2000.
122. Berlex Oncology Foundation Clinical Pharmacology of Anticancer Drugs. Lansdowne, VA. Growth Factors and Cytokines. October 23, 2000.
123. American Society of Hematology Corporate Friday Symposium, San Francisco, CA. Future Directions in Biologic Therapy. December 1, 2000.
124. American Society of Hematology Corporate Friday Symposium, San Francisco, CA. Immune modulation in AML: The emerging role of human natural killer cell receptors in mismatched BMT. December 1, 2000.
125. 4<sup>th</sup> Foundations of Clinical Cancer Research, M.D. Anderson Cancer Center, Houston, TX. Viral Switches in Oncology: EBV as a Model. March 8, 2001.
126. Dana Farber Cancer Center, Boston, MA. Role of Cytokines in Normal & Malignant Hematopoiesis. March 13, 2001.
127. Acute Leukemia Forum 2001, San Francisco, CA. Immunologic Manipulation in AML: From the Bench to the Bedside. April 20, 2001.
128. National Institutes of Health, NIAID Twinbrook II Noon Seminar Series, Bethesda, MD. Interleukin 15 in Natural Killer Cell Development, Innate Defense, and Leukemogenesis. May 1, 2001.
129. M.D. Anderson Cancer Center Medical Grand Rounds, Houston, TX. Mother Nature, immunity and Cancer: Two Against One. May 22, 2001.
130. M.D. Anderson Cancer Center BIT Seminar, Houston, TX. IL-15: Its Role in Innate Immunity and Genesis of Cancer. May 22, 2001.
131. Mount Sinai School of Medicine, Rutenberg Cancer Center Medical Grand Rounds, New York, NY. Advance Immunotherapy in Cancer: Tips from Mother Nature. June 22, 2001.
132. Chiron Corporation Investigators Meeting, San Francisco, CA. Immune Modulation of Fc-bearing cells by Proleukin; Potential Applications in the Treatment of Lymphoma. July 10, 2001.
133. Virginia Mason Medical Center Seattle Summer Symposium in Rheumatology, Blaine, WA. Cancer and TNF. July 21, 2001.

134. Berlex Oncology Foundation Clinical Pharmacology of Anticancer Drugs. Growth Factors and Cytokines. Lansdowne, VA. October 15, 2001.
135. American Society of Hematology 43<sup>rd</sup> Annual Meeting. Biology of NK Cells: Role of IL-15 and IL-2. Orlando, FL. December 8, 2001.
136. International Workshop Chronic Lymphocytic Leukemia (IWCLL). Posttransplant lymphoma: cure in the absence of chemotherapy. San Diego, CA. March 23, 2002.
137. National Institutes of Health Workshop: Immune Reconstitution After Stem Cell Transplant. NK allorecognition: biology and clinical application in transplantation. Bethesda, MD. April 26, 2002.
138. Roswell Park Cancer Institute Staff Conference Lecture. Natural Killer Cells: biology and relevance to cancer cures. Buffalo, NY. May 1, 2002
139. Chiron Corporation: IL2 & Monoclonal Antibodies Investigator Meeting at ASCO. Efficacy and response correlates ADCC/IL-2 dose relationship. Orlando, FL. May 19, 2002.
140. National Institutes of Health ETIB Seminar. MLL & FLT3 in AML. Bethesda, MD. June 6, 2002.
141. John Hopkins Transplant Research Lecture. PTLD mouse modeling/clinical application. Baltimore, MD. June 7, 2002.
142. Chiron Investigators IL2NHL03 Meeting. Scientific rationale and functional assays. LaJolla, CA. July 12, 2002.
143. Leukemia 2002 Towards the Cure. Is Immunotherapy possible? Miami, FL. September 19, 2002.
144. Japanese Society Meeting. Human Natural Killer Cells: an update on biology and novel application in cancer therapy. Osaka, Japan. October 23, 2002.
145. 14<sup>th</sup> EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. IL-15: Cytokines in cancer biology and treatment. Frankfurt, Germany. November 20, 2002.
146. Chiron Corporation: Investigators Meeting at ASH. Combination Immune Therapy for Non-Hodgkins Lymphoma. December 6, 2002.
147. University of Chicago Grand Rounds. Clinical Impact of Natural Killer Cell Biology. Chicago, IL. February 24, 2003.
148. University of Connecticut Health Center Grand Rounds. Natural Killer Cells: From Basic Biology to Clinical Application. Farmington, CT. February 27, 2003.
149. Memorial Sloan Kettering Cancer Center. Human Natural Killer Cells: an update on biology and novel application in cancer therapy. New York, NY. March 24, 2003.
150. Chiron Corporation: IL-2 + Rituxan Investigators Meeting at ASCO. Combination Immune Therapy for Non-Hodgkins Lymphoma. Chicago, IL. June 1, 2003.
151. Fred Hutchinson Cancer Research Center Grand Rounds. Biology and Clinical Impact of Human Natural Killer Cells. Seattle, Washington. June 23, 2003.
152. 94<sup>th</sup> American Association Cancer Research Annual Meeting. Exploiting Natural Killer Cell Biology. Washington, DC. July 11, 2003.



153. First Annual Conference - Targeted Therapeutics for Treatment of Hematological Malignancies. Natural Killer Cell Receptors: Biology and Therapeutic Applications for AML. Kona, Hawaii. July 16, 2003.
154. American Society Clinical Oncology/American Association Cancer Research Workshop. The Biology and Clinical Significance of the Hematopoietic Growth Factors. Vail, Colorado. July 26, 2003.
155. Trials and Triumphs Program. The Cancer Clinical Trials: The Basics. Drake Center in Cincinnati, Ohio. August 20, 2003.
156. Mt. Sinai Chemotherapy Foundation Symposium. Modulating IL-2 for Non-Hodgkin's Lymphoma. New York, New York. November 12, 2003.
157. National Cancer Institute sponsored Roundtable Session Panel Member. Leveraging Multisector Technology Development Resources and Capabilities to Accelerate Progress Against Cancer. Washington, DC. January 20-21, 2004.
158. Yale University Immunobiology Seminar. Natural Killer Cells: Biology & Clinical Implications. New York, NY. February 19, 2004.
159. St. Joseph Collegiate High School. Career in Medicine. Buffalo, NY. February 20, 2004.
160. Van Andel Research Institute Grand Rounds. Natural Killer Cells: Biology & Clinical Implications. Grand Rapids, MI. March 10, 2004.
161. Robert H. Lurie Comprehensive Cancer Center of Northwestern University Grand Rounds. Biology and clinical Cancer Applications of Human Natural Killer Cells. Chicago, IL. March 19, 2004.
162. American Association for Cancer Research Scientist-Survivor Program at Annual Meeting. Tumor Immunology and Immunotherapy. Orlando, FL. March 28, 2004.
163. American Association for Cancer Research Annual Meeting. NK Cells; Linking innate and antigen specific immunity. Orlando, FL. March 30, 2004.
164. International Conference on Malignancies in AIDS. Innate Immunity and ARM. Bethesda, MD. April 29, 2004.
165. International Congress of Immunology. IL-15: Cytokines in Cancer Biology and Treatment. Montreal, Canada. July 20, 2004.
166. American Society Clinical Oncology/American Association Cancer Research Workshop. The Biology and Clinical Significance of the Hematopoietic Growth Factors. Vail, CO. August 4, 2004.
167. Leukemia 2004 towards the cure. Immune Therapy – which cell? Houston, TX. October 9, 2004.
168. Chiron Workshop: Interleukin-2 plus rituximab in the treatment of non-Hodgkin's lymphomas. Review of Phase I studies with IL-2 plus rituximab for relapsed or refractory low-grade lymphomas. New York, NY. October 13, 2004.
169. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Visiting Professor Lectureship. When cytogenetics aren't talking; the partial tandem duplication of MLL.. Bethesda, MD. March 17, 2005

170. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Oncology Grand Rounds. Natural Killer Cells: Biology and Clinical Applications. Bethesda, MD. March 17, 2005.
171. AAAAI Annual Meeting. Natural Killer Cells in Transplantation. San Antonio, TX. March 21, 2005.
172. Keystone Symposia Scientific Conferences on Biomedical and Life Science Topics. IL-2 vs. IL-15 in NK development and cancer therapy. Keystone, CO. March 23, 2005.
173. American Association for Cancer Research Annual Meeting. The partial tandem duplication of MLL: New insights into leukemogenesis. Santa Ana, CA. April 20, 2005.
174. The Cancer Institute of New Jersey. Natural killer cells: Biology and clinical applications. Newark, NJ. May 25, 2005.
175. American Association for Cancer Research Scientist – Survivor Workshop. Basic biology and cancer. Bethesda, MD. June 12, 2005.
176. ASCO/AACR Workshop: Methods in Clinical Cancer Research. Cancer Vaccines/Immunotherapy. Vail, CO. July 31, 2005.
177. ASCO/AACR Workshop: Methods in Clinical Cancer Research. Written and Oral Research Presentations that Audiences Remember. Vail, CO. July 31, 2005.
178. ASCO/AACR Workshop: Methods in Clinical Cancer Research. Laboratory Correlates Panel Discussion. Vail, CO. July 31, 2005.
179. Asia Pacific Cancer Conference. Human natural killer cells development: new insights & implications. Seoul, Korea. Sept. 8, 2005.
180. Asia Pacific Cancer Conference. Current Trends in anti-tumor cell therapy. Seoul, Korea. Sept. 8, 2005.
181. Presidential Symposium: American Society of Hematology, Atlanta GA. December 11, 2005
182. National Association of Cancer Center Development Officers and Public Affairs Network (NACCDO/PAN). The Clinical Staff Perspective on Working with Development and Grateful Patients. Niagara-on-the-Lake, Canada. May 7, 2006.
183. Second International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's lymphoma. Natural Killer Cell Biology and Immune Therapy. New York, NY. May 18, 2006.
184. ASCO/AACR Workshop: Methods in Clinical Cancer Research. Cancer Vaccines/Immunotherapy. Vail, CO. July 23, 2006.
185. ASCO/AACR Workshop: Methods in Clinical Cancer Research. Written and Oral Research Presentations that Audiences Remember. Vail, CO. July 24, 2006.
186. ASCO/AACR Workshop: Methods in Clinical Cancer Research. Laboratory Correlates Panel Discussion. Vail, CO. July 24, 2006.
187. American Society of Hematology CRTI. Career Retrospective. Dana Point, CA. August 7, 2006.
188. American Society of Hematology CRTI. Phase I & II Studies. Dana Point, CA. August 8, 2006.
189. Cincinnati Children's Experimental Therapeutics/Hematology/Oncology Seminar Series. Natural Killer Cells: Biology & Clinical Applications. Cincinnati, OH. September 11, 2006.

190. AACR Tumor Immunology Conference. Immunotherapy of Natural Killer Cells. Miami, FL. December 2, 2006.
191. Johns Hopkins Comprehensive Cancer Center Medical Grand Rounds. Inflammation and Cancer: Modeling for Clues to Carcinogenesis, Treatment and Prevention. Baltimore, MD. February 27, 2007.
192. University of Minnesota Medical Cancer Center Grand Rounds. Investigation of the Cytokine-Cancer Connection. Minneapolis, MN. March 20, 2007.
193. Tenth Meeting of Society for Natural Immunity and Natural Killer Cell Workshop. Uterine NK Cells Satellite Meeting. Origin: In situ, migration and subsets. Cambridge, London. April 10, 2007.
194. Tenth Meeting of Society for Natural Immunity and Natural Killer Cell Workshop. Natural Killer Cell Development inside the human lymph node. Cambridge, London. April 13, 2007.
195. American Association for Cancer Research Annual Meeting. Disseminating Research: The ABC's of Paper Publishing. Los Angeles, CA. April 17, 2007.
196. Fifth Meeting of Midwest Blood Club. Keynote Speaker. In vivo demethylating therapy for T-NK acute lymphoblastic leukemia. Cincinnati, OH. April 27, 2007.
197. Seventh Meeting of Molecular Oncology. The role of IL-15 in NK cell development and NK cell leukemia. Positano, Italy. May 14, 2007.
198. Institute Gianniana Gaslini Medical Grand Rounds. Clues to the pathogenesis and treatment of LGL leukemia. Genova, Italy. May 17, 2007.
199. St. Joe's Collegiate Institute. Graduation Keynote Speaker. Buffalo, NY. May 24, 2007.
200. ASCO/AACR Workshop: Methods in Clinical Cancer Research. Measuring Immunologic Outcomes. Vail, CO. July 30, 2007.
201. ASCO/AACR Workshop: Methods in Clinical Cancer Research. Written and Oral Research Presentations that Audiences Remember. Vail, CO. July 30, 2007.
202. ASCO/AACR Workshop: Methods in Clinical Cancer Research. You're In Charge: Investigator Responsibilities. Vail, CO. Aug 1, 2007.
203. International Association for Comparative Research on Leukemia and Related Diseases Annual Meeting. Natural Killer Cells: Biology and Leukemogenesis. Freiburg, Germany. September 9, 2007.
204. University of Freiburg Medical Grand Rounds. Natural Killer Cells: Biology and Leukemogenesis. Freiburg, Germany. September 10, 2007.
205. University of California San Francisco Immunology Program Seminar Series. Natural Killer Cells: from biology to clinical application. San Francisco, CA. November 26, 2007.
206. Stanford University Medical Grand Rounds. Natural Killer Cells: from biology to clinical application. Palo Alto, CA. November 27, 2007.
207. American Society of Hematology Annual Meeting. Human Natural Killer Cell Biology. Atlanta, GA. December 5, 2007.

208. Memorial Sloan Kettering Cancer Center Grand Rounds. Natural Kill Cells: From Biology to Clinical Application. New York, NY. December 20, 2007.
209. Association for American Cancer Institutes Educational Panel. Cancer Research Saves Lives. Washington, DC. January 16, 2008.
210. Keystone Symposium. Development of Natural Killer Cells in Humans. Keystone, CO. February 26, 2008.
211. Society for Surgical Oncologists – John Wayne Clinical Research lecture: clues toward the pathogenesis, prevention and treatment of EBV lymphoma. Chicago, IL. March 15, 2008.
212. University of Pittsburgh Cancer Institute retreat. Keynote address “Natural Killer Cells in Cancer Biology and Therapy”. Pittsburgh, PA. June 19, 2008.
213. National Academies’ Institute of Medicine, National Cancer Policy Forum Workshop on Multi-Center Phase III Clinical Trials and NCI Cooperative Groups. Washington, DC. July 1, 2008.
214. AACI annual meeting, Participated on panel: “Cancer: Challenges and Opportunities in the 21st Century”. Chicago, IL. October 6, 2008.
215. Roswell Park The Director’s Conference “Innate Immunity and the Cancer Connection”. Buffalo, NY. October 8, 2008.
216. Beth Israel Deaconess Medical Center and Harvard Medical School. Hematology/Oncology Grand Rounds: “Post transplant lymphoproliferative disorder: Pathogenesis & opportunities for prevention” and Medical Grand Rounds: “Human Natural Killers Cells: Receptor biology and clinical applications”. Boston, MA. January 21, 2009.
217. Univ. of Chicago Biomedical Sciences Committee on Immunology Seminar Series “Human Natural Killer Cells: Receptor Biology Spills the Secrets”. Chicago, IL. January 26, 2009.
218. Emory University Winship Cancer Institute Grand Rounds “Clinical Application of Human Natural Killer Cell Biology”. Atlanta, GA. February 25, 2009.
219. AACR Annual Meeting, Opening Plenary Session. Denver, CO. April 19, 2009.
220. Memorial Sloan Kettering CCC Experimental Therapeutics Center Retreat Advisory Panel: Drug Discovery and Development in Industry and in Academia. New York, NY. April 28, 2009.
221. American Association of Immunologists Annual Meeting, Chair Society for Natural Immunity (SNI) Symposium: NK Cell Development and Tolerance: Implications for Immunotherapy: NK cell development. Seattle, WA. May 10, 2009.
222. 5th International Innate Immunity Conference. NK Cells, “Differentiation and application in human disease”. Crete, Greece. June 23, 2009.
223. caBIG® 2009 Annual Meeting. Discussion on Cancer Centers and 21st Century Medicine Panel: “Enabling 21st Century Cancer Research: Experiences from the Cancer Community”. Washington, DC. July 21, 2009.
224. University of Michigan Cancer Center Immunology Series. “Natural Killer Cells: Receptor Biology Leads Us to Clinical Applications in Cancer.” Ann Arbor, MI. October 5, 2009.
225. Cutaneous Lymphoma Foundation Cutaneous Lymphoma Summit. “Animal Models of Cutaneous Lymphoma.” New York, NY. October 9, 2009.

226. Association of American Cancer Institutes/ Cancer Center Administrators Forum Annual Meeting. President's Initiatives. Washington, DC. October 18 & 19, 2009.
227. Fellowship Lecture: Hematology Branch - National Heart, Lung, and Blood Institute/National Institutes of Health. "Natural killer cells: receptor biology and clinical applications. Bethesda, MD. March 10, 2010."
228. American Association for Cancer Research Annual Meeting. Physician-Scientist Pathway: Navigating the murky waters between clinical medicine and scientific research discovery. Washington, DC. April 19, 2010.
229. American Association for Cancer Research Annual Meeting. Chairperson and Introduction, Professional Advancement Series: "Getting Your Research Published: Insider Views." Washington, DC. April 20, 2010.
230. 7th International Conference on Innate Immunity. "The Stage-Specific Effect of Interleukin-1 Beta (IL-1 $\beta$ ) during Human Natural Killer Cell Development." Rhodes, Greece. July 5, 2010.
231. 12th Meeting of the Society for Natural Immunity. "IL-1b and human NK cell development." Dubrovnik, Croatia. September 12, 2010.
232. Forbeck Foundation Scholar's Meeting. "Development and Biology of Natural Killer Cells." Lake Geneva, Wisconsin. September 17, 2010.
233. National Cancer Institute Eminent Lecture Series. "NK Cells: Development Through Malignant Transformation." Bethesda MDs. October 25, 2010.
234. New York University Cancer Institute Seminar Series. "Natural Killer Cells: Biology and Clinical Application." New York, NY. November 17, 2010.
235. CureTech CT-011 for Cancer Immunotherapy. "New Prospects in Cancer Immunotherapy." Tel-Aviv, Israel. November 21, 2010.
236. American Association for Cancer Research Annual Meeting. Chairperson, Professional Advancement Series: "How to get your Research Published." Orlando, FL. April 2, 2011.
237. American Association for Cancer Research Annual Meeting. Faculty, "Cancer Immunology for the Non-Immunologist." Orlando, FL. April 2, 2011.
238. American Association for Cancer Research Annual Meeting. Professional Advancement Series: "Securing a Faculty Position: Building a Competitive Portfolio and Landing the Job." Orlando, FL. April 5, 2011.
239. American Association for Cancer Research Annual Meeting. "The Role of Health Information in Reforming Our Healthcare System: What It Means for Cancer Patients." Orlando, FL. April 5, 2011.
240. American Society of Preventive Oncology Annual Meeting. Panel participant: "Cancer Center Director: How Does Population Science Fit?" and "A Cancer-Free World: Collaboration in Science to Get There." Las Vegas, NV. March 6, 2011
241. Acute Leukemia Forum. "What is the Future on Immunotherapy in AML?" San Francisco, CA. March 25, 2011.
242. Institute of Medicine Workshop: Implementing a National Cancer Clinical Trial System for the 21<sup>st</sup> Century. Washington, DC. March 21, 2011.

243. Chinese PLA Hospital, Department of Hematology. "Ohio State University Comprehensive Cancer Center Overview" and "Partial Tandem Duplication of the MLL Gene in AML." Beijing, China. April 16, 2011.
244. 8<sup>th</sup> International Conference on Innate Immunity. "Malignant Transformation on Innate Immune Cell: Pathogenesis and Effective Therapeutic Targeting." Chania, Crete, Greece. June 19, 2011.
245. Roche/*Nature Medicine* Symposium on Cancer Immunology and Immunotherapy. "Interleukin-15: A new oncogene." Nutley, NJ. September 13, 2011.

**Community Presentations on Cancer, The James, and Pelotonia:**

1. Central Ohio Society of Clinical Oncology. Cancer and Immunity: What does one have to do with the other? Worthington, OH. September 16, 1997.
2. Interviewed for National Public Radio "Living on Earth". Columbus, OH. November 14, 1997.
3. Interviewed for the Marion Star. Forms of leukemia and their prevalence. Columbus, OH. November 26, 1997.
4. Interviewed for the Columbus Dispatch. Discovery of genetic marker in AML patients. Columbus, OH. January 6, 1998.
5. Interviewed by WBNS-10TV. Discovery of genetic marker in AML patients. Columbus, OH. February 19, 1998.
6. Park Medical Center Grand Rounds: Clinical Research: CALGB, Phase II Research Consortium and other 1998 initiatives. Columbus, OH. March 6, 1998.
7. Upper Arlington High School: Science in the Cinema "Marvin's Room". Portrayal of scientific/medical information of cancer and leukemia with a movie and discussion. Columbus, OH. July 22, 1998.
8. Interviewed by Columbus Monthly magazine. Cancer Research, May 2001.
9. The Rotary Club of Columbus. OSU Comprehensive Cancer Center Progress Report. March 14, 2004.
10. Health Care Heroes Breakfast Keynote Speaker. Business First. July 15, 2010.
11. Invited speaker, Limited Brands. October 21, 2010
12. Invited speaker, Cardinal Health. March 22, 2011
13. Invited speaker, AEP. March 24, 2011
14. Guest speaker, Grove City Rotary meeting. May 19, 2011
15. Invited speaker, Limited Brands. May 20, 2011.
16. Guest speaker, city of Washington Court House Pelotonia rally. May 25, 2011
17. Invited speaker, Limited Brands. June 9, 2011.

18. Invited speaker, McGraw Hill. July 15, 2011.
19. Invited speaker, Victoria's Secret. July 19, 2011.
20. Invited speaker, U.S. Department of Justice, U.S. Attorney's Office, Southern District of Ohio. August 3, 2011.
21. Invited speaker, Limited Brands. August 16, 2011.
22. Invited speaker, 10<sup>th</sup> annual Abercrombie and Fitch Challenge. September 8, 2011.
23. Invited speaker, Kegler, Brown, Hill & Ritter. September 21, 2011.

**Lectures-The Ohio State University:**

1. Transplant Seminar. The Hu-PBL-SCID as a model for human EBV lymphoproliferative disease. September 24, 1997.
2. Immunobiology 701. Hematopoietic cell differentiation. September 30, 1997.
3. Comprehensive Cancer Center Grand Rounds. Acute Leukemia. Molecular mechanisms and clinical outcome. October 3, 1997.
4. Tumor Registry Seminar Series. Immunotherapy of AIDS lymphoma. October 29, 1997.
5. Departmental Seminars in Pathology Program. Insights into the pathogenesis of immunodeficiency related lymphomas. November 3, 1997.
6. Division of Hematology/Oncology Fellow Lecture Series. Basics of Molecular Biology. November 10, 1997.
7. Division of Immunology Seminar Series. Clues to the pathogenesis and treatment of AIDS lymphoma. November 24, 1997.
8. Medical Scientist Student Organization. Careers for Medical Scientists. December 12, 1997.
9. Division of Allergy/Immunology/Rheumatology Conference. IL-15, a potential player in the innate immunity response. December 19, 1997.
10. The Ohio State University Winter College. Invited Guest. Sarasota, Florida. March 5-6, 1998.
11. The Ohio State University in California. Invited Guest. Los Angeles, California. March 10-13, 1998.
12. Division of Veterinary Biosciences Research Seminar. Clues to the pathogenesis and treatment of immunodeficiency lymphomas. April 21, 1998.
13. Division of Surgery Medical Grand Rounds. Clues toward the pathogenesis and treatment of posttransplant lymphoproliferative disease (PTLD). April 30, 1998.
14. Clinical Cancer Genetics Honors Program. The genetics of leukemia/lymphoma. May 20, 1998.

15. Department of Medical Biochemistry. The innate immune response-cytokines and signaling. June 3, 1998.
16. Division of Surgery Medical Grand Rounds. Acute leukemia. June 12, 1998
17. Department of Medicine: Medical Grand Rounds. Immunodeficiency and cancer: Lessons learned from mother nature. June 25, 1998
18. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 25, 1998
19. Department of Transplant. Experimental and Clinical PTLD. September 30, 1998
20. Department of Transplant. Experimental and Clinical PTLD. January 27, 1999
21. Department of Medicine. Morning Report. April 22, 1999
22. Department of Pathology: Immunology Series. Role of IL-15 and NK Cell Development. May 18, 1999.
23. Department of Medicine. Housestaff Lecture. Acute leukemia. July 7, 1999.
24. Heart & Lung Institute. The biology of interleukin 15. September 8, 1999.
25. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 27, 1999.
26. Department of Medicine: Noon Conference. Bridging The Gap. November 5, 1999.
27. Division of Hematology/Oncology Fellow Lecture Series. Basics of Molecular Biology. November 22, 1999.
28. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 25, 2000.
29. Department of Medicine: Noon Conference. Acute Leukemia, December 5, 2000.
30. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 24, 2001.
31. Division of Hematology/Oncology Fellow Lecture Series. Basics of Molecular Biology. December 4, 2001.
32. Department of Medicine. Med II Lecture Series. Acute leukemias, February 12, 2002.
33. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 27, 2002.
34. Department of Medicine. Med I Lecture Series. Cancer and Immunity: Lessons Learned from Mother Nature. April 6, 2003.
35. Department of Medicine: Bench to Bedside. When Stem Cells won't Behave. August 20, 2003.
36. Biomedical Research Tower Groundbreaking Mini-Symposia. EBV Lymphoma: Moving in for the kill. October 3, 2003.



37. Department of Medicine. Med I Lecture Series. Cancer and Immunity: Lessons Learned from Mother Nature. April 7, 2004.
38. Landacre Student Research Honor Society. Keynote Speaker. April 23, 2004.
39. OSU Undergraduate Student Government. Keynote Speaker. June 2, 2004.
40. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 23, 2004.
41. Integrated Biomedical Graduate Program. IBGP-707 Fundamentals of Grant Writing-1Center Grants. November 15, 2004.
42. Department of Medicine. Med I Lecture Series. Cancer and Immunity: Lessons Learned from Mother Nature. April 4, 2005.
43. Department of Medicine. Med I Lecture Series. Cancer and Immunity: Lessons Learned from Mother Nature. April 5, 2006.
44. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 21, 2006.
45. Division of Hematology/Oncology Fellows Conference. How to give a lecture. December 19, 2006.
46. College of Dentistry Omicron Kappa Upsilon (OKU) and Sigma Phi Alpha annual banquet. Keynote Speaker. May 31, 2007.
47. College of Medicine Interview Day. September 19 & October 24, 2007.
48. Pain and Palliative Care Department Seminar. Update of the OSU Cancer Center. November 7, 2007.
49. Department of Pathology Seminar Series. Natural Killer Cells: Biology, Disease and Anti-Cancer Therapy. May 27, 2008.
50. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 29, 2008.
51. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 28, 2009.
52. Microbiology and Molecular Virology, Immunology and Medical Genetics. Cellular and Molecular Immunology 701. Hematopoietic cell differentiation. September 27, 2010.

**Local-Western New York:**

1. Medical Grand Rounds. WCA Hospital, Jamestown NY. Bone marrow transplantation. June 8, 1990.
2. Medical Grand Rounds. Sisters of Charity Hospital, Buffalo, NY. Bone marrow transplantation. September 18, 1990.
3. Medical Grand Rounds. S.U.N.Y. at Buffalo School of Medicine, Buffalo, NY. Hematopoietic growth factors & bone marrow transplantation. October 6, 1990.

4. Central New York Academy of Medicine. The Tenth Biannual Lemuel Bowden Cancer Teaching Day. Bone Marrow Transplants in Leukemias and Lymphoma. May 16, 1991.
5. Mercy Hospital of Buffalo, NY. Medical Staff Seminar. Bone marrow transplant: an update. May 23, 1991.
6. Children's Hospital/Department of Allergy and Immunology Seminar. Biotherapy of cancer. April 12, 1993.
7. Medical Grand Rounds. Sisters Hospital. Biotherapy and cancer. February 15, 1994.
8. Medical Grand Rounds. S.U.N.Y. at Buffalo School of Medicine, Buffalo, NY. Department of Medicine. Pathogenesis and treatment of AIDS lymphoma. September 1994. Core Lecture Series and Immunology Reviews. The Children's Hospital of Buffalo. Clues to pathogenesis & treatment of AIDS lymphoma-SCID mouse model. January 22, 1996.
10. Interviewed for Leukemia Society Cure 2000 Telethon. WBEN TV, Buffalo, NY. March 11, 1996.
11. Leukemia Society of America. Update on Research. June 20, 1996.
12. The Third Annual Cancer Survivor Day. Recent breakthroughs in cancer research. September 30, 1996.

**Lectures at RPCI and S.U.N.Y./Buffalo:**

- |           |   |
|-----------|---|
| 1990-     | University of Buffalo Medical School. Microbiology 600 (Immunology) Medical School Course. Bone Marrow Transplantation. |
| 1990-     | Natural Sciences Seminar, Roswell Park Graduate School. Bone Marrow Transplantation.                                    |
| 1990-     | Oncology for Scientists, Roswell Park Graduate School. Biologic Response Modifiers.                                     |
| 1990-     | Microbiology and Immunology Course 501: Natural Killer Cells and the Immune Response.                                   |
| 1990-     | Microbiology and Immunology Course 502: 1) Hematopoiesis<br>2) Cytokines 3) Clinical Applications of Cytokines.         |
| 1990-1994 | Gannon University Physician Assistant Program: Introduction to Oncology.  |
| 1991-     | Surgical Grand Rounds, RPCI. Cancer and Immunotherapy.  |
| 1992-     | Biochemistry 551. Biochemistry of Hormones. Hematopoietic Growth Hormones.  |
| 1992-     | Pharmacology 551. Principles of Cancer Chemotherapy. Clinical Applications of Immunotherapy.                            |
| 1994-     | Millard Fillmore Medical Housestaff Teaching Rounds: Bone Marrow Transplantation.                                       |

1995 - Medical Technology 540. Immune Modulation by Cytokines.

11/21/96 Cancer Chemotherapy Program: Principles of Chemotherapy

2/7/96 Division of Medicine Staff Conference: Clues Toward Understanding the Pathogenesis and Treatment of EBV-Associated Lymphoma.

2/5/96 Research Conference of the Department of Medicine, SUNY-Buffalo. Interleukin 15 and the Innate Immune Response.

1/29/96 Nurse Orientation Roswell Park Cancer Institute: Chemotherapy.

1/24/96 Interdisciplinary Vascular & Metabolic Research Group, SUNY-Buffalo. The Rationale for the use of IL-2 in the Treatment of AIDS Lymphoma.

7/29/95 MD/PhD Research Day: Choice of Residency.

11/28/95 Seminar Series of the Departments of Molecular Immunology and Molecular Medicine: The Role of IL 15 in the Genesis of Human NK Cells.

5/15/95 Third Year Selective Overview of Clinical Oncology: Translational Research.

1990, 1993 Millard Fillmore Medical Housestaff Teaching Rounds: Oncogenes and The Hematopoietic Growth Factors; Bone Marrow Transplantation.

10/4/93 Nurse Orientation: Immunotherapy.

1/8/93 Nurse Orientation: Hematopoietic Growth Factors.

1/11/93 Nurse Orientation: The Cell Cycle and Classes of Chemotherapy Agents.

9/14/92 Nurse Orientation: The HLA System.

2/22/94 Nurse Orientation: The Leukemias.

9/14/92 Nurse Orientation: Hematopoietic Growth Factors.

5/6/92 Nurse Recognition Week: Management of Hodgkin's Disease.

5/30-31/91 Oncology Nursing Update on BMT: RPCI. Growth Factors and GVHD in BMT

5/28/91 S.U.N.Y. Dermatology Grand Rounds. Swift Auditorium, Buffalo General Hospital. Oncogenes, Part II.

10/23/90 S.U.N.Y. Dermatology Grand Rounds. Swift Auditorium, Buffalo General Hospital. Oncogenes, Part I.

10/22/90 Biophysics Seminar, Roswell Park Cancer Institute. The IL-2 Receptor: Biophysical Considerations.

1990 Co-Chairperson, Oncology Seminar Series, RPCI. BMT: An Update.